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Functionalized quinolines and their benzo/hetero-fused ana logs are an important
class of organic molecule s that have attracted the attention of synthetic and medicinal
chemist s, becau se of their presence in numerous natural product s and their wide range of
biological activitie s. The quinolines, particularly those substituted at position 4, have
marked antimalarial, antibacterial, anti-inflammatory, anticancer, and antiviral activities.
The remarkab le app lications of these compo unds have not only prompted many
chemists to synthesize these t ypes 0 f com pound s, they have also beco me an active
resea rch area of con tinuing interest.
In this work a structure-based drug design was done using l-Iyperchem-3™ in order
to develop a quinoline-originated Topoisomerase inhibitor with a potenti al ant icancer and
a better pharm acokinetic profile . The work involve s the design and synthesis of many
ring fused quinoline sys tems including thieno -, thiazeto-, thiazolo- and furobenzo[h]
quinolines in order to clarify the structural requir ements for the activity ; the in-silico data
determined in this work provides a deep under standin g of the bindin g affinities of these
types of derivat ives.
The result s obtained in this study showed that the synthesized quinoline derivati ves
have good binding affi nitie s to I-Iuman Topoiso merase II, particu lary in the AT? bindin g
region . Also, these derivatives were not able to chelate with Mg2+ which helped to
account for the lack of cytotoxic ity exi hibited by these derivatives.
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CHAPTERl
Introduction and Overview
1.1 Str uct ure -based dru g design
The drug desig n industry is now one of the major players in the bioinformatics and
biotechnology indu str ies; the field is in great need for a rapid sea rch for small molecules
which will bind to the appropria te targets. Drug design is the process of finding new
medications based on the knowledge of the biological target; the succes s in drug design
necessitates both the combin ed use of chemical and biological research. Computat ional
appro aches are now playing a major part in rational drug design in combin at ion with
structural information derived from macromolecular x-ray crystall ography and nuclear
magnetic resonanc e (NMR ) investi gations . Structure-based drug design is perhaps the
most reliable approach for discovering compound s possessing high specificity and
efficacy. In the last few decades, novel methods of synthes izing large libraries of
potentially bioactive small molecules using combinatorial methods possessi ng screening
strateg ies have led to increasingly important roles in drug discovery.
There are two major types of drug design . The first is referred to as ligand-based
drug design and the seco nd, as structure-based drug design [I] .
1.1.1 Liga nd- base d dru g design
Ligand-ba sed dru g design can be identified on the basis of the knowledge of some
other molecu les exhib iting bindin g to the biological target of interest, and figurin g out the
possib le bind ing interact ions which in turn will lead to the identification of a
pharmacophore. A pharmacophore is the model whic h exhibits the minimum necessary
structural characteristics needed for a molecule to bind to the target [2] .
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1.1.2 Structure-based dru g design (SBDD)
SBDD is identifie d on the basis of the know ledge of the three -dimens ional
structure of the biological target obtained through X-ray crys tallogra phy, or, via Nuclear
Magnetic Resonance (NM R) spectroscopy. SBDD involves detailed knowledge of the
binding sites of targets (such as proteins) associa ted with the particular disease of interest.
The lock and key mechanism is the most applicable design for an effec tive drug. This
drug design method involves basic knowledge of bioin formatics, proteomics,
biochemistry, and comp uter modeling of three-dim ensional pro tein structures [3].
1.1.3 Str ucture-based drug design steps
a) Drug target identifi cation
b) Identification of the bindin g site
c) Virtual scree ning
d) Evaluation of potenti al lead candidate
1.1.3.1 Drug target identifi cation
A drug target can be identi fied as a key biological molecule invo lved in a specific
metabolic or signa ling pathway which is related either to a parti cula r disease condition, or
the infectivity and surviva l of a microbia l pathogen. The target molecule usually has a
well-define d binding pock et in which small molecules can compete in order to modul ate
the functio n of the target. Also, the target molecule should be unique. No other pathway
should be ab le to provide the funct ion of the target and ove rcome the presence of the
inhibit or. In order to identify the potential target for the disease. di fferent tools such as
genomics, bioin form atics and proteom ics [4].
/./ .3.2 Identifica tion oftile binding site
X-ray crystallogra phy (XRC), NMR, Homology Mode ling or Comparative
Modeling are the most commonly used methods to identi fy the binding site. XRC is the
main source of inform ation for drug design as it can give high resoluti on structures. Once
the three -dimen sion al structure of a protein is determin ed, the co-ordin ates of the atoms
are used by the comp uter to con struct the protein structure.
Homology modelin g is only used when there is no exact predetermin ed three-
dimensional structure of the target (not determined either by XRC or NMR) based on an
available sequence, usuall y provided with an empirical structure tem plate with at least
30% sequence ident ity. After the structure of the target has been determined, the binding
region shou ld be determined. The bindin g site is considered as a cavity which exhibi ts
hydrogen bond donors as well as hydroph obic characteris tics [5].
/./.3.3 Virtual screening (In-silico drug design)
ln silica methods can help in determinin g drug targets via bioinform atics tools.
Also, they can be used to analyze differ ent target structures for checking possi ble
bindin g/active sites, dockin g possible ligand molecu les with the target, rankin g them
accordin g to their bindi ng affinite s (scoring functions), and finall y optimi zing the
structura l feature s of tested molecul es in order to impro ve their bindin g characteris tics to
develop the best candidate [4].
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1.1.3.4 Evaluation ofpotential lead candidate
In order to evaluate a lead drug. Lipinski's "Rule of 5 "s hould be followed. Its name
implie s that all of the four paramet ers which are listed below and which are used to j udge
the expected efficac y of the drug should be close to five. or a mult iple of 5. Lipinski [6]
states that poor absorpti on or permeation is more likely when :
There are more than five H-bond donors.
ii. The molecular weig ht is over 500 Oa.
iii. The 10gP (partition coe fficient) is over 5.
iv. The sums ofN's and O's are over 10.
1.2 Research scope
The scope of the research presented in this thesis mainly include s:
Appl ying the above-mentioned method ology (SBOO) to the synthes is of novel
quin oline derivatives possessing potenti al biological activities .
ii. Performin g isosteric and bioisosteric replacements for the newly-synthesized
derivati ves in order to come up with a clear idea about their Structur e-Activity
Relationships (SARs), and
iii. Shedding light on the requirements for the quinoli ne nucleus to develop
anticancer der ivatives.
13 Thests nvcrvi ew
A manuscript-based thesis has been written to describe the entire work of the
developed research. It combines live manuscripts following the thesis writing guidelines
approved by Memorial University. .lhc first manuscript is a literature review; the second.
third and fourth manuscripts describe the first objective of the thesis achieved; and the
last manuscript describes the second and third objectives of the thesis achieved. The
organizational structure of the entire thesis is shown in "'i~uf(" I· ) and the overview of
the different chapters is discussed hereafter:
I Chaph' r l : Introd uct ion I
I
1
Cha ptl,'r2 : Literature Review
I
I
1
I
1
ICha ll tl,' r~ : Extension of developed.a~l1.laehes for Isynthesis of bioisosteric dcnvativ es
I
1
Cha ptcr 6: COllclusions and
Future research
Ftgure I-I: Thesis organizatio n.
I
Chapter 1 introduce s a broad overview of structure-based drug design , its types
and the signific ance of each . Basic definition s and assumption s of structure-based drug
des ign are also discu ssed . Finally, the research objectives are laid out.
Chapter 2 provides a discussion of the non-classical biological activities associated
with the quino line scaffold. The recent literature reviews on those activitie s are also
discussed. This chapter co mpr ises a manuscr ipt whic h has been submitted for publication
on Nov. 3'd and accep ted for publicat ion online on Dec. 9th in the Journ al of pharmac y
and pharm aceuti cal sciences under the title of No nclassica l Biological Act ivities of
Quinolone Derivatives, 15 ( I) , 52-72, 20 11 (ava ilable online) .
Chapter 3, Chapter 4 and Chapter 5 com prise four different research papers
which indivi dually exp lore the frameworks , methodologies, and approaches to synthesize
nove l quino line derivatives with different ring fusions.
Chapter 3: Abeer Ahmed and Mohsen Daneshtalab. Polycyclic Quinolone s (Part I)
-Thieno [2,3-b] Benzo [11] Qui noline Derivati ves : Design , Synthe sis, Preliminary in vitro
and in silica Studie s, Hetero cycl es , V. 85, 2012 . DOl : 10.3987/COM- ll-1 2374 (in press,
ava ilable onli ne).
Chapter 4: Abeer Ahmed , Louise N. Dawe and Mohsen Daneshtalab . Polycyclic
Quino lones (Part 2) - Synthesis Of Nove l-4-0xo- I,4-Di hydro Benzo [11] [1,3] Thiazeto
[3,2-a ] Quinoline Carboxy lic Acids via Oxidative Cyc lization Of The Correspo nding
Mercaptoquinoline Precursors, Heterocycles, V. 85,20 12. DOl : 10.3987/COM-ll -12375
(in press, avai lable online) .
Chapler J: lntrotlud ;on andol 'en';ew.
Appendix 4A: Structur e of 4-0xo-I ,4-Dih ydrobenzo- [h][I ,3-Thiazeto-[3,2-
a]Qu inolin e-I ,3-Dic arboxylic Acid. Acta Cryst. 20 11, E67, 0529 (avai lable online).
Chapter 5: Developm ent of Anti-Viral Angular Furo[2,3-b]Benzo[h] Quinoline
Agents Using Molecular Modeling and Virtual Screening Techniques (in prep).
Chapter 6 provi des the summary and conclusio ns, and describes the originality of
the research . In addition, recomm endations for future research are provided.
Chapter 2: Literature Review: Non classical biologica l act ivities of quinolone dertvatives
CHAPTER 2
Literature Review: Non-Cla ssical Biological
Activities of Quinolone Derivatives
Abeer Ahmed" and Mohsen Daneshtalab?"
J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(1), 52-72, 2011
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Chapter 2: LiteratllreR eview: Non classical biological aclil'ities oifquinolone derivatives
Abstract
Quin olones are a family of multi- faceted drugs; their chemical synthesis is flexibl e
and can be easil y adapted to prepa re new congeners with rationally devised structures.
This is show n by the description of many thousands of derivatives in the scientific
literatur e. Scientists co uld accurate ly descr ibe their quantitative structure activity
relationship (QSA R), which is essentia l for effective drug design. This also gave them thc
chance to discov er new and unprecedented activitie s, which makes quin olones an endless
source of hope and enable s further development of new clinicall y useful drug s.
Quin olone s are among the most common framewo rks present in the bioactive drug
molecules that have domin ated the market for more than four decades. Since 1962,
4(1H)-quinolone-3-carboxylic acid derivatives have been widely used as antibacterial
agents. Quin olones have a broad and poten t spec trum of activi ty and are also used as
second-line drugs to treat tuberculosis (TB). Recentl y, qu inolones exihibited "non-
classical" biological activities, such as antitumor, anti-HIV- I integrase, anti-HCV- S3
helicase and anti-NS5B -polymerase activities.
The present review focuses on the structura l modifications responsible for the
transform ation of an antibacter ial into an anticancer a gent and/or an antiviral agent.
Indeed, quinolones ' antimicrobia l action is distinguishable amo ng antibacterial agents,
because they target different type II topoi somerase enzymes. Many derivatives of this
family show high activity against bacterial topoisomerases and eukaryotic
topoisomer ases, and are also toxic to cultured mamm alian cells and in vivo tumor models.
Moreover, quin olones have shown antiviral activity aga inst HIV and HCV viruses. In this
II
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context the quin olones famil y of drugs seem to link three different biological activities
(antibacterial, anticancer chemotherapy, and the antivira l activity) and the review will
also provide an insight into the different mechani sms responsible for these activities
among different species .
2.1 Intro duction
Quinolones as "privileged building blocks" with simp le and flexib le synthetic
routes, allow for the production of libraries of quin olone derivat ives. Because of their
diversity, drug-li ke propertie s and similarities to specific targets, they are considered a
central scaffold to build chemi cal libraries with promising bioactivity potential.
The first quin olone discovery, as with many important discoveries, was a result of
serendipity. Lesher et af. (1962) [1] discovered the first qu inolone derivative as an
impurity in the chemical manu facturing of a batch of the antima larial agent, chloroqu ine.
Since then, more than 10,000 quin olone derivatives have been patented or published
which explains the enormous progress that has been made in under standin g the molecular
mechanisms of action behind the different pharm acological actions of this privileged
molecule.
Quinolones as a class of antibacterial agents have been know n for over 40 years .
Although considerable resul ts in the research of new antibacter ial quinolo nes have
already been achieve d, they are still a matter of study because of the continuo us demand
of novel comp ound s active against resistant strains of bacteria. Research ef forts are
mainly focused on obtaining new compounds which are active agains t very resistant
bacterial strains or acti ng on the mechanisms of resistance [1-4].
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Currently, fluoroq uinolo nes are approved as seco nd-line drugs by the \\ '110 10 treat
lB but their usc in MDR·TB is increasing due to the fact that the y have a broad and
potent spectrum of activity and can also be administered orally, Moreover. they haw
favourable pharmacokinetic profiles and good abso rption, including exce llent penetration
into host macrophages, As of today, the potential of tluoroqu inolones as first-line drugs is
still under invest igatio n 15·7).
2.2 T ht:c hcmi stt1nf ..l-q uino lont's
The orig inal method for the preparat ion of a-qut nclon es relie s on the Gould -Jacobs
reaction between aniline and a dialkyl alko xymethylcnemalonate [HI
o 0
+ o~o"""""'"
) 0
~
o 0
~OHlivlwJJ
~
j
o 0
~O'"livlNJI
H
Scheme 2·1 : Synthes is of 4-qu inoloncs using the Go uld-Jacob s reaction
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Lappin cyclizatio n [9] results in cyctoacylotion to fonn 3. on heating at a high
temperatu re to provide the quinoline-t-one system as shown in Schem e 2-1. SN2
alkylation at N-I follo wed by ester hydrolysis affords the substi tuted 4(1H)- quinolone-J.
carboxy lic acid 5
The Gould-Jacobs approac h allows only the introduction of primary alkyl groups.
thus limiting the preparation of derivatives with more com plex substitucnts at N-I . In this
respect the Orchc-Hcitzcr rycloacy lation expanded the synthetic possibi lities of
quinoloncs as depicted in Scheme 2-2 [10).
~lAcl
o
~CIlAcl
o 0
~OHlAN'JI
R
5
6
If
o 0
CH~COO£'~ ~o""'-HClOf.'~ .AC,O
lAcl
8
o 0
o:Y'''' I O~ •
-<' - -N
R
11
o 0
~O~lAcl Lo
~
9
lj
~O/
lAcl llNH
R
10
Scheme 2-2 : Synthesis of -t-quinolones using Grobe-It eitzcr reaction
In the Grohc- Hcitzer synthesis. the active methylene in a Ji-ketoester is condensed
under dehydrating cond itions with an orthoester . resulting in the formation of the enol
ether which is further subjec ted to an addition-elimination reaction using an appropriate
primary amine. The product obtai ned is cyclized through an aromatic nucleophil ic
displacemen t of a leaving group (typically Cl, F) atthe onho positio n with respec t to the
activating carbonyl group. Final hydrolysis of the ester function under either basic or
acidic conditions gives the quinolonc-j-carboxylic acid [11].
4(lH)-Quinolone-3-carbtlxylic acid derivatives containing a variety of subst itucnts
at different positions have also been prepared by palladium-catalyzed curbonyhnivc
hctcrocyctization (12). Palladium cycliza tion enab les the synthesis of several 4(1lf)-
quinolo nc-j-carboxylic acid derivat ives in 24-82% yields. Palladium-catalyzed
cyclization has the potential to accommoda te substitue nts at position 2 which in tum
offers flexibilit y for the design of quinolinone derivatives as depicted in Scheme 2-3
cex(O0'"I I co. Pel (q
,,6 NH R -
12
13
14
Sc heme 2·3: Synthesis ofa-quinnlonc-J-cu rboxylic acid derivatives by palladium-
catalyzed carbonylative hctcroc yclization .
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2.3 IJifl l u~ica l ta rgets or ant ibacte rial quinulones
Generall y. quinolo nes direc tly inhib it DNA synthesis by binding to the enzyme-
DNA complex. Quino loncs also stabi lize DNA strand break s created by DNA gyrasc and
topoisomerase IV. Ternary complexes of drug . enzyme. and DNA block progre ss of the
replicat ion fork. The cytotoxicit y of tluoroquino lones can he explai ned on the basis of a
2-step proce ss: (I ) the conver sion of the ternary com plex (topoisomcrasc-quinolcne-
DNA) into an irrever sible form; and (2) the produc tion of a dou ble-strand break by
denaturation of the topoisomcruse. The molecular bas is necessary for the trans ition from
step 1 to step 2 is still und ear [ J3] .
Fi~U rl' 2-1: Mechanism of action of Iluoroquinolon cs
(adopted from Zhanc l et al., 1999 ),
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Gyrase
+ONA
GyrasHJNA GyrasHJNA
wrapped
Fi\i:urt"2-2: DNA cleavage-religation mechanism of DNA Gyrasc
(adopted from Gore 1:'1(.II.. 2 (06 ),
(a) Gyrase binds to a DNA segment as a tetramer and wraps a DNA segment (120 - 140
bp) into a positive supercoil. (h) ATP binds to the GyrB subunits and a conformational
change occurs. The subunits dirnerise. capturing the 'L segmcnt. At the same time, a
double-strand break is introd uced into the G-segment. (e) The Tvsegmcm is transported
through the G segment break, towards the central hole of the GyrA dirner. (d ) Following
the T-segment passage, the G-segment is religated and the Tvsegr ncnt is released through
a transient opening of the primary dimer interface on the GyrA dimcr. Religation of the
IS
DNA break introduces two negative supercoils on the DNA. AIr hydrolysis promotes
enzyme turnover and regenerates the starting state.
The DNA break is formed through a transcstcriflcation step which leads to the
attachment of the Y- phorphoryl group on DNA to the hydroxyl on I yr-122 on GyrA
[18). The DNA is cuI in a sequence-specific manner. creating a -l-bp staggered break on
opposite strands of the DNA. In a stud)' by Morrison et (/1., [19J the cleavage of four
double-stranded DNAs was examined , Each double-stranded DNA strand was cleaved
between T and G on the one strand; however. the cleavage on the comple mentary strand
seemed to have no sequence specifici ty.
2.5 Important structural fea tu res of antibac te ria l quin ulones
It is really important to highlight the structural requirements for a quinoline
pharmacophore to extbibit antibacterial activity, as presented in Ftgure 2-3.
Figure 2-3: General structure of the most-commonly used quinolone molecule.
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Position 1: This position is part of the enzy me-DNA bind ing com plex, and has a
hydro phobic interaction with the major grove of DNA [20] . A cyclo propy l substitue nt is
considered the most poten t substitution here ; the seco nd important substitution for the
required activity is the addition of a 2,4-difluoro phenyl [21].
Position 2: Thi s location is very close to the site for the gyrase binding site (or
topoisomera se IV) and it is well- known that any added bulk inhi bits the transport and
result s in a lower level of mic robiological acti vity [20]. Onl y a sulfur , incorporated into a
small ring, has been able to replace hydro gen at the R-2 position [20].
Positions 3 ami 4: These two position s on the quinolone nucleu s are essential for gyrase
bindin g and bacteri al tran sport and no other useful substitutions have been reported yet.
There fore, the 3-ca rboxy late and 4-carb onyl gro ups are co ns idere d esse ntia l for
antimic robial acti vity [22].
Position 5: Substituents at this posit ion of the basic qui nolone nucleus appear to have the
capac ity to co ntro l potency. Electron-donating gro ups such as an amino, hydroxyl, or
methyl gro up were found to increase in vitro activity aga inst gra m-positive bacte ria [23) .
Position 6: The substitution with a fluorine atom had markedl y imp roved antimicro bial
activity compared to the or iginal quin olone age nts, and gave rise to the now wide ly-used
and clinically-succ essful fluor oquinolone compounds. As sugges ted by Ledoussal et al.
[24] the 6-H is equiv alent in acti vity to the 6-fluo ro analog ue even at the enzy me level.
Position 7: Five- or six-m embered nitrogen heterocycles are the most comm onl y applied
moi etie s at thi s position. This position is consid ered to be one that directl y interacts with
DNA gyrase [25].
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Position 8: Of particul ar interest is the observation that speci fic changes in position 8
appear to dramatically alter the initial target in fluoroquin olones. For examp le, the
presence of a simple hydrogen atom as in ciprofloxacin, or a fused ring (for examp le,
ofloxacin and levofloxacin that have a benzoxazine bridge between C-8 and N-I)
typically leads to high act ivity aga inst topoisomerase IV, with little clinic ally-useful
activity against DNA gyrase .
The current knowl edge of structure-activity relationship s has been gathered through the
past development of a large numb er of compounds within the quin olone class and goes
on to improve the antimicrobial activit y and extend the useful life of such c1inically-
important comp ound s.
2.6 Dual tar gets mechani sm of actio n
Quinol ones act in a similar fashion aga inst the two prokaryotic Ty pe 11enzymes .
They essentially block the topoisomerase catalytic cycle when the protein is cova lently
linked to the cleaved DNA (cleavage complex). Stabilizat ion of the enzyrne-D A
complex has been confirmed to block the progression of the replicative machinery and to
create DNA lesions that induc e a bacterial SOS response [26,27]. Amino acid mutations
in the Quin olon e Resistance Determinin g Region (QRDR) greatly reduce the affinity of
quinolone s for the enzyme-DNA complex. The most relevant positions in E. coli are
Ser83 and Asp87 in GyrA, and the corresponding Ser79 and Asp83 in ParC [28,29]. The
structural featur es of the interactions between quino lone-gyra se-DNA complex were
identified by the sequencing of additi onal mutant gyrA and gyrB genes that produce the
altered quinolone susceptibility [30] . Experimental evidence sugges ts that quinolones, in
21
Chapter 2: Literature Review: NOli classical biotogical activities of quinokme derivotives
the presence of appropriate metal ions, bind single-stranded DNA and GyrA with
moderate affinity [31,32]. However, they bind efficiently to the gyrase -DNA complex
[33]. At the DNA level. cleavage is not required to stimulate drug binding: the structura l
distortion of the double helix, bound to the protein and stab ilized by select ive contacts
with protein residues, appears to be sufficient to provide a favourable interaction site for
quinolones [34]. Additionally, the presence of quinolones alters not only the structural
features of GyrA (binding site) but also those of the overa ll A2B2-DNA comp lex [32,35 ]
inducing modific ations in the kinetic rates of different catalytic steps.
2.6.1 Differ ences between DNA gyrasc and eukaryo tic topo II
In eukaryotes, DNA gyrase and topoisomerase IV are functionally replaced by two
isoenzymes: topoisomerase IIa and lIb, 170 and 180 kDa proteins respec tively [3]. These
proteins share a similar catalytic cycle, the main difference being in the fact that the
active form of eukaryo tic topoisomerase II (Top02) is constituted by a homodimer.
However, as supported by the extended sequence homology, Top02. can be seen as the
fusion of the GyrA -GyrB or ParC- ParE subunits.
Common features in the mechanism of action of antibacter ial quinolones and
antitumor drugs have sugges ted that both compounds have a similar mode of interaction
with the type II DNA topoisomerase-DNA complexes. In particular, comparison between
quinolones and antitumor drugs of the epipodophyllotoxin family (etoposide and
teniposide) has been considered, since neither type of drug is a DNA intercalator [36].
Archaebacteria are considered as being an intermediate phylogenetic position between
eukaryotes and eubacter ia [37]. In these systems, comparable sensitivity to poisons of
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each Type II topoisomerase was observed and the DNA cleavage patterns induced by
ciprofloxac in and etopos ide were found to be very simi lar [38,39 ]. These findings
strongly supported a common mode of interaction with the DNA- topoisomerase II
complexes for ciprofloxac in and eto poside.
2.7 Quin olone-based anticancer derivatives
Quin olon e derivati ves represent a large numb er of antiproliferative agents
exhibiting cytoto xicit y through DNA intercal ation , causing interfer ence in the replicati on
process [40-42] . Actinom ycin D, doxorubicin, mitoxantron e and streptonigrin are
quinoline analo gs possessing antibacterial or anti-c ancer activity through DNA
intercalation . Most of these drugs are currentl y used in the treatm ent of human
malignancies targetin g topoisomerase (Types II) enzy mes [43-45].
An interestin g point which was highlight ed in many quin olones' previous reviews.
is: how can small molecules discrim inate efficiently between such simi lar enzymes ? It
was found that a minut e change in the quin oline structure enab led the drug to act on
another different target. High throughput screening revealed that there are two major
types of modification that appear to drive the qu inolone action from antibacteria l to
anticancer: i) The disrupti on of the zwitterionic propert ies of the compo unds by
modi fying either the C7 basic substituent or the C3 carbonyl group, or both , will affect
the electron density distrib ution and protonat ion equilibria; ii) The increase in the extent
of aromatic/condensed rings mostly lead to increase the affinity of qu inolones for doubl e-
stranded DNA, while antibacterial quino lones interact better with single-stranded DNA
[46].
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2.7.1 Historic development of cytotoxic quinolon es.
Topoisomerase II is the primary target for several classes of antineoplastic drug s
[47,48,49] . These agents are widely used for the treatment of human cancers [47,48,49]
and their clinical efficacies correlate with their abilitie s to stabili ze covalent enzyme-
cleaved DNA complexes that are intermediates in the cata lytic cycle of the enzyme [47-
5 1]. While quinolone-based drugs have been deve loped extensively as antimicrobial
agents (targete d to DNA gyrase, the prokaryotic counterpart of topoisome rase II) [52,53],
these studies provided evidence that quinolones may have potent ial as antineop lastic
drugs. When compa ring the known sequences of topoisomerases from bacteria to
mammals, the sequences appear to be similar around active site tyrosine , not only among
type II topoiso merase but also among type I. They also share the same mechanism of cell
killing which is performed by trapping topoisomerase II in an intermedi ary cleavable
comp lex with DNA , termed the "cleavab le complex ," which is detected as DNA doubl e
strand breaks [54] . The pioneering study in this field showed that ciprofloxa cin and
ofloxacin interfer only slight ly with the function of Calf Thymu s Topo II , the prokaryotic
gyrase be ing approximately IOO-fold more sensitive to inhibition than its eukar yotic
counterpa rt [55].
Rosoxac in, a 7-(4-pyridinyl)quinolone derivative Figure 2-4, showed great promise
in treating gonococcal infections [56] . Morover, the 7-(4-py ridinyl) deriva tives produced
an unacceptable toxicity pro file in vitro, inducing a genetic toxicity endpoint [57].
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Since that time , different directions were followed to elucidate the structural
activity relation ship s responsible for the interference of quinol ones with eukaryotic
topoi somerase II.
I~
N .&-
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~
Figure 2-4: Structure of the cytotoxic quinolo ne Rosoxacin .
2.7.2 Important stru ctural features of anticancer quinolones
2.7.2.1 Position 3 substituents
It is well established that. in antibacterial quin olones, the 3-carboxy l functional
group or its isosteric replacement is a fundamenta l requirement for activity. However,
this functio nal group can be replaced even with a hydrogen atom , and effective poisonin g
of Top02 can still be maintained . It seems that , to inhibit the eukaryotic enzyme, the
basic requir ement is the cop lanar ity of the C-3 substituent with the quin oline ring. Thus,
although in 3-H deri vati ves small substituents can be beneficial at C-2 , no such residue
can be introduc ed if the carboxyl group is present , as it will destabil ize the coplanar
orientation of the acidic moiet y [58]. Remov al of the carboxylic group opened up new
synthetic opportunities . In fact, introduction of a phenyl grou p or a related heteroar omatic
ring at C-2 enhanced Topo2 poisoning activity [59]. The distance between the two
aromatic moietie s is apparently cruci al, as only a meth ylene linker allowed the
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maintainance of biological activity. Further increase in cytotoxic activity was obtained
upon introduction of hydroxyl- substituents into the C-2 phenyl group. In particular, the
2.6-dihydroxy benzyl derivative (WI:"'o' 64593, FiAUf(' 2-5 ) is the most active quinolone
derivative. In quinolo ncs carrying the carboxyl group, the acid ic moiety can participate
with the ketone at position 4 in chelating metal ions, or can be involved in hydrogen
bonding with the target macromo lecules.
OH
I '"
N '"
WIN-64593 FWO °I I NH<:;; 0 N S·
H
2N
F .6.
A-65282
FWO °I I NHr N 0 N 5'
HN~ F 6,
A-65281
Fi~urc 2-5: Anti-cancer quinolones.
I hc substitution of the nitrogen at position I with a sulfur atom leads to inactive
derivatives (58). However, as reported, other positions can support the introduction of
this heteroatom without the loss of activity. An example is represented by the isothiazolo
quinoloncs ,\-6 528 1 and ,\-65 282 (60]. These derivatives exhibit a heterocyclic moiety
fused onto the quinolonc system. which can be considered as a modification of the
carboxylic group. It is worth noting that, in spite of the fact that these derivatives do not
exhibit an aromatic substituent at position C-7.they are active against both bacterial and
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eukarvotic type II topoisomcrases. More recent ly. [61] derivatives bearing a 3-
dimethylaminopropy l substituent on the quinolone nitrogen and a mcthoxycarbonyl
group at position 9 (Compound IS) exhibited prominent antitumor activity. Cytotoxicity
was reduced when an anilido substituent was present at position I) (Compou nd 16, Figure
2-6)
Fil:ur e 2-6: Structures of Compound s 15 and 16
2.7.2.2 Positions 6 "lid 8
A study done in 1991 (62) showed that 6.8-dill uoroquinolone s were potent in
affecting the eukaryotic topoisomerase II. Following another study 163] showing the
contribution of the C-Il fluorine to drug potency, the authors compared the effects of ell-
115.955 [o-flucr o-z-t4-hydroxyphenyl)- I-cyclo propyl-4-quinolone -3-carboxylic acid]
Ftgure 2-7 on the enzymatic activities uf Drosoph tla melanogastcr topoisomcrase II with
those of CP-115,953 (the 6,K-di lluoro parent compound 0I'CI'-115,955). Results showed
that removal of the C·1l fluoro substituent decreased the ability of the quinolonc to
enhance the enzyme-mediated DNA cleavage - 2.5-fold.
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Figure 2-7: Structuresof 6 and or 8-dil1uoroquinoloncs
2.7.2.3 Ring position /V· l
Considerable ev idence [64] indicates that the presence of a cyclop ropy l as opposed
to an ethyl grou p at position N· ] increases quinolonc potency agai nst DNA gyrasc and by
comparing the DNA cleavage-enhancing activity of cip rcfl oxacin with that of norfloxacin
or the activity of e p- II S.9:;] with that of C P-67,80-l. Ftgure 2-1l. il was determ ined that
substitution of an ethyl group at N-l decreased quinolonc potency against calf thymus
topoisorneraseII between -30- to -40- fold. respectively.
o 0
HO
OH
Figu re 2-8: Structu re of Compound C I'-6 7.S0" .
2.7.2.4 S " bstitutiol1(II C-7
A variety of substitutions were also introduced al pos ition C-7 . In fact, the presence
of a basic ami no group in the aliphatic cyclic substit uent at position C-7 is a strict
28
requir ement for antibac terial activ ity. Additiona lly, modifications at th is position were
show n to play a key role in directin g the drug preferent iall y towards Gyr or To po 4 [65].
These result s sugges ted a direct interaction of this portion of the qu inolone with the
enzyme . Conce ivably, the C-7 substituent should affect the prokaryoti c/eukaryotic
enzyme selective ly. Indeed , meth yl substituents at the C-7 pip erazine gro up influenced
potency aga inst the mamm alian enzy me. In fact 3,5 -dimethylpiperaz inyl de riva tives were
active in stimulating enzy me-mediated DNA cleavage only in the trans configura tion.
This was particul arl y inter estin g becaus e cis- or trans-m ethyl substitution on the
piper azine had littl e effect on the acti vity against Gyr , sugg esting that only in the
mamm alian enzyme does an asy mmetric barri er ex ists which influences productive
quinolone intera ction. and favo urs the less bulky trans-3,5-d imethylp iperazine substi tuent
at C-7 [66]. Parallel studies demonstrated that compounds wit h C-7 pyrro lidine
substituents were more cytot ox ic than those with piperazine substituents [67]. This is
actually in line with obser vati ons made on derivati ves related to the ea rlier cytotoxic
quin olones [68]. Looking both at the stimulation of DNA cleavage and the cytotox icity
agai nst cultur ed mammalian ce lls, it was observe d that the presence of an aro matic gro up
contributed grea tly to dru g activity. In particul ar , 4'-hydroxyph enyl substituent at the C-7
position was found to be criti cal for potency towards the mamm alian To po 2 [64] . From
this series CP-1l5953, a 6,8-d ifluoro-7- (4'-h ydroxyph enyl)-I -cyclop rop yl-4-quinolone-
3-carboxylic acid was found to be the most cytotoxic quinolone deriv ative [62] .
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2.7.3 Quinoline/one derivati ves as topoisomerase inhihitors
Vosaroxin Figu re 2-9 [69) (formerly vorelox in) is an anticancer quinolonc
derivative that intercalates DNA and inhibits topoisomerasc II. inducing she-selective
double-strand breaks (DSR). G2 arrest and apoptosis. The quinolone-bascd scaffold
differentiates vosarox in from the umhracyclines and antbraccnediones . It has been
reponed that vosaroxin induces a cell cycle specific pattern of DNA damage and repair
that is distinct from anthracycline and doxorubicin [69).
"'iAur e 2·9: Structure ofVorcloxin.
In 1989. KyorinlKyowa-IIakko described thiazoloquinolone carboxy lic acids with
an impressive anticance r profile (Compound A. Ftgur e 2· 10) (70]. Th e clinical candidate
had exhibited favourable drug-like properties in different animal modcls in preclinical
studies.
Compound A. like other quinolone carboxylic acid derivatives. was presumed to
interact with topoisomerase II via its p-keto acid functional group by chclating with the
Mg2+ ion to inhibit the enzyme. Considering this mode of action. (711 we hypothesized
that a quinolonc with a Il-diketo functionality may be able to mimic the action of P-
ketoesrcr functionality. thus potentially providing the same level of complexity with the
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Mg2+ ion at the active site of the topoisomerase II. Also, due to the absence of free
carboxy lic acid, the target qu inolone may cause less gastric damage when used via oral
administration.
The design of target compounds was based on a structure-based design program
using the Hyperch em- 3™ molecular modelin g program. By applying Molecular
Mechani cs Optim ization (MMO) and Molecul ar Dynamic Option methods we were able
to identify linear tricyclic quinol ones with ~-diketo comp onents that matched the angular
feature of Compound A. In this respect , Compound B, 9-benzy l-7-f1uoro-3 -
hydroxyt hieno [4,5-b]quinoline-4(9H) -one, at its opt imized steric/energetic
confi gurat ion, was found to have the best match with a perfect 3-point ove rlay with
Compound A as depicted in Figure 2-10.
Compound B and its derivatives were synthesized in our group using the Gould
Jacob method. Thi s series of comp ound s displayed promising cytotoxic activity aga inst
several cancer cell lines [72].
Compound 611 also was designed to act in the same manner as compounds B and A
applying the most important structural features which is the coplanar ity of the ~-diketo
functionality.
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Figure 2-1I : Overlapping image of Compounds 6a (green color) and Kyonn/Kyowa
llakko compound (A-blue color) at the ATP binding site of IQZR.
Ftgu re 2-12: Compound 6a docked at the ATP binding site or IQZR .
))
These derivatives did not show cytotoxicity against cancer cell lines. We attributed
this finding to a solubility problem and effl ux pump mechanisms.
2.7.4 Signa l tr an sdu cers a nd act ivators cr tr anseription (STATs) inhibition
STATs are an important family of molecules that mediate signal transduction in cells
[74,75]. Accumulating evidence indicates that STAT family members play important
roles in carcinogenesis and, in particular. STAT] has emerged as a good target for cancer
therapy (76.7R]. Vcry recently, a high throughput screening approach allowed the
identification of the highly
Fluorinated quinolone derivative 17 (Rl'" R2'" F). Figu re 2-13. that inhibits the STAT]
pathway and causes cell apoptosls (ECw =4.6 IJM). Lead optimization with modification
of the phenyl moiety led to the identification of the -t-cyanopbcnyl derivative HI (Rl"-CN.
Rt"-II) with a 30-fold increase in potency (EC~o '" 170 nM) in which cell apoptosis
induction correlates well with inhibition of steady state and cytokine induced JAK and
STAT3 activation (79J.
•' ij1;ure 2-13: Structures of Compounds 17 and IN
J4
In a rece ptor -based virtual screening of around 70.000 compounds. some j -carboxy-
4(11f)-q uinolones were revealed to be human protein kinase CK2 inhibitors [80). Protein
kinase CK2 participates not on ly in the development of some lypes of cancer s but also in
viral infections and inflam matory failures, Thus . quinolones could be considered not only
poten tial antitumor, but also anti-infectious and anti-inllammatory drug s. The compounds
with high docking scores were selected for in vitro tests. and Compounds 19 and 20
displayed IC50 values of 0.3 and 1 pM. respectively. Thesc findings led to mvesrigaung
othe r derivatives of this class in order to dete rmine the effects of certai n subs tituent s on
theirinhibitory activity .
Ftg ure 2-14: Co mpoun d 19 : R1 =' R2", R~ =0 CL RJ =0 II and Compound 211 : R1 =0 R2 =0 II .
2.8 Q uinolon e scaffokl -based anlh'ira l age nts
Quinolines arc not new to the field o f antiviral agen ts. Previousl y reponed data on
their binding with bacte rial chromosome had strengthened the hypothes is that these drugs
cou ld also bind to the viral nucle ic acid. and prompted the investigation of their antiviral
activity 181. 86]
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Many structures cont ainin g the basic quin olone carboxy lic acid template and
different lipophil ic substituents were patented as antivira l agents : most of them were
tested against human immun odeficiency virus- I (HIV-I ) and were cla imed to be
effective in the treatment or prophylaxis of Acquired Immune Deficie ncy Syndro me
(AIDS) [87-89]. However, their mechanism of action was not reported.
2.8.1 Quinolone-bascd anti-HIV agents
An earl ier wor k done by Furusawa et al. [90], reporte d that several
f1uoroquino lones protect cells from HIV-mediated cytotoxic ity. The resu lts showed that
after of1oxacin 21 treatment, the protected cells were able to survive for an extra 3
month s without any loss in cell viability. The I-isomer of of1oxacin (DR-3355) [91] was
also reported to protect cells from HIV- l mediated cyto lysis in which the surviving cells
were unable to produce an infective virus and also lost expressio n of the CD4 antigen
[90].
The exac t mechanism of action of antiviral quinolones is still unknown . The
followi ng class ificatio n is done accor ding to the authors' post ulations .
Figure 2-15: Struc ture ofof1oxacin (Com pound 21).
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2.8.1.1 Int egration ofpro viral DNA into mR NA
S aba et al. [92] found that antibacterial fluoroquinolon es can exhibi t an tiv ira l
activi ty as we ll. An alogues , bearing a 8-difluoro methoxy - l-e thyl-6- fluoro- IA-di dehydro-
7-[4-(2 -me thoxy pheny l)- I-piperazi ny l]-4-oxoquino line -3-ca rboxy lic ac id (22), exhibited
ECso < 50 nM in chro nica lly-infec ted cells. Co mpo und 22 suppressed tum or necrosis
factor alpha (TNF-a)-induce d HIV- I express ion in latentl y in fected ce lls (OM-lO. l) and
cons titutive vira l produ ct ion in chronica lly -infected ce lls (MOLT-4/ IIIB) at a
concentration o f 0.8 mM . It wa s reporte d that Compo und 22 cou ld also inhibit HIV- l
antigen ex pre ss ion in OM- IO. l and MOLT-4/111B ce lls at the same co ncentra tion [92] .
Inh ibitors of this step, which is con sidered a crucia l step in Hl V replica tion. wi ll be ab le
to suppress Hl V rep lica tio n not only in acutely - but also in chro nica lly- infec ted cells
[93] .
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Figure 2-16: Struc ture of Co mpo und 22 .
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Z.8. I.Z Interf erence will, u pmt illtegratimrul target ofthe IJI V- J repticenon cycle
Much of the pertinent literature (94-96J has addressed the potential of 6-
aminoquinoline series to inhibit the IIIV replication cycle. The prototype was Compound
23. The synthesized derivatives showed very strong activity on IIIV-l acutely-infected
MT-4. CEM. and PBMCs cells. as well as on chronically infected Hun8. A potent
antiviral activity was also observed in latently Htv -t -infcctcd M/M cells at drug
concentrations as low as 40 I]glmL. This activity ",'as further continued in an in \ 'il'O
model for IIIV·\ latency. which provided encouraging evidence for the use of quinolones
in the control of IIIV- l infection [97J. The studies on the mechanism of action revealed
that 6.DFQs interfere with a postiruegrational target of the IIIV- l replication cycle.
Figure 2-17: Structure of Compound 23
Z.8.1.3 IIl V-I integrase intnbttors
IIIV·1 integrase (IN) [98.103 ). along with 1I1V· l reverse transcriptasc and IIIV· !
protease, arc essentia l enzymes for rctroviral replication and represent important targets
for interrupting the viral replication cycle. The UIV integrase catalytic cycle is illustrated
in Fi~ure2..s
IN is an attractive target because it has no counterpart in mammalian cells;
therefore . most IN inhibitors should possess high selectivity and low toxicity. Quinolone
derivatives. as a class of HIV-I inhibitors . have become of great interest due to their high
molecular versatilit y. easy synthesis at low cost and on a large sca le. and well-recognized
biochemical propertie s that make them very suitable phanna cophore structures. The first
quinolone -bascd structure Elvitcgravir (GS-9137) with very strong anti retrovira l
properties owe s its ant i-III V activity exclusively to the inhibitio n of the viral enzyme
jntegrase.
'" CI
' 0
Figu re 2-UI: Strucure of Com pound GS-913 7.
The quinolonc-based structure was also assumed to be the new phanna cophore for
designing new generation IIIV-I IN inhibitors. The dikcto acid moiety (j -kctonc .
cnofizab lc a -ketone . and carboxy lic acid) was believed to be essential for the inhibitory
activity of this series of intcgrasc inhibitors (101) and the structures of dikctotriazolc
(104J diketotetrazole (105) dikctopyrid mc [106) and 7-oxo-8-hydroxy-( 1,6)-
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naphthyridme (107, IO&J were repone d to be bioisos icres of the diketo acid
pharmacophore. It was found that the carboxyl ic acid could be replaced not only with
acid ic bioisos tcrcs. such as tctrazole and triaznlc groups, but also hy a basic heterocycle
bearing a lone pair donor atom. such as a pyrid ine ring. Also. The cnolizablc ketone at
the a-pos ition of diketo acids can be replaced with a phenolic hydroxyl group, indicating
that the a- enol form of each diketo acid is its biologica lly active coplanar conformation.
The -l-quinokme-J-g lyoxylic ad d 24 was treated as a new scaffold that maintained the
coplanarity of diketo acid funct ional groups. Interestingly. the a-quin olone-Lglyoxlic
acid and also its precu rsor a -quinolone-j -ca rboxylic ad d 25 showed integrase inhibitory
act ivity [101). The 4-quinolone-3-carboxylic acid only had two functional groups . a {/-
ketone and a carboxylic add, which were coplanar . This result showed that the coplanar
monokcto acid moti f in -l-quinolone-Lc arboxylic acid could be an alte rnative Itl the
diketo acid motif. and provided novel insight into the structural require ments and the
binding mode of this type of inhibitor [l 08J.
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Fi)!;urc 2-19: Structures of Compounds 24 and 25
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The emer genc e of resistant mutants aga inst ava ilable antiretrov iral drugs brings out
the need to develop new therapeutic targets. HIV integrase inhibitors open up a new way
as a promising class of antiretroviral drugs. They act by inhibiting the action of the
integrase, a vira l enzyme that inserts the viral genome into the DNA of the host cell
preventin g form ation of the provirus. The replicat ive life cycle of the HIV virus requires
the integration of viral DNA into genomic DNA of the host cell, a process which is
mediated by the viral protein integrase (IN). The developm ent of inhib itors of IN activity
constitut es a new challenge for the treatment of HIV- I infection . Diketoacid funct ionality
is critic al for enzyme inhibition . Their derivati ves as well constitute one of the most
successful classes of IN inhibitor s that exhibit potent strand transfer (ST) inhibition as
well as good antiviral activity. Recently [109] a series of potential HIV integrase
inhibitors deri ved from quin olone antibiotics was described . The structurally optimized
and highly potent monoketo Compound GS-9137 was ident ified as the most promising
candidate, exhibiting potent inhibitory activity aga inst integrase-catalyzed DNA strand
transfer. GS-9137 was show n to be well tolerated in healthy volunteers and HIV-infected
patients. Moreover, monotherapy resulted in substantial antivira l activi ty in infected
subjec ts. The agent is undergoing phase III clini cal eva luation for the treatment of HIV- I
infection.
Another IN inhibitor [110] GS-9160 has potent and selective antiviral activity in
primary human T-lymphocytes producing an EC50 of - 2 nM with a selectivity index
(CC50/EC50) of - 2000, but later on, GS-9160 suffered from unfavorabl e pharmacokinetic
properties .
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GS-913 7 GS·9160
Fil.\urc 2-211: Structures of Compound s GS-9 J37 and GS-9160
Diketoacid compound s (DKA) constitute a promising class of Ii IV IN inhibitors with in
vivo antiviral activity [111, 112). Styrylquinolines (SQ) are another group that are also
capable of IN inhibition (113,1 14). Several compounds of both classes arc under clinical
trials. S· J360 [115] or L·S70SI O (DKA) [116). or earl ier stages of drug development
projects. FZ.41(SQ) [117]. Comparison of these two classes shows some similarities. hut
they also differ in their inhibitory activity. Compound SQ I which is synthesized in an
attempt to mimic the DKA pharrnacophore in the styrylquinoline series, showed inactive
in vitro profile against IN 11181. On the other hand. this compound exhibited a significant
antiviral activity in the in vivo experiment [I 18J,
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Fi~urt'2-21 : Structures of Compounds [...8701'110. ..7....41. S- 1360 and SQ I.
Moreo ver. Engels I!I al (1191. described the microwave-assisted synthesis of
tluoroquinoloncnuclco sidcs 26, 27 and their evaluation as IIIV·I integrase inhibitors.
These compounds were proved to be inactive against IIIV-! replication at subtoxic
concentrations in the MT-4/Mrr assay.
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Accordingl y, the activity of quino lones is likely due to seque stration of divalent metal
ions within the IN act ive site in complex with viral DNA [121]. Although the
crystallograp hic structure of IN in com plex with vira l DNA has not yet been resolved, it
has been reported that Tn5 transposa se (Tnp), which belong s to the superfamily of
polynucleotid yl transferases as does IN, can be considered as an excellent surroga te
model for studying the mech anism of action of ST inhibitors [121] . In this context,
docking calcul at ions on these derivati ves together with 8-1360 were performed on the
Tn5 Tnp-DNA comp lex by followi ng the comp utational protocol descr ibed by Barreca et
al. [121]. In its best docking pose (conformat ion with the highest fitness score and
belonging to the most pop ulated cluster) , Elvitagravir presented the carbox ylate group.
hydrogen-bond ed to 1-/329, chelating the metal ion betwe en E326 and D97 and the fJ-
ketone oxyge n toge ther with the fluorine atom coo rdinating the other metal ion. It was
found that the bindin g mode proposed for Elvitagravi r was in accordance with its
mutation profile as well as with the pharmacophoric mode l for quinolon es recent ly
reported [120].
2.8.2 Quinolones as anti-HCY (Hepatitis C viru s) agents
Antiviral drugs can be classified into direct and indirect agents; the direct agents
target the structural comp onents or enzymes encoded by the virus while the indirect
antiviral agent s target the host cell components (immun omodu lators etc.) [122].
Inhibitors of the NS3 protease, the NS5 B polymerase, and the viral RNA arc the most
intensively explored antiv iral agents. The actual treatment of Hey will be a combination
of drugs of variable mechani sms in order to reduce the emergence of resis tance r122].
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Ftgure 2-23: Structure of Compound .\-782759
A-782759. a 2-(1-aminoquinolone-3-yl) benzothiadiazine derivative. was identified
as an inhibitor of HCV NS5B Rdk p [1281. The comb ination therapy between Hepatitis C
virus (HCV) polyme rase A-782759 with either Boehringer lngelheim HCV NS3 protease
inhibitor BILN-2061 or interferon (IFN) [129. 130] showed an interesting additive effect
to synergistic relationships over a range of concentra tions of two-drug combination s.
Treatment of IICV rcplicon with A-782759. 1F:,\or n1LN·21161 for about 16 days
resulted in dramatic reductions in IICV RNA (5.1. 3.0 and 3.9 log RNA copies.
respect!vely). Surprising ly, none of these compounds when tested atone showed any
rcplicon RNA reduction. Results showed that a monothcrapy with either drug alone
possibly results in development of resistant mutants . Howevcr, a combinat ion therapy
lowers the likelihood of resista nce development (1311.
Antiviral qu inolones are promising compounds in the search for new therapeu tica lly
effective agents. Dikcto functionality seems to play an important role in targeting the
viral enzymes .The information gained so far will be usefu l for future rational drug design
aimed at developing new compoun ds with optimized antiv iral activiry.
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2.9 Conclusion
The 4-quinolon e scaffo ld exhibits many pharm acol ogical profil es. Beside the
antibacterial aciv ity there are antii schemic, ani xo lyt ic, antitumor and antivi ral activities .
In this revi ew we have tried to highli ght the most imp ortant pharm acological act ivit ies
(antibacterial, anti tumo r and antiv ira l activ ities) . SA R studies revea led that very fine
changes in the main ske leto n as we ll as changin g the fused rin gs will effec tivel y affect
the pharmacoph ore pharm acological activity .
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Preface
The manu script deve loped for this chapter provides a desc ription of an extensive
synthesis of a new series of ring fused angul ar quin olin e derivatives based on a structure-
based design approac h. The chemistry. in vitro testing, docking experi ments and also,
structure elucidat ion using different instrumental analyses are descr ibed . A version of this
manuscript has been pub lished in Heterocycl es .
Abstract
Heteroc yclic sys tems with a quin oline nucleus represent the most spectacular exam ple of
privileged molecules in med icinal chemistry, as their biolog ical activities are modulated
by minor changes in structural features . Quinoline derivatives have been shown to
disp lay a wide spectru m of biologica l activities such as antibacterial. antifungal ,
antiparas itic, antiviral, cytotoxic and anti -inflammatory activit ies. In this study. several 7-
hydroxy-8-oxo-8 ,9-d ihydro benzo[h)thieno[2,3-b]quino line-9-carboxy lic acids were
designed, synthesize d, and were further subjec ted to chemica l reac tions such as
alkylation and anne lation. The synthesize d com pounds were also subj ected to docking
studies and bio logica l eva luation . This work was mainly designed to shed light on the
require ments needed for the quinoline nucleu s to act as an anticanc er agent.
Unexpectedly, the synthesized derivatives showed weak or no cytotoxicity again st cancer
cell lines and the increase in the extent of aromatic/co ndensed rings did not increase the
affini ty toward the do uble-stranded DNA . Our virtual screeni ng demonstrated that the
chelation with Mg2+ is a determining factor in the expected interac tion with
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Topoisomerases. Key synthetic issues, and crystallographic and docking studies are also
encountered in this chapter.
Keyword s: Thienoquinoline s, thiazoloquinolines, Topoisomer ase II, docking study,
angular quinoline.
3.1 Intro duction
Quinoline derivatives represent a major class of heterocycles. The quinoline ring
system occurs in various natural products, especially in alkaloids. Its skeleton is often
used for the design of many synthetic compounds with diverse pharmacological
properties [1]. The 4(1H)-quinolone-3-carboxylic acid is one of the most studied
quinoline-originated multivalent scaffolds that has been used in constructing a diverse
series of biologically-active compounds such as antibacterial, anticancer and antiviral
agents [2,3).
The benzo(h)quinoline s can be seen as being a structural analogue to the antitumor
benzo(c)phenanthridin es, or, as heterocyclic isomers of acridines and phenanthridine-
based antitumor agents [4).
In a search for novel small molecule heterocycles with potential antineoplastic
activity, a joint patent by the Japanese pharmaceutical companies Kyorin/Kyowa-Hakko,
describing thiazoloquinolone carboxylic acids with an impressive anticancer profile
(Compound A, Figur e 3-1) was of interest [5]. The clinical candidate compound had
exhibited favourable drug-like properties in different animal models in preclinical
studies.
70
Chapter J: Thleno !1.3-bjbe";.o!Ir!qui,,olille derivatives: design, s ynthesis . prellmlnury in vitro tllltl 111silica ~·t'l(~I'.
Compound A, like other quinolone carboxylic acid derivat ives, was presumed to
interac t with topoisomerase II via its p-keto acid functional group and che lation with the
Mg2+ ion to inhibit the enzyme. Considering this mode of action [6], it was hypothesized
that a quin olone with a p-diketo functionality may be ab le to mim ic the action of the P-
keto acid functionality in Compound A, thus potentially providing the same level of
complexity as the Mg2+ ion at the active site of the topoisomerase II. Also, due to the
absence of a free carboxy lic acid, the target quinolone may cause less gastric damage
when used via oral administration.
The target comp ound s were designed using the Hyperch em- Jj molecular
modelin g program . By applying Molecular Mechanics Opt imization (MMO) and
Molecular Dynam ic Option methods, we were able to identify linear tricyclic quinolones
with p-diketo comp onents that matched the angular feature of Compo und A. In this
respect, "Co mpound B", (9-benzy l-7-fluoro-3-hydroxy thieno [4,5-b]qu inoline-4(9H)-
one), at its optimized steric /energetic configurat ion, was found to have the best match.
with a perfect 3-point ove rlay with Compound A.
Compound B and its derivat ives were synthesize d in the Daneshtalab group using
the Gould-Jaco b method. This series of comp ounds displayed promisi ng cytotoxic
activity aga inst severa l cancer cell lines [7a,b].
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Fi~ lIrc 3-1: Different over lays of the struct ure of Compound A (dolled lines) and
Compound B (solid lines) .
During ini tial studies , we found out that the thiawloquinolonccarhoxylic acid
derivatives demonst rated anti-neop lastic activi ty even without the presence of the
required substituent at position 7 (aromatic & aliphatic amine substitucnts for compounds
targeting euokaryotic topo isomcrasc II) [8. 121. and also with the absence of mandatory
fluorine atoms at C-6 and C-R pos itions [10,12,13 ).
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Antitumor cytotoxic agent s possessing DNA-intercalati ve prop erties are
characte rized by the presence of a planar pharmacophore, generall y a tri- or tetrac yclic
ring system and one or two flexible subst ituent groups [14].
Compo unds possessing a large cop lanar aromatic chromophore are likely to
intercalate rever sibly to the doubl e-helica l DNA. Most derivatives are not obviously
related in any way except in sharing the exhibiti on of coplanar chromophores that favour
the intercalation ; for this reason they are designated as DNA intercalators. Moreover,
most cyto toxic DNA-intercalating agents involv e the inhibition of the enzyme DNA-
topoiso merase I or II [15].
Considering the above discu ssion, our first target was the annelation of a thien o ring
to the benzo[h]quinoline nucleu s in an angular pattern. In this context , we attempt ed the
syntheses of benzo[h ]thieno[2 ,3-b]quinoline deriv ative s.
As a startin g point , the synthes is of ethyl-7-hydroxy-8-oxo- 8,9-
dihydrobenzo[h]thieno [2,3-b]q uino line-9-carboxy late (6a) was attempted, as illustrated
in Scheme 3-1.
I-Nap hthyli sothiocyanate was used as a main starting material which , by reactin g
with dieth ylmalon ate and sodium hydride in acetonitrile, afforded the salt l a. This
intermediate was allowed to react with dif ferent reagents to give rise to intermediates 2.
Thermal cycli zation under vacuum enabled us to cyclize Compounds 2 in very good
yie lds (up to 80%) . Dieck man cycli zation on Compo und 3a afforded Compound 6a ,
saponification of which , yielded the carboxylic acid derivativ e 6b as depicted in Scheme
3- 1.
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6a 32% 6b 40%
Scheme 3· ) : Genera l synthesis scheme for Compound 6a
3.2 O-Alk)J al cd prod ucts
Alkylation reaction s were attemp ted on derivatives _' ll using either 1,3-
dibromopropanc or Mitso nobu reac tion condition s to obtain product s 3J!;and Ji, React ion
of Compound 3h with Diet hylsulfate gave rise 10 the O.alkylated deri vative 3h as shown
in Scheme 3-2 .
Schem e 3-2: Differen t O-alkylatcd deri vatives ofintermediate 3.
8 35%
Scheme 3-3: Synthesis of9-ey allo-7-hydro :>;y-S-oxo-R.9-dihydrobcnl.olh ]thicllo(2.3-
h]quinolinc 8.
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In order to prepare Compound H. deprotcction of Co mpou nd 31> was first n...-ccssary.
The deprotcction reaction was performe d using cone. lI el in dioxane to obta in the thiol
derivat ive ~ . Compo und -I was then subjected 10 alkylation using bromoaceronitrilc in
TH F for 4 hours followed by Dieckm an cyclization us ing sod ium ethoxide in ethanol to
yield Compound 8. as shown in Scheme .'·3.
DES (26eq)lK,COj KI
Dimelhy10< d"'lhyl sullale (1 eq .)lK,CO,lKI
H I
ox*CO'Et
=I .: S1'-_ ---"'----'---'----_
Scheme 3--1:Reactions on Compo und 6a.
C02EtROCH,,6c , eo%
R OC,H. , 6ct 65%
N-Alkylation reactions were attempted 0 11 Compound 6u using diethylsulfate in
different proportions and dihalopropane derivatives. Interestingly. all the reactions
formed the O-alkylatcd deriva tives as depicted in Sche me 3·~
An intensive investigat ion on the qui noline nucleus revea ls that the 4-pyrido ne-3-
carboxy lic acid component rema ins a commo n featur e of most inhibit ors of DNA g)TaSC
and topoiso mcrusc IV. Positions C-3 and C-~ (the [l-kcto acid group . collect ively) are
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considered nece ssary for the bindin g of quinolones to DNA gyrase in the ternary complex
[16].
It was found that replacement of the 3-carboxylic acid group of quinol ones with
isosteres such as sulfonic acid , acetic acid , hydroxamic acid , pho sphori c acid and
sulfonamides result ed in redu ced antibacterial activity [17] . One successful strategy for
the repl acement of the 3-ca rboxy lic ac id gro up with retained (or enhance d) antibacterial
activity empl oyed a ring-fu sed isothi azolone group [18]. Isothi azole moiety, either in
fused or isolat ed form s, has been frequently found to play an import ant role in various
biological activities such as anti-inflammatory, antifungal, antibiotic, antiviral,
cholestero l lowerin g, microbi cide and the producti on of agrochemica ls [19-25].
Our next strategy was based on annelation of the isoth iazole ring onto the quinoline
moiety constru cted in previous steps. In this context we tried the synthesis of
isothia zolob enzo[h]quinoline using the reported tran samin ation of 2-s ulfenamoy l-
benzoates with variou s amine s [26, 27]. We applied many report ed procedur es in order to
synthes ize the SNl-h [28 , 29] . The only success ful proc edur e was the reaction of the thiol
intermediate 4 with hydro xylamin e-O-sulph onic acid to yield the corres ponding
thioamino deri vati ve (5).
The use of hyd roxylamin e-O-sul fonic acid as a co ndensing age nt in the presence of
the ester group has been reported to yield an isothi azole ring [30- 32]. In our case, it only
yielded the thioamino deri vativ e which further underwent cycli zation to the targeted
isothi azoloquinolin e 7 using Dieckm ann cycli zation reaction conditi ons, as dep icted in
Scheme 3-5 .
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Scheme 3-5: Synthesis of 7-hydroxybenzo (h1I1.2]lhiazolo[5,4-h ]quinolin-8(91I)-one.
In another attempt 10 increase the hydrophilicity of the quinoline system, we
allowed Compo und 6a to react with hydrazine hydrate 10 yield the pcntacyclic
pyrazoloquinnlinc 9. The chemistry of pyrazoloquinolincs is well-established . This
system has proved to be a very attractive scaffold for medicinal chemists in recent years.
Pyrazoloquinolines have been extensively studied as bioacnvc compounds and are known
to possess remarkab le biological activities such as anti-cancer, anti-anxiety , anti-
inllammatory, anti-asthmatic , ccrebro-protcctivc and antiviral. among others. For many
of the activities. the molecular modes of actions are known 133).
The pemacyclic henzo(h)quinoline 9 was formed as a result of reaction of 6a with
hydrazine hydrate and cyclization in acetic anhydride solution as illustrated in Scheme .'\-
6. The structure of Compound 9 was confirmed by spectra l analysis and X-ray'
crystallography, as shown in "-i~u re 3-2
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Sch...me 3-l.: Synthesis of Q-acct}'1-9H-b.:nzo[hJpyra7.olo(3'A':4.5lthic:no(2.3-hlquinoJinc-
7.l o-diyl diacetate.
Fil:un ' 3-2: ORT EP Representation of the linear pentacyclic deri vative \}with 50%
probabi lity ell ipsoids.
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The synthesis of Compound 9 prompt ed us to further exp lore the effec t of
annelating dif ferent ring sys tems with quin ol ine-based building blocks whic h may
possibl y result in identification of novel polycyclic molecul es with potent ial bioact ivity.
In this contex t, we attempt ed the synthes is of lH- 3-th ia-ll c-azaazuleno [1,8,7,6c-6fJ
phenanthrene- I ,6(5H)-dio ne. In this struc ture, a thiazo loaze pinone moiety is annelated to
the benzo quinoli ne sys tem.
Since nalid ixic acid was reported by Lesher et al. (1962) [I ], pyrido ne carboxy lic
acid antibacterials have becom e an important class of the rapeut ically useful compounds.
Ofloxacin [34] (a tricycli c pyrid one carboxylic ac id, havin g an oxaz ine ring) is one of
these age nts . The oxyge n atom of the oxaz ine ring ofofloxac in was fou nd to give opti mal
antibac terial activity vs nitrogen. sulfur, or the carbon atom. Also, the tetracyclic
pyrido ne carboxylic acids having a thiazo lo-oxazi ne ring [35]. as shown in structure C.
have proven to imp rove antibac teria l activity aga inst both Gra m-posi tive and Gram-
negative bacteri a.
o 0FYX'I OHN ~ N/0 O~S Hel
In the above study, repl acement of the oxyge n atom of the thiazolo-oxazine ring by
nitro gen , sulfur, or a carbon yl group was attempt ed. The antibac teria l assessment of the
resulting compounds reveale d that the replacement of an oxyge n atom of the thiazolo-
oxazine ring by a nitroge n atom enhance d both in vitro and in vivo antibac teria l activit y.
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I'he synthesis of Compound t t was achieved via the reaction of Ia with 4·
chloroethylacetoacetate. followed by thermal cyclization under vacuum to afford
Compoun d 10. Compound to was subjected to cycliza tion using I'I' A, to yield the novel
phenanthrene derivative It .
&to C;(CO,EI:Y I 2 Jl:Y I ~ $ Na+~ H ClCH,COCH,CO ,C,H,ffHFIrt/12 h
10 50%
$,0,N S: 1 .-
a
11 29%
PoIyphosph oric&cid ll50 "CJ3h
Scheme 3·7 : Synthes is of 11/-3-thia- I Ic-azaazulc no] \' 8,7,6-eJ eflphcnanthrene' 1.6(51I).
dion c I I .
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Fil:un' 3-3: ORTEI' representation of Compound 10 with 50% probability ellipsoids.
.13 Materials and method s
.1.3.1 /" )'ilrtJ testinl:
3.3. /. 1 Brim! shrimp lelllalily bioassay (BS LJ
The determination of toxicity of the compounds against brine shrimp was conducted
according to Meyer' s procedure 136], with minor modificat ions. Toxicities of compounds
were tested at 0.2,10,100, and 1000 ug/ml, sea-water solutions with 1% DMSO [v/v},
Ten one-day nauplii were used in each test tube and the percentage of the survivors was
measured after 48 h. Three replications were used for each concentration.
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3.3. J.2 MTT c)' ltJtox i ci t)' hi llu_na)'
The general principle for the detection of cell growth or cell kill via the Mn
cytotoxicity assay is the conversion of the yellow-coloured tetrazolium salt (MIT) to the
purple-coloured product formazan. The concentration can be measured photometrically at
570 nm. The formation of formazan takes place via intact mitochondria
The most cytotoxic derivatives were tested against lIel.a and KB cell lines using the
MIT cytotoxicity bioassay [37,381.
Q
~~N~NXo N 5
B'
MTT, yeliow
mi lochon driil l enzyme
Fonn u iln , purp le
Hel.a cells. human cervix adenocarcinoma. were grown in D~fEr-.1 (GIBCO) with
15% FBS and antibiotics (penicillin 100 Ulml. streptomycin 100 uglml). Cells were
maintained at 3TC in a humidified 5% COl atmosphere.
Cells were trypsmizcd and seeded into 96-well cell culture plates as 180ullwell
(about 5000 cells/well). After 16 h incubation. the cells were treated for 48 h h)' the
compound at final concentrations of 100. 10. I. 0.1 /-lg 1m !. The compounds were
prepared in DMSO (stock solution of 10 I-lglml) and further diluted with culture medium
to obtain the desired concentrations. All tests included controls with equivalent
concentrations of media OMSO corresponding to the relevant dilutions of the test
compound, The 3-(4.5-dimeth)'lthiazo l-2-yl)·2.5.diphellyl tctrazolium bromide (MT f)
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was added in the fina l concentratio n of I mg/ml , and 30 ul/well . After 4 h incubat ion
the MTT- formaza n prod uct was solubilized using DMSO (150 ul/well) with sha king for
10 min. The absorba nce measurements were carrie d out using a microplate reade r at 570
The weak cytotox icity on HeLa and KB cell lines by the most cytotoxic der ivatives
in the BSL bioassay prompt ed us to explore the possibilit y of these derivatives to act as
topoisomerase inhibitors theoret ically.
3.4 Mo lecular mode ling
3.4.1 Met hods
Dockin g ca lculations were car ried out acco rding to the Dockin gServer methodology
[39]. The MM FF94 force field [40] was used for energy minim izat ion of the ligand
molecules using DockingServer. PM6 semi-empirical charges calculated by
MO PAC2 009 (J. P. Stewa rt, Computer code MOPAC2009, Stewart Computationa l
Chemistry, 2009) were added to the ligand atoms. Non- polar hydroge n atoms and
rotatab le bond s were defined.
Dockin g calcul at ions were carried out on the topoisomerase II structure with the
pdb code IQZR. Essential hydro gen atoms, Kollm an united atom type charges, and
solvation parameters were added with the aid of AutoDock tools [41] . Affinity (grid)
maps with 25x25 x25 A grid point s and 0.375 A spacing were generated using the
Autogrid program . AutoDock param eter set- and distance-dependent dielectri c funct ions
were used in the calculation of the van der Waals and the electros tatic term s, respectively.
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Dockin g simulations were performed using the Lamar ckian genetic algorithm
(LOA) and the Solis & Wets local search method [42] . Initial position, orientation, and
torsions of the ligand molecules were set randomly. Each docking experime nt was
derived from 100 different runs that were set to termin ate after a maximum of 2,500 ,000
energy eva luations. The popul ation size was set to 150. Durin g the searc h, a translational
step of 0.2 A,and quaternion and torsion steps of 5 were applied.
3.4.1.1 Human topoisomerase JI docking
Topoi somera se II is an ATPase belonging to the OHKL (Gyrase, Hsp90, histidin e
Kinase, mutL) famil y. The mechanism of function of human toposiomera se II is to
simultaneously cut both strands of the DNA helix using the energy derived from ATP
hydrol ysis. The inhibiti on of human topoisomerase II is one of the targets of current
oncology research . There are seve ral ways to inhibit the enzy me's action [43]:
I-While exert ing its funct ion, the enzyme creates a transient cova lent DNA-enzyme
complex. To poisomerase II poisons exert their effec t by stabilizing this transient
complex, thus cau sing DNA damage. Since these compounds are very toxic to normal
cells, alternative ways of topoisomerase II inhibition are subje cts of interest in drug
research.
2-An alternative way of inhibiti on is to block the enzyme before the DNA cleavage
step or in the last step of its catalytic cycle. The competiti on for the ATP bindin g site as
well as stabilization of a transient dimer interface between two ATPase monomer s have
been described [42,44]. Neverth eless, these ways of inhibiti on take place at the ATPase
region of the protein. Among the ava ilable structures of the human topoisomerase II
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protein , Ipy a and IQZR carry the ATPase region. Additionally, Ipya contains
modified methionine residues (MSE) , while IQZR contains phosphoaminophosphonic
acid-adenylate ester (A P) at the ATP binding site and an inhibitor ICRF-187 at the
interface of the homodimer. All our docking calculations were done using IQZR .
3.4.1.2 Docking experiment
In orde r to define possib le binding sites in the protein, the known human
topoisomera se II inhibit or, Co mpound A, was docked into the crysta l struct ure . First, a
blind dockin g procedure was applied. The dockin g result showed no clu ster possessing
significa ntly higher frequency or lower energy as compared to the other clusters. Thus,
blind docking in this case was not able to clearly defi ne the possib le bind ing site .
Therefore, biochemical knowledge was used for binding site identification. The cluster
possessing the highest interaction surface between the docked ligand and the protein
indicating strong binding was located at the ATP binding site. one of the results were
found at the inhibitor's (ICRF-187) binding site. Thus, focused docking calculations were
carried out at the ATP binding site of the protein.
3.4.1.3 Focused docking results
Compound A was subjected to focuse d docki ng calcu lations at the ATP binding site
of the prot ein with docki ng energy equal to -7.39 kcallmol.
All comp ound s were ca lculated to bind at the ATP bindin g site with reasonable
af finity, with 6:1 possessing the lowest dockin g energy . It is noted that in the X-ray
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structure Mg+2 is coordinated by 3 oxygen atom s coming from ANP. Compound A is also
able to donate non-bond ing electrons to the I\lg 2+ ion.
Tahl t· J -l : Docking energie s of the investigated compounds at the ATP binding site.
Com pou nd Uockin~ energy (kcall mo l)
6a -9.21
9 ·9.1 9
6b -9.00
6, · 8.64
6d -8.29
II · 8.24
6f -8.04
7 -7.94
8 -7.88
6, ·7.76
10 -7.76
Fi~u rc 3-4: COOlJXlUnd 6a docked at the ATP bind ing site of l QZR.
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Tabl e 3.1 shows the calculated interaction energies at the ATI' binding site. The
estimated binding energies can he used to rank the ligands according to thcir binding
affinity.
I' igun: 3-5: Overlapping image of Compounds 6a (green colour) and A (blue colour) at
the ATP binding site of IQZR.
Compound 611 indicates a hydrogen bonding interaction with ASN70 and LYSI47 .
Namely, the amino group of ASN70 hydrogen-bonds to the aromatic nitrogen and rhe
prutonatcd nitrogen of LYS147 hydrogen-bonds to the ester carbonyl of 6a . The aromatic
planar ring system of 6a is stab ilized by a number of hydrophobic interactions with
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surrounding hydrophobic amino ac id residu es at the binding site : [LE67, [LE120,
ALA 71, VAL 197 and with the aro matic side chai n of PH E 121. [t is important to note that
none of the comp ou nds used in the dockin g studies were invo lved in interactions with
Mg2+, in contrast to Co mpound A.
Focused dockin g ca lculat ions at the ATP binding site revealed that the investigated
compounds are able to bind to hum an topoisomerase II with a reaso nab le binding affinity .
The main dif ference between comp ound A and the investigated compounds is in its
abi lity to coordi nate with the Mg2+ ion and that ex plains the potent cytotoxic and
topoisomerase II inhibito ry effect of compound A, compar ed to the weak cytotoxic
effects demonstrat ed by the comp ound s synthes ized in our study .
3.5 Result s and discu ssion
3.5.1 Brin e Shr imp Lethality bioa ssay result s
The numb er of shrimps surviving afte r 48 h exposure to compounds were co unted,
and based on that, the percentage inhibition was eva luated. The 50% lethal conc entr ation
(LC so) was ca lculated, which is presented in Table 3-2 using taxo l as a reference
standard. The percentage mortalit y at each vial and co ntro l was det ermined using the
equation:
'Yomortality = (no . of dead nauplii/ initial no. of live nauplli) x 100
Prob it ana lysis by Finney (1971) was used to deter mine thee oncentration at which
lethality to brine shrimp represents 50% (LCso).
The resu lts showed that only three of the synthes ized derivati ves (6a , 7, 8) were
considere d as cytotoxic (less than 100 ug/m l.). The Brine Shrimp Letha lity bioassay
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represents a rapid, inexpen sive and simple bioassay method which in most cases
correlates reasonabl y well with cytotoxic and antitumor properti es.
Ta ble 3-2 : Brine shrimp lethality bioassay results.
Struc ture no. LCso (ug/ ml.)
6a 50
6b 500
6c > 1000
6d > 1000
6e 850
6f 920
7 70
8 95
9 950
10 > 1000
Taxo l 0.2
3.5.2 MTT Cyto tox icity result s
The viability was calcul ated with regard to the untreated cell control, which was set
to 100% viability. A lysis control where the cells were treated with Doxorubicin was set
to 0% viability, and was found to be sufficient to induce 100% cell death .
Table 3-3: Results of cytotoxicity testing against J-IeLa and Kb cell lines.
Structure no. HeL:l-ICso(uM) Kb-I Cso(uM)
6a 17.7 20.67
7 >30 27.29
8 22 24.4
Cytotoxicity assessments were performed at Taiho and Naeja pharmac euticals.
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3.6 Conclusion
The qu inoline system i s considere d an attrac tive scaffo ld upon which to bui ld
chem ical librari es with promi sing bioactivity potential s. Its uniqu e structura l feature has
prompted scientists to design, synthesize, and eva luate different quinoline-based
structures which exhib it diverse biological activities.
In this study, novel polycyclic quinoline-based molecu les were designed having a
structural relationship to a molecule that is currently under clinica l investigation as an
antineoplastic age nt. The structure-based molecular modelin g approac h led us to ethyl-7-
hydroxy-8-oxo-8 ,9-dih ydroben zo[h]thi eno [2,3-b]quin oline- 9-carboxylate (6:1). A series
of 6:1analogues was synthesized and tested for cyc totox icity agai nst diffe rent cancer cell
lines. The test results revea led a lack of cytotoxic potenc y for these compounds. In order
to rationalize the non-toxic profile of these compo unds, docki ng experiments with the
topisomerase II protein structure were eva luated using "Co mpo und A" , as a standard-
reference topoisomerase II inhibit or. The dockin g experiments revealed that while the
synthes ized compounds interac t with the protein carrying the ATP binding region, they
do not coordinate with Mg2+ ion. However , whi le Compo und A forms a stable
coordination comp lex with the Mg2+ ion. this could possib ly exp lain the weak
cytotox icity demonstrated by the synthesized compounds. Further bioas says of these
compounds to find other potenti al bioactivities are ongo ing in the Daneshtalab group.
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3.7 Exper imenta l
Solvents and reagents were obtained from commercial supplie rs and were used
without further pur ificat ion . Meltin g points were not optimized . ' H and 13C NM R spec tra,
HSQC, and COSY spectra were recorded on a Bruker AVANCE-500 MHz NM R
spectrometer using TMS as an internal standard. Mass spectra were obtained on an
Agilent 1100 series LC/MS O chromatographic system. High-resoluti on mass spectra (EI
or ESI) were obtained on Waters GCT Premie r Microm ass Spectrometer. X-ray
structures were measured with a Rigaku Saturn 70 instrument, equipped with a CCO area
detector and a SHIN E optic , using Mo Ka radiation. Silicycle Ultrapure silica gel (0-20
urn) G and F-254 were used for the thin- layer chrom atography (TLC), and Silicycle Silia-
P Ultrapure Flash silica gel (40-63 urn) was used for flash column chromatography. TLC
was conduct ed on Polygram SIL GlUV25 4 precoated plastic sheets. The reaction yields
are includ ed in correspond ing schemes .
Sodium 3-ethoxy-2-(ethoxycarbonyl)- l -(naphthalen-I-y larnino )-3-oxopro p- I-ene- l -
thiolate (La):
To a suspension of sodium hydride (0.60 g, 25 010101) in MeCN (50 .00 mL) at 5- 10 °c
was added dropwi se diethyl malonate (4.00 rnl. , 26.34 010101) ove r a period of 15 min.
The mixture was stirred at 5- 10 °c for 30 rnin., then I-n aphth ylisothi ocyanate (5.00 g,
26.99 010101) was added portionwi se at the same temp erature, and stirring was continued
for extra 30 min. Evaporation of MeCN yielded a yellowish solid which was washed with
EtlO; mp 118-120 °C; IH-NM R: (500 MHz, OMSO-d6) : 0 = 12.33 (s, NH), 8.57 (d, J =
7.1 Hz, IH), 8.16 (t, J = 7.7 Hz, IH), 7.9 1-7.86 (01,1H), 7.52 (ddd, J = 4.7, 11.1, 8.8 Hz,
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3H), 7.46-7 .38 (rn, IH), 4.02 (q, 2 X 0 .GlliCH 3, J = 7.0 Hz. 4H), 1.16 (t, 2 X OCH&..lli,
J = 7.0 Hz, 6H); 13CNMR ( 175 MHz, DMSO -d6) : I) = 181.6, 166.4, 136.1, 132.5, 127.0,
126.6, 124.3, 124.2, 123.9, 121.2, 120.6, 119.4, 116.8, 95.2, 56.8 (2CH 2), 13.3 (2CH3);
APCI-MS: 368.40 (M++I , 100).
Ethyl 2-[(ethoxy met hyl)thio]-4-hyd rox)'benzo[h[quin oline-d-carboxylat c (3a):
To the above yellow solid (La, 2.00 g, 5.44 mmol) in THF (50 mL) was added
BrCH2C02Et (0.60 ml. , 5.44 mmol ) dropwis e at 0 °c and stirring was continu ed for an
extra hour at room temperature, evaporated the solvent, extracted with CHCb and dried
over Na2S04. The organic layer was evaporated by rotar y evapor ator to give yellow oil
(2a) . The obtained oil was heated at 170-180 °c in an oil bath under vacuum for 10 min .
The resultin g oil was so lidified, then washed with ether result ing in (3a) as colourless
needle s; mp 136- 138 °C; IH-NMR: (500 MHz, CDCb) : I) = 13.11 (s, IH , OH), 9.22-9 .15
(m, IH), 8.10 (d, J = 8.9 Hz. IH), 7.89 (dd, J = 3. 1.6.0 Hz, IH ). 7.76-7.68 (m, 3H).
4.61 (g, J = 7.0.6.9 Hz, 2H). 4.22 (g,J = 7.0, 6.9 Hz. 2H), 4.13 (s, 2H), 1.60 (t,J = 7.0
Hz, 3H), 1.29 (t, J = 7.0 Hz, 3H); 13C NMR (175 MHz, CDCI3): I) = 170.9, 170.4, 168.2,
158.1,147.6,1 35.8,130.6,1 29.4,1 28. 1,1 27.1, 126.2, 125.9, 119.9, 115.1, 104.0,63 .2,
6 1.9, 34.6, 14.6, 14.6; HR-MS (TOFEI) calcd for C2oHI9NOsS (385.0984); found
(385.099 1).
Ethyl 2-[(etho xymcthyl)thiol -4-hydro xybcnzolhlquinolinc-3-clIrboxylat e (3b):
This compound was prepared according to the same procedur e as that appli ed for 3a
using chiorometh yl ethyl ether; yellow crystals; mp 120-1 22 °C; IH-NMR: (500 MHz,
CDCb): I) = 13.11 (s, IH), 9.26-9.19 (m, IH), 8.13 ( d, J = 9.0 Hz. IH), 7.91 (d, ./ = 3.3
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Hz, IH), 7.75 (d, J = 9.0 Hz, I H), 7.72 (dd, J = 3.2, 6.1 Hz, 2H), 5.76 (s, 2H), 4.60 (q, J
= 7.1 Hz, 2H), 3.76 (q, J = 7.0 Hz, 2H), 1.59 (t, J = 7.0 I-Iz, 3H), 1.25 (t, J = 7.0 Hz,
31-1);I3C NM R ( 175 MH z, CDC!): 0 = 171.1 , 168.3, 158.2, 147.4 , 135 .8, 129.4 , 128.2,
127.3, 126.2, 125 .7, 120 .0, 115.1, 104.3, 71.4 , 65 .7, 63.1, 3 1.2, 15.4 , 14.6; I-IR-MS
(TOFE I): calcd for CI9HI9N04S (357.1035); found (357.103 1).
Ethyl 4-hydr oxy-2-(mcthylthio )bcnzo l"Iquinolin c-3-carbo xylat c(3c):
Prepared accor ding to the method applied for 3b, using Iequiva lent Me l; ye llow powder;
mp 158-160 DC; IH-NMR: (500 MHz, CDC!) : 0 = 13.09 (s, 11-1 , OH), 9.22-9 .16 (m,
IH), 8.10 (d, J = 8.9 I-Iz, IH), 7.87 (dd, J = 2.8, 6.0 Hz, IH ), 7.71 (d, J = 8.8 Hz, IH ),
7.69-7 .65 (m, 2H), 4.57 (q, J = 7.2 Hz, 2H), 2.81 (s, 3H), 1.57 (t, J = 7.25 Hz, 3H); 13C
NMR (175 MH z, CDC!): 0 = 170.9, 167.7, 160.1. 147.0, 135.4 , 130.4 , 128.9, 127.8,
126.7, 125 .4, 125.3, 119.6, 114.2, 103.7, 62.6, 15.1, 14.2; I-IR-MS (TOFE I) calc d for
C 17l-1l sN0 3S (3 13.0773); found (3 13.0779) .
EthyI 4-hydroxy-2-1(4-mcthoxybcnzyl)thio)bcnzo [IIIquinolinc-j-carboxylat e (3d) :
Prepared acc ordin g to the met hod applied for 3b , using I equivalent P-MeOBn CI;
co lourless crystals; mp 135-136 DC; II-I-NMR: (500 MH z, CDC I3) : 0 = 13.14 (s, IH,
0 1-1),9.16 (dd, J =8.2, 5.9I-1z, 11-I), 8. 10 (d, J =9.0 Hz, IH ), 7.88 (dd, J =6.7,2.4 Hz,
IH ), 7.75-7.69 (m, 11-1). 7.66 (dt, J = 7.0, 3.9 Hz, 2H), 7.43 (t, J = 5.8 I-Iz, 21-1), 7.25 (s,
I H), 6.85 (dd, J = 9.2, 2.5 Hz, 21-1), 4 .70 (s, 21-1), 4.53 (q, J = 7.1 I-Iz, 21-1), 3.83 (s, 3H),
1.50 (t, J = 7.2 Hz, 31-1); I3C NMR (175 MHz, CDC !) : 0 = 170.8, 167 .8, 159.7 , 158.7,
147.0,1 35 .5,130.4,130.3,1 29 .7,1 29.0, 127.8 ,1 26.8, 125 .5, 125.3, 123.1, 121.2, 119.7,
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114.5, 114.0, 103.5, 62.7, 55.2, 35.4, 14.3; H R-MS (TOFE I) calcd for C24H2,N04S
(419.119 1); found (4 19.119 1).
EthyI 4-hydroxy-2-{I(2Z)-3-phenylprop-2-en- l -yl] thio } benzojs] quinoline-3-
carbo xylat e (3e):
Prepared according to the method applied for 3b, using I equiva lent CICI-hC6HsCH=CH;
white powder; mp 157-159 °C; ' H-NM R: (500 MHz, CDC!}): 0 = 13.13 (s, 1H, OH),
9.21 (rn, IH ), 8.12 (d, J = 8.8 Hz, IH), 7.91 (m, IH), 7.74 (d, J = 9.1 Hz, IH) , 7.71
(2H, m), 7.35 (d, J = 7.2 Hz, 2H), 7.26 (m, 3H), 7.20 (d, J = 7.2 Hz, IH ) 6.76 (d, J = 7.5
Hz, IH)" 4.58 (q, J = 7.1,7.0 Hz, 2H), 4.28 (d, .1= 5.6 Hz 2H), 1.56 (t, J = 5.8 Hz, 3\-1);
13C NMR (175 MHz, CDCl3): 0 = 165.6,1 62.6,1 53.8, 14 1.8, 13 1.8, 130.2, 127.6, 125.2,
123.8, 123.2, 122.6, 122.2, 121.6, 12 1.1, 120.5 , 120.3, 120.0, 119.1, 114.4, 109.2, 98.4,
57.5, 28.7, 15.0, 9.0; HR-M S (TO FEI) calcd for C2sH2,N03S (4 15.1242); found
(415.1246).
Ethyl 2-(benz ylthio )-4-h ydrox ybenzollt] qulnolinc-Lcarboxylnt e (31):
Prepared according to the method applied for 3b, using I equiva lent BnCI; white
crystalline product; mp 130-132 °C; ' H-NMR: (500 MHz, CDC!}): 0 = 13.07 (s,1H, OH),
9.10 (dd, J = 8.3, 6.6 Hz, IH), 8.09-8.04 (rn, IH), 7.88-7.82 (m, IH ), 7.68 (d,J = 8.9 Hz,
2H), 7.66-7.59 (m, IH), 7.52 (d, J = 7. 1 Hz, 2H), 7.36-7.29 (rn, 2H) 7.28-7.22 (m, IH),
4.73 (s, 2H), 4.52 (q, J = 7.1 Hz, 2H), 1.49 (t, .1 = 7.0 Hz, 3\-1); I3C NMR ( 175 MHz,
CDC!}): 0 = 170.8, 167.8, 159.4, 147.0, 138.0, 135.5, 130.3, 129.2, 129.0, 128.5, 127.8,
127.0, 126.8, 125.6, 125.3, 123.2, 121. 1, 119.7, 114.5, 103.5, 62.7, 35.9, 14.3; HR-MS
(TOFE I) calcd for C23HI9N0 3S (389. 1086); found (389.1093) .
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Ethyl 4-(3-bromopropoxy)-2-( (2-ethoxy-2-oxoethyl)thio)benzolh [quinnline-Sv
carboxylate (3g) :
To a mixture of the quinoline derivative 3a (0.385 g, 1.00 mmol) and K2C0 3 (0.386 g,
2.800 mmol) in dry DMF (25 mL) under nitrogen atmosphere, 1,3-dibrom opropane
(0.565 g, 2.80 mmol) and KI (catalytic amount) were added. The reaction mixture was
heated at 70°C for 24 h, then poured into ice-Hjf) , the resulting product was collected by
filtration and recrystalized from hexane.Cl-lCl, (I :3) resulting in a white powder; mp
162-164 °C; 'I-I-NMR: (500 MHz, CDCI3): 8 = 9.21-9. 14 (m, IH), 7.95 (d, ./ = 8.9 Hz,
11-1), 7.91-7.85 (m, IH), 7.76 (d, ./ = 8.9 Hz, IH), 7.70 (m, 2H), 4.53 (q, ./ = 7.1 Hz, 21-1),
4.35 (t, ./ = 5.8 Hz, 2H), 4.22 (q, ./ = 7.1 I-Iz, 21-1), 4.15 (s, 2H), 3.70 (t,./ = 6.4 Hz, 2H),
2.42 (q, ./ =6.1 Hz, 2H), 1.49 (t, ./ = 7.1 Hz, 3H), 1.27 (t, ./ = 7.1 Hz, 31-1); I3C NMR (175
Ml-lz, CDCb) : 8 = 162.1, 160.6, 160.2, 153.7, 148.0, 134.2, 130.2, 129.0, 127.6, 127.0,
125.9, 125.4, 119.9, 115.8, 113.8,70.9, 70.0, 6 1.2, 33.8, 29.8, 25.0 . 14.4. 14.3; APCI-
MS: 506.40 (M++ I, 100).
Ethy I 4-ethoxy-2- I(ethoxymethy l)th io)benzo lh lquinoline-3-cllr boxyla te (3h) :
Utilizing the same alkylation procedure as applied for preparation of 3g using
diethylsulfate starting from 3b ; white crystals; mp 80-82 DC; ' H-NMR: (500 MHz.
CDCb) : 8 = 9.17 (rn, IH), 8.07 (m, IH), 7.98 (dd, ./ = 9.0,22.2 I-Iz. 2H), 7.81 (m, 21-1),
5.76 (s, 2H), 4.46 (q, ./ = 7.0 Hz, 21-1), 4.29 (q, ./ = 6.9 Hz, 2H), 3.6 1 (q, ./ = 7.0, 2H), 1.45
(t, ./ = 6.9 Hz, 3H), 1.39 (t,./ = 7.1 Hz, 3H), 1.11 (t, ./ = 7.0 I-Iz, 31-1) ; 13C NMR (I75Ml-lz,
CDCb) : 8 = 166.2, 163.2, 160.7, 154.9, 147.3,1 34.9,1 32.9, 131.9, 129.1, 128.9, 127.0,
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125.2,1 20.1,11 9.5,11 8.8, 72.1 , 65.3, 62.9,1 6.3,15 .6, 14 .8; HR-MS (TaFEl) caled for
C21H23NS0 4 (385.1426); found (385.144 1).
Ethy l 4-(b en zy loxy)-2- [(2- eth oxy-2 -oxoethyI)thioJben zo [" Jqu inoline-3-ca rb oxy la tc
(3i):
A 250 m L round botto m flask was charge d wi th triphenylp hosph ine (2.70 g, 10.30
mmol) to which was added 70 m L T HF . Th e resulti ng clear solution was coo led to -78 °C
and DEAD ( 1.63 ml., 10 .30 mm ol) was added over 5 min . The ye llow reac tion mixt ure
was stirred for ex tra 5 min after which benzyl alco hol ( 1.169 mL , 11.30 mm ol) was
added and stirre d for 5 m in. Neopen tyl aleo ho l (0.50 g, 5.70 mm o l) and 3a (3 .96 g, 10.30
mmol) wer e add ed sequentia lly to the react ion mixtu re as so lids . The resulting
suspension was allowe d to rem ain at _78°C for 5 min durin g whi ch most o f the starting
materi al dissol ved. The coo ling bath was then remove d and the reaction was stirred
ove rnight at roo m tem pera ture, T LC indicated co mp lete cons umption of the reactant. The
clea r solution was co ncen tra ted to approxima tely Y.of the orig inal vo lume under vaccum
then applied to a si lica gel co lum n and eluted with 5:1 hexane/EtOAc resu lting in a whit e
crys ta lline produc t; mp 105-1 07 °C; IH-NM R: (500 MHz, CDCb): 6 = 9.08 (rn, IH ),
8.05 (m, IH ), 7.94 (m, 2H,), 7.81 (rn, 2H), 7.79 (m, 2\-1), 7.4 1 (rn, 3H), 5.26 (s, 2H), 4.44
(q, J = 5.3 Hz, 2H), 4 .25 (s, 2 \-1), 4.12 (q, J = 5.1 Hz, 21-1), 1.35 (t, J = 6.8 Hz, 3H), 1.21
(t, J = 7.5 Hz, 3H); IJC N M R ( 175 MH z, CDCb): 6 = 166.2,1 60.6, 154 .9,147.4,1 34 .3,
130 .6, 128.7,1 27 .8, 127 . 1, 126. 6, 124 .9, 119.4, 118.5(8 carb ons), 7 1.9, 7 1.2, 65 .1, 62. 1,
15.7,1 4. 9, 14.1 ; HR-M S (TaFEl) caled for C27H2SNO sS (475 .1453) ; found (475. 1458) .
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Ethy l 2-[ (3-chloro-2-oxop ropy l)th io]-4-h ydroxybcnzollt [quinolin e-Lcarboxyln te
(3j) :
Uti lizing the sa me alky lation procedure as app lied for preparation of 3 b using 1,3 -
dichloroa cetone; ye llowis h brown powder; mp 98- 100 °C; IH-NM R: (500 MHz, CDC b ):
8 = 13.09 (s, OH ), 8.93 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.9 Hz, IH), 7.89 (d, J = 7.3 Hz,
IH ), 7.79-7.69 ( m, 3H), 4.61 (q, J = 7.16, 7.17 Hz, 2H), 4.40 (s, 2H,), 4.32 (s, 21-1), 1.58
(t, J = 7.1 Hz, 31-1); 13C NMR (175 MHz, CDCb): 8 = 169.3,1 68 .0, 164 .3,157.4,1 46.21 ,
134.6, 129.3, 129.2, 127. 8, 126.9, 125.8, 124.6, 119.1, 114.3, 105.4, 35 .6, 33 .3, 14.0,
13.9; HR-MS (TO FEI) calcd for C I9HI6CIN04 S (389.0489); fou nd : (389 .0495).
Ethy I 2-I(cya nomethy l)th io]-4-hy d r oxy benzo llt ]quinolinc-3-ca r boxy hlte (3k) :
To a stirring so lution of 4 (0 .80 g, 2.67 mmol) in Tl-IF (10 mL) and H20 (40 mL) was
added Na HC0 3 (1.0 g, 7.23 mm ol), and stirred for 15 min ., then brom oaceton itrile (0.50
g, 4.16 mmol) was added to the resulting so lution and stirred for 4 h at room temperature.
After co mpletio n of the reaction, the so lution was ac idified by ace tic ac id, extracted with
chlorofo rm , dried over Na2S0 4, filtered to give 3k as a white pow de r; mp 208-2 10 °C;
II-I-NM R: (500 Ml-lz, DMSO-(h ): 8 = 12.42 (s, 11-1, OH), 9.26-9 .2 1 (01, 11-1),8.12 (d, J =
8.8 I-Iz, 11-1),8.10- 8.07 (01, 11-1),7.97 (d , J = 9. 1 Hz, IH ), 7.82 (01, 2H), 4.53 (q, J = 7.0
Hz, 2H), 4.4 3 (s, 21-1), 1.45 (t, J = 7.1 Hz, 31-1); 13C NM R (17 5 Ml-lz, DMSO-d6) : 8 =
169.9,1 68.0,1 55.0, 147.2, 135.5, 130.1,1 29.4,1 27.9, 127.4 , 126.6, 125.3, 119.3, 117.4,
115.0, 103.4, 63.1, 17.2, 14.2; I-IR-MS (TOFEl ) calcd . for C IsHI4N20 3S (33 8.0725) ;
found (33 8.0722) .
E thy l 2-(aminothio)-4-hy d r oxybenzo lit[qulnoline-Lcarboxylnt e (5) :
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To a stirring so lutio n of 4 (0 .8 g, 2.67 mm ol) in THF (10 mL) and H20 (40 mL) was
added Na HCO J ( 1.0 g, 7.23 rnmol), and stirred for 15 min., then hydroxylamine-O-
su lfonic acid (0 .50 g, 4.42 mmo l) was added to the resulting solution and stirred for 4 h
at room temp erature. Afte r comp letion of the reactio n, the solution was acidified by
acet ic acid, extracted wit h CHCi) , dried ove r Na2S04, filtered to give 5 as a white fluffy
powder; mp 175- 177 °C; IH-NMR : (500 MHz, DMSO-d6) : 8 = 8.54 (s, IH, OH), 8.12 (t,
./ = 7.7 Hz, 2H), 7.86 (d,./ = 8.7 Hz, IH ), 7.84-7.82 (rn, 2H), 4.31 (q,./ = 7.0 Hz, 2J-l),
1.33 (t, ./ = 7.0 Hz, 3H); 1JC NM R (17 5 MHz, DM SO-d 6) : 8 = 166.9, 162.5, 134.5, 128.9,
128.7, 127 .9, 127.8 , 127. 5, 124.5, 121.5 , 12 1.3, 105.4 , 64.2, 6 1.6, 60 .3, 14.3; HR-MS
(TOFEI) ca lcd for CI6HI4N20 JS: (3 14.072 5); found (3 14.0736) .
Ethy l 7-hydroxy-8-oxo-8,9-dihydrobcnzolhlthicnoI2,3-blquinolin c-9-carboxylatc
(6a) :
Sodium ethox ide (0 .29 g, 4.3 mmo l) was added to the sol ution of 3a ( 1.49g, 3.89 mmol)
in EtOH (50 mL) and refluxed for 4 h. After comp letion of the reactio n, EtOH was
removed , adde d H20 (50 ml.), and ac idifie d by AcO H, separated solid was collected and
dried as a yellow ish pow der: mp >250 °C; ' H-NMR: (500 MHz, DMSO -d6) : 8 = 13.37
(s, IH, OH), 8.74 - 8.69 (m, I H), 8.16 (d, ./ = 8.8 Hz, I H), 8. 11 (dd,./ = 6.8, 2.3 Hz, II-I),
7.87 - 7.83 (m, 2H), 7.84 - 7.79 (m, IH ), 4.29 (q,./ = 7.0 Hz, 2H), 3.34 (s, IH), 1.07 (t, ./
= 7.0 Hz, 3H).13C NMR ( 175 MHz, DMSO-d6) : 8 = 175.3, 161.8 , 157.0, 156.9, 150.5,
138.4 , 134 .9, 129.3,1 28 .8,1 27 .2,1 23.8, 122.8, 120 .5, 118.4, 114.3, 95.3, 60 .2, 14.4; HR-
MS (TOFEI) calcd . for C ,sH13N04S ( 339 .056 5); found (339 .0560) .
7-hydroxyb cn zolhlll ,2 Ith iazolo IS,4-blquinolin-8(9H) -o nc (7) :
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Sodium ethoxid e (0.20 g, 3.0 mmol) was added to the solution of S (0.84 g, 2.7 mmol) in
EtOH (50 mL) and refluxed for 4 h. After completion of the reaction, EtOH was
removed, added H20 (50 ml.) , and acidified by AcOH, separated solid was collected and
dried as a light brown powder; mp>250 DC; IH-NMR : (500 MHz, DMSO-d 6) : 8 = 13.13
(s, 1H, OH), 8.61 (d, J = 7.8 Hz, 1H), 8.21 (d, J = 8.73 Hz, 1H), 8.14-8.11 (m, 11-1),7.85-
7.79 (m, 3H); 13C NMR (175 MHz. DMSO-d 6) : 8 = 172.9, 165.0, 162.2, 137.7. 134.9,
129.0,128.6,1 27.1 ,1 25.2,1 23.5,1 23.0,121.4,1 20.2, 107.4; HR-MS (TOFE1) calcd . for
CI4HgN202 S ( 268 .0306) ; found (268.0310).
7-hydrox y-8-oxo-8,9-dih ydrobcnzo[h)thicno[2,3-b)quinolinc-9-carbo xylic acid (6b):
A mixture of ester (6a) (0.339 g, 1.0 mmol) and NaOH (0.088 g, 2.2 mmol) in H20 (20
mL) was stirred at 100 °C for 4 h. After being cooled , the reaction mixture was
neutrali zed with 1 M HCI, extracted with CH2Clz and dried. Evaporation followed by
crystallization from EtOH afforded the acid as an orange red powder ; mp>250 DC; 11-1-
NMR: (500 MHz, DMSO-d 6) : 8 = 13.10 (s, IH, OH), 12.95 (s, 1H, OH) , 12.09 ( s, 11-1 ,
OH), 8.91 (d, J = 8.4Hz, IH) , 8.05 (d, J = 7.9 Hz, IH), 7.96 (d. .J= 8.8 Hz, 1H). 7.80 (t, J
= 7.4 Hz. 1H), 7.76-7.68 (rn, 2H); 13C NMR (175 MHz, DMSO-d 6) : 8 = 166.2. 159.8.
158.2,156.3, 149.4. 140.4, 133.9, 128.2, 127.3, 127.2, 123.5, 122.3, 120.4, 119.2. 115.3,
98.2; TOF-MS EI: calcd . for CI6H9N0 4S (3 11.16); found (3 11.16).
Ethyl 7-mctho xy-8-oxo-8 ,9-dih ydrobcnzolhlthicno[2,3-b]quinolinc-9-carboxylatc
(6c):
To a mixture of 6a (0.339 g, I mmol) and K2C0 3 (0.386 g, 2.8 mmol) in dry DMF (25
mL) under nitrogen atmo sphere was added dimethyl sulfate (0.126 g, 1 mmol) along with
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K[ (catalytic amount). The reaction mixture was heated at 70 DC for 24 h, and then poured
into ice-Hjt) . The resulting alkylated derivative was collected by filtration and
recrystalized from hexane : CHCb (I :3) to afford a yellowish powder; mp charring ~ 280
°C; I H-NMR: (500 MHz, DMSO-d 6) : 8 = 9.15-9.07 (m, [H), 8.11 (d, J = 9.0 Hz, II-[),
7.98 (dd, J = 2.7, 6.2Hz, IH), 7.75 (d, J= 9.1 Hz, IH), 7.74-7.69 (rn, 2H), 4.35 (s.3H),
4.10 (q, J = 7.0 Hz. 2H), 1.25 (1. J = 7.0 Hz, 3H); 13C NMR (175 MHz. DMSO-d6) : 8 =
176.3,160.8,1 58.0,155.9,150.5,1 39.4.131.9,1 28.3, 128.8, 125.2, 123.8, 122.8, 120.5,
118.4, 117.3,95 .3,60.2,47.2, 14.3; HR-MS (TOFE[) calcd for C I9HISN04S (353.0722) ;
found (353.073 1).
Ethyl 7-cthoxy-8-oxo- 8,9-dihydrobcnz olh )thicnoI2,3-b)quinolinc-9-car boxylatc (6d):
Utilizing the same alkylation procedure as applied for preparation of 6c using diethyl
sulfate (0.154 g, Immol); yellow powder; mp 170-172 °C; IH-NMR: (500 MHz, CDCb ):
8 = 10.94 (s, IH,OH), 9.35-9.28 (m, IH),8 .16 (d, J = 9.1 Hz, IH), 7.88 (dt, J =3 .2 Hz,
IH), 7.77-7.69 (m, 3H), 4.50 (q, .J= 7.0 Hz, 21-1), 4.46 (q, .J= 7.1 Hz, 21-1), 1.58 (t, .J=
7.0 Hz, 31-1),1.45 (t, J = 7.1 Hz, 3H); i3C NMR (175 MHz, CDCI3): 8 = 168.1, 161.1,
160.5,1 57.9,1 50.4,134.8,130.9,1 29.6,1 28.1,1 27.5, 126.9, 125.8, 120.2, 119.1, 116.4,
100.4,74.2,62.1, 16.1, 14.7; HR-MS (TOFEI): calcd for C2oH17N04S (367.0871); found
(367.0872).
Ethyl 7,8-d icth oxybcnzo[hlthicno[2,3-b]quin olinc-9-carb oxylat c (6c):
Utilizing the same alkylation procedure as applied for preparation of 6d using diethyl
sulfate (0.431 g, 2.8 mmol) orange powder ; m p 120-[22 °C; I H-NMR : (500 MHz,
CDCb) : 8 = 9.41-9.29 (m, IH), 8.13 (d, J = 9. 1 Hz, IH), 7.94-7.87 (m, IH), 7.80-7.69
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(m, 3H), 4.44 (q, J = 7.0 Hz, 4H), 4.39 (q, J = 7.0 Hz, 2H), 1.56 (t, J = 6.6 Hz, 6H), 1.45
(t, J = 7.1 Hz, 3H); DC NMR (175 MHz, CDC!]): 0 = 162.2, 160.2, 159.9, 153.3, 149.8,
134.5, 130.5, 129.0, 128.1, 128.0, 127.5, 125.2, 119.4, 119.2, 118.8, 116.6, 73.6, 72.2,
61.3, 15.5, 15.3, 14.2; HR-MS (TOFEI) calcd for C22\-121N04S (395.1191); found
(395.1195).
EthyI 8,9-d ihydro-7, IO-dioxa-12-thia-13-azaaz ulenoI8, 1-abJphenanthrene- l l -
carboxylat e (61):
This compo und was prepared using the same procedure as that used for the synthesis of
6e using 1,2-dib romoethane to afford a yellow crystalline product; mp 250-252 DC; 1H_
NMR: (500 MHz. CDCIJ): 0 =9.3 5-9.28 (m, IH),8.14 (d,J = 9.1 I-Iz, 11-1), 7.93-7.87(m,
IH), 7.74 (dt,J = 5.9, 9.7 Hz, 3H), 4.96-4.92 (m, 2\-1), 4.84-4.79 (m, 2\-1),4.42 (q,.J = 7.1
Hz, 2\-1), 1.43 (t, J = 7. 1 Hz, 3H); 1JC NMR (175 MHz, CDC!]): 0 = 162.1, 159.5, 158.2,
152.8,148.3,1 34.3,130.1,1 29.1,1 27.6, 127.0,1 25.8, 125.4, 119.4, 113.8, 111.4. 104.8,
73.6, 72.2, 6 1.1, 14.4; HR-MS (TOFEI) calcd for C2oHISN04S (365 .0722); found
(365.0727).
9-Cyano-7-h)'droxy-8-oxo-8 ,9-dih ydrobenzollt IthienoI2,3-b [quinoline (8):
Sodium ethoxide (0.20 g, 3 mmol) was added to the solution of 3k (0.91 g, 2.7 mmol) in
EtOH (50 mL) and reflu xed for 4 h. After completion of the reaction, EtOH was
removed, added \-1 20 (50 mL), and acidified by AcOH; the separated solid was collected
and dried as a brown powder; mp>250 DC; IH-NMR: (500 MHz, DMSO-d6) : 0 = 13.39
(s, 0 1-1),8.66 (s, IH), 8.16 (d, J = 8.7 Hz, IH), 8.10 (d, J = 9.1Hz, 11-1), 7.83 (dd, J = 6.8,
14.0 Hz, 4H); DC NMR (175 MHz, DMSO-lh ): 0 = 173.4, 165.2, 167.0, 162.5. 140.0.
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138.7, 135.2, 130.0, 129.4, 127.4, 125.1, 124.5, 122.0, 12 1.3, 120.1, 105.3; HR-MS
(TOFEI) calcd. for CI6HgN202S (292 .3019); found (292 .3017) .
9-Acet) '1-9H-benzollt Ipyrazoloj.J ',4':4,51thienoI2,3-b [quinoline-Z,1O-diyl diac etate
(9):
Compo und 6:1 (0.50 g, 1.5 mmo l) was allowed to react with hydra zine hydrate (10.1 g,
20 1 mmol) by refluxing in EtOH for 3 h. then cooling . Afte r evaporation of the solvent,
the remaining mixture was refluxed with AC20 (5 mL) for 4 h. The reaction mixture was
then coo led and was diluted with water (30 mL) and stirred for 30 min. The precip itate
was collected, dried and recrystalized from TI-IF to yie ld compound 9 as yellow crystals;
mp 2:250 DC; I H-NMR: (500 MHz. CDCb): Ii = 9.32 (dd . J = 9.7 , 16.2 Hz, IH), 7.94 (dd,
J = 4.2 , 8.8 Hz, 2H) , 7.86 (d, J = 9.0 Hz, IH), 7.8 1-7.70 (m, 21-1), 2.77 (s, 3H), 2.64 (s,
3H) , 2.64 (s, 3H) ; 13C NMR : ( 175 MHz, CDC I)) : Ii = 169.6, 167.4. 166.9, 166.8, 150.5.
149.4, 149. 1, 139.7, 134.1 ,130.4, 129.3. 127.9,127.9, 127.6, 125.3, 118.2. 117.9. 113.1.
108.8, 23.4 , 20.8, 20.6; HR-MS (TOFEI) : calcd for C2ol-I13N)04S (39 1.0627); found
(39 1.0638) (-COCH)).
Diethyl 14-(2-cthox y-2-oxocthyl)-3- (D:tphthalcn-I-yl)-1 ,3-thhtzol-2(3H) -
ylidenclpropnned ioate (10):
To a stirred solution of compo und 1:1 (0.367 g, I mmol) in THF (50 mL) was added
chloroethy lacetoace tate (0 .164 g, I mmol) dropwise at 0 "C and stirri ng was continued
for an extra 12 h at room temp eratur e. The solvent was eva pora ted, and the resulting oil
was extracted with CI-[Cb and dried over Na2S04 The organ ic layer was evaporated by
rotary eva porator to give yellow oil. The obtained oil was heated at 170- 180 "C in an oil
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bath under vacuo for I0 min. The result ing oil was solidified then washed with ether
affording compound 10 as yellow crystals; mp 140-142 °C; 'H-NMR: (500 MHz,
CDCb) : 0 = 7.95 (dt, J = 1.14, 1.14,8.02 Hz, IH), 7.92-7.89 (rn, 11-1), 7.55 (rn, 2H),7.51
(d,J = 7.85 Hz, IH), 7.49 (d, J = 1.54 Hz, IH), 7.43 (m, IH), 6.59 (d,J = 0.97 Hz, IH),
3.81 (rn, 2H), 3.71-3.60 (rn, 21-1), 3.38 (rn, 2H), 3.12 (dd, J = 0.9 1, 17.24 Hz, IH), 2.9 (d,
J = 1.05, 17.28 Hz, IH), 1.02 (t, J = 7.16 Hz, 3H), 0.89 (t, .J= 7. 15 Hz, 6H); 13CNMR:
(175 MHz, CDCb): 0 = 168.1, 166.2, 163.1, 134.3, 134.1, 132.5, 130.6, 129.1, 128.4,
128.1, 127.0, 125.1, 122.4, 106.7, 90.0,61.3 , 60.6 , 60.0, 38.1, 34.0, 30.9, 14.5, 13.8,
13.8; HR-MS (TOF EI) calcd for C24H2SN06S (455.1403); found (455. 1398).
IH-3-thia-11 c-azaazulenoj J,8, 7,6-edefl phenanthrene-1,6(5H)-dionc(11):
The appropriate ester (10) (0.455 g, I mmol) was added to PPA (2.27 g, 5 parts by
weight) preheated to 150 °C, and the mixture was stirred for 3 h before being cooled to
room temperature, H20 was added, the solution was made basic with cone. NH40H, and
extracted severa l times with CI-{zCIz. The combined extracts were dried (MgS04), filtered
and evaporated in vaello to yield essentially pure brownish black crystals; mp 200-202
°C; I H-NMR: (500 MHz, CDCl3) : 0 = 8.80 (d, .J= 8.7 Hz, IH), 8.28 (dd, .J = 6.9,5.4 Hz,
2H), 8.09 (d, .J= 8.7 Hz, IH), 7.79-7.72 (m, IH), 6.93 (s, IH), 6.79 (s, IH), 4.09 (d,.J =
14.8 Hz, 2H). I3C NMR: (175 MHz. CDCb): 0 = 172.6, 157.0, 136.3. 135.9, 135.7.
133.0,1 32.1, 130.4,1 28.3. 127.4,1 26.6,1 24.8,1 22.5, 115.6, 106.1, 105.6, 44.8; HR-MS
(TOFEI ) calcd for C17H9N02S (291.0354); found (291.0349).
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Preface
The developed manuscript for this chapter provides a detailed synthes is of the nove l
benzo[h]thi azeto quin oline system via the oxidative cycl ization mechanism. A versio n of
this manuscript has been publ ished in the Heterocycles.
Abstract
The first synt hes is of a serie s of 4-oxo- I.4-dihydro benzo[h][I,3]thiazeto[3 ,2-
a ]quinoline carboxylic acids and their esters via ox idative cycliza tion of ethy l 2-((2-
ethoxy-2- oxoe thy l)thio)-4-hydroxybe nzo[h]quinoline-3-carboxy late in the presence of a
vicinal dihalolakane, KI, and K2C03 is described . Struct ures of the synt hesized
compo unds were characterized by spec trometric and X-ray crysta llographic analyse s.
Keywo rds : Thiazeto qui no lines , vic-diha loalkanes, X-ray crysta llography, pseudohalide
(lBr).
4.1 Introduction
4-0xo- I,4-di hydroq uinoli ne-3-carboxy lic acid derivat ives (quino lones) have
dominated the antibacte ria l market for decades. Qu inolones have a unique mechani sm of
action: they inh ibit DNA synt hesis by promoting cleavage of bacter ial DNA in the DNA-
enzyme complexes of DNA gyrase (the main target in Gram-nega tive bacteria) and type
IV topoisom erase (the main target in Gram-positive bacter ia), result ing in rapid bacterial
death [1-3].
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Inhibitory activity of quin olones agai nst human topoisomerase-2 has been reporte d
by Kyorin-K yowa-H akko researchers via introduction of a series of tricyclic
thiazo loquino lones that exhibited impressive antica ncer activity [4].
In continuation of our ongoing research towards the discovery of novel polycyclic
quinoline-based ant ineoplastic agents using conventional synthetic procedures, we were
able to isolate and identify, unexpectedl y, a 4-oxo-benzo[h]thi azetoqu inoline derivative
(4a) . The structure of this novel molecule was elucidated by ' H-NMR, 13C-NMR, HR-
MS, and X-ra y crystallog raphy. Despite the availability of several publ ished works on the
syntheses and bioacti vity of angular 4-oxo-th iazolo[ 3,2-a]quin oline-3-carboxylic acid
derivatives,[4-9] there are limited reports on the synthesis of 4-oxo-thi azeto[3,2-
a]quinolines and there is no reported synthes is of 4-oxo- benzo [h]thiazeto[3 ,2-a]q uinoline
derivatives.
Prulitlo xacin [10] Figure 4-1 (A) is a representative of 4-oxo-t hiaze toquino line
antibiotics. It is a prodru g which is metabolized in the body to the act ive compo und
ulitloxacin [I I]. It was deve loped ove r two decades ago by Nippon Shinyaku Co. and
was patented in Japan in 1987 and in the United States in 1989 [12- 14].
Figure 4-1: Structure of Prulitloxac in (A).
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In the same context, Ito et {/I. [15J succeeded in the synthesis or 4-oxo-I.4-dihydro-
11.3]thiazeto[3.2-aJquinoline-3-earboxylic acid derivative (B) as an antibacterial,
antitumor. and anti- AIDS agent.
In 1999. Matsuoka et oi.. reported the synthesis or 6-fluoro-I-methyl-4-oxo-7- (I-
pipcrazinyl}-411-[I.3]thiazeto[3.2-a Jquinoline-3-carboxylic acid (C, NM394) which
showed excellent in vitro antibacterial activity [Iea].
a a
-r-Y0 ""FJlANJ\yS
a a
F~OH
r NAANJ\H'N-J yS
F i~u r-e 4-2: Structure or Compounds (11) and (C).
The rationale behind the prulifloxacin synthesis was to connect the quinoline N-I
and C·2 positions ,·ia a bridge in order to minimize the stcric hindrance or the C-2
substituent toward the C-3 carboxyl group. and which can lead to active antibacterial
agents (l 6b].
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Filtllre 4.J: Prulifloxacin synthesis schematic
(adopted from 1. Med. Ch"HI. 1992, 35,4727).
In order 10 achieve this goal. the authors used appropriate ly-substituted
phcnylisothiccyenatc which. upon reaction with diethylmalon atc and chloromcthylcthyl
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ether, followed by therm al cycl ization and deprotection of the sulfide, afforded the
correspondin g ethyl 2-mercapto-4 ( IH)-oxo-quinoline-3-carb oxylic acid (IV). Reaction
of this compound with an alkyl- or arylsubstititu ed ge m-dibromomethane derivative in
the presence of K2C0 3 and KI gave rise to the alkyl/a ryl substituted 4-oxo-th iazeto[3,2-
a]quinoline-3-carboxy lic acid as depicted in Figure 4-1. The disadvantage of using this
methodology is the limitation in the nature of subst ituents on the carbo n connecti ng - S-
and - N- atoms in the thiazeto ring, which originates from the corres ponding gem-
dibrom omethan e precur sors.
In the synthesis described in this chapt er (Scheme 4-1), the 4-oxo-thia zetoquinoline
nucleus is form ed via reaction of the carbanion at the alkylsul fide group of the C-2
posit ion of the qu inoline ring with a pseudohalogen (IBr), formed via reaction of iodide
anion with the vic-dihaloalkane, or a halogen (12), followed by nucleophilic attack of the
N- I on halogenated carbon and the departur e of halogen. The role of the vicinal
dihaloalkane in this process is the provision of a pseudoh alogen (such as IBr) without
direct interaction with the quin oline system. This synthetic procedu re produced diverse 4-
oxo-thiazetoquinoline-3-carboxy lic acid derivatives possessing electro n-wit hdrawi ng
groups at the C- I position .
4.2 Chemistry
The synth esis of 4-oxo-b enzo[h]thia zetoquin olin e carboxylic acid deri vatives is
outlined in Scheme 4-1.
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Sche me 4-1: Synthes is of 4-oxo-bcnzo(h]thiazetoquin olinc carboxylic acid derivat ives.
Naphthyliso thioc yanate was allowed to react with dicth ylmalonatc in the presence
of sodium hydride 10 yield the salt la which was furt her reacted with ethyl bromoacctatc
to affo rd 2a. Therma l cycliza tion of 2a . under vacuum. yielded Com pound 3a. This
compound was later reacted with 1.2-dibromopropanc in the presence of KI and K2CO J
to obtain -ta. whic h was further saponified to alford 4h.
Symhesis of Compound 4.: was then carried out in an analogou s manner to 4a using
KI and K2COJ in the presence of L2-dihromopropane. starting from 3c, as depicted in
Schcmc 4·2 .
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Sch em e -1-2: Synthesis of Compound -Ie.
The most interesting step in the schemes was the cyclization using a vicinal
dihaloalkanc instead of germinal ones . which were used in all previously reported
syntheses. Also, the vic inal dihaloalkanc did not appear in the final structure, which
confirms the role of the vicinal dihaloalkane as a controlled source of the halogenatin g
reagent which allow s for cycl ization to occur after it halogenate s the carbon u to the thiol.
In order to investigate the details of the cyclizatlon process, the following reactions
were atte mpted '
3a + KI + 1,2-dibromopropanc;
3a + K2C03 + 1,2-dibromopropanc;
3a + KI + K2CO.1+ I. 2-dib romopropanc.
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No cyclised product was separated in the first 3 experiments and only the 4th
procedure yielded the title Compound 4a
Based on the above information. the following pathway is suggested as a plausible
mechanism for the formation of 4a from 3a . Nucleophilic reaction of iodide anion with
1,2-dibromopmpane would result in the formation of propene, bromide ion, and
iodobromide (pseudohalide). Nucleophilic attack of the carbanion form of 33 on
iodobromide would afford the iodo intermediate .' a-a, which upon nucleophilic
cyclization yields 4a, as depicted in Scheme 4-3
..",I( 'YB'
"
Scheme 4-3: A plausible mechanism for the formation of 4a from .' a
In order to prove the critical role of 1.2-dihaloalkanes in the formation of the above
-t-oxo-thiazctoquinolincs. we attempted the same reaction using 1,2-dibromobutanc und
t. z-dibromohexanc instead of 1.2-dibromopropune. In all trials , Compound 4a was
obtained in a very good yield. On the other hand. when Compound 3a was allowed to
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react with J.3-dibromopropane and 1.2·d ibromocthane, the corresponding O-alkY'lated
products (5 and 6) were obtained as shown in Schcm(, ..1-1
3a
KI/K2COj 1,3-dibromopropane
OMFnO·C
KI/~CO/1 . 2 -d ibromopropane
OMFnO'C
6 61%
Scheme ..1-1: O-alkylall-dproducts (5 and 6).
In order to confirm the involvement of the pseudohalidc [iodohromidc] , formed by'
the reaction of 1.2-dibromopropane and KI, in the oxidative cyclizatlon of Compound -'a
to -ta, we attempted the reaction of .'awith either iodobromidc (JUr) or iodine (h) in the
presence of K2COJ. In both attempts. we were able to obtain Compound -Ia in good
yields.
The X-ray crystallographic structures of Compo und -ra and its carboxylic acid
derivative (-Ib) [17J are shown in Ftgu re -1-2.
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Fil:url' 4-4: ORT !:!' representation s of the X-ray structures ofthiazctoquinolinc
derivatives 4a and 40, with 50% probabili ty el lipso ids.
124
Chupter 4: Synthesi.. of Novel s-Oxo-Ls -Dihydro Bel/lo/""l.3/T"iazelo/3.1'''/Ql/itrolitreCarboxylic Acid.. ...
We also attempted the decarboxylation of 4b using conventional decarboxylation
procedures with no success. Unexpectedly, when 4b was allowed to react with
ethylchloroformate followed by hydroxylamine hydrochloride, Compound 4d was
afforded. Formation of 4d can be explained via the reaction of ethyl chloroformate with
the carboxy late anions (formed in the presence of Et3N) to afford a mixed-anhydride
intermediate 4b -b , which upon reaction with hydroxylamine hydrochloride leads to
decarboxylation of the conjugated anhydride, while the unconjugated anhydride
transforms into a carboxy lic ac id, as depicted in Scheme 4-5.
OH
H I CH3
o 0 0 0 2~0 ,) 0
cY¥1 1 OH CIC0 2Et ~II ~O &{II H""" I N S """ I N S ----- """1 N S:::,.. 1 N-methylmorpholine "" 01 ".. 1
o OH 1 0 OH
4b 0 ( 0/"----CH3 4d 42%
H2~H
4b-b
Scheme 4-5: Sugge sted mechanism for mono decarboxylation of Compound 4b .
4.3 III vitro testin g
Compo unds 411-4d and 6 were tested for cytotox icity against I-1eLa cells in
compar ison with doxo rubici n, as a refere nce compound. The test resu lts revea led the lack
of cytotox icity of the tested compou nds against I-1eLa cells.
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Table 4-1: Cyto toxicity results of tested derivatives.
lnhi%at lnh i% at lnh i% at lnh i% at rc.,
100ug/ml 10ug/ml lu g/ml O. lug /m l ug/ml
4a -2.90 -62.26 -65.23 100
4b 25.18 -11.01 -15.45 90
4c 36.00 -35.26 -43 .54 > 100
4d -17.46 -45 .83 -55 .34 > 100
6 15.13 38.64 -46.04 > 100
Ref. 23.28 18.04 5.97 76.65
4.4 Molecular mod elin g
4.4.1 Method s
Docking calculatio ns were carried out accordi ng to the DockingServer methodology
[18]. The MMFF94 force field [19] was used for energy minimi zation of the ligand
molecule using Docki ngServer. PM6 semie mpirical charges calcu lated by MOPAC2009
(1. P. Stewart , Comp uter code MOPAC2009, Stewart Computational Chemistry, 2009)
were added to the ligand atoms. Non-polar hydrogen atoms and rotatable bonds were
defined.
Docki ng calculations were carr ied out on the topoisomerase II structure with the
pdb code IQZR. Esse ntia l hydrogen atoms, Kollman united atom type char ges, and
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solvation parameters were added with the aid of AutoDock tools [20]. Affinity (grid)
maps of25 x25 x25 A grid points and 0.375 A spacing were generated using the Autogrid
program . AutoDock parameter set- and distance-dependent dielectric functions were
used in the calculation of the van der Waals and the electrostatic terms , respectivel y.
Docking simulations were performed using the Lamarckian genetic algorithm
(LGA) and the Solis & Wets local search method [21]. Initial position , orientation. and
torsions of the ligand molecules were set randomly. Each docking experimen t was
derived from 100 different runs that were set to terminate after a maximum of 2,500,000
energy evaluations. The population size was set to 150. During the search, a translationa l
step of 0.2 A, and quaternion and torsion steps of 5 were applied.
4.4.2 Human topoisomcrasc II docking
Topoisomera se II is an ATPase belonging to the GHKL (Gyrase, l-lsp90, histidine
Kinase, mutL) family . The mechanism of function of human toposiomerase II is to
simultaneously cut both strands of the DNA helix using the energy derived from ATP
hydrolysis. The inhibition of human topoisomerase II is the target of oncology research.
There are more ways to inhibit the enzyme 's action [22]:
I-Whil e exerti ng its function, the enzyme creates a transien t cova lent DNA-enzyme
complex. Topoisomerase II poisons exert their effec t by stabi lizing this transient
complex, thus, causing DNA damage. Since these compounds are very toxic to normal
cells, alternative ways of topoisomerase II inhib ition are subjec ts of interest in drug
research.
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2-An altern ative way of inhibition is to block the enzyme before the DNA cleavage
step or in the last step of its catalytic cycle. The comp etition for the ATP binding site as
well as stabilization of a transient dimer interface between two AT Pase monomers have
been described [23]. Neverthel ess, these ways of inhib ition take place at the ATPase
region of the protein. Amon g the available structures of the human topoisomerase II
protein , I pya and 1QZR carry the ATPase region. Additionally, I py a contains
modified methionine residue s (MSE), whi le IQZR contain s phospho aminoph osphonic
acid-adenylate ester (ANP) at the ATP binding site and an inhib itor lCRF-187 at the
interface of the homodimer. All docking calcu lations were done using lQ ZR.
4.4.3 Dockin g expe r iment
First, the blind dock ing procedur e was applied. The dockin g result showed no
cluster possessing significantly higher frequency or lower energy as compared to the
other cluster s. Thu s, blind dockin g in this case was not able to clearly define the possible
binding site. Therefore, biochemical knowledge was used for bindin g site identifi cation.
The cluster possessing the highest interaction surface between the docked ligand and the
protein indicatin g strong bindin g was located at the AT P bindin g site. None of the result s
were found at the inhibit or' s (lCRF-187 ) bindin g site. Thu s, focused dockin g calculati ons
were carried out at the ATP bindin g site of the protein .
4.5 Focused dock ing result s
All compounds were calcu lated to bind at the ATP bind ing site with reasonable
affinit y, with 4b possessing the lowest docking energ y. It is noted that in the X-ray
128
structure Mg2+ is coordina ted by 3 oxygen atoms coming from ANP. None of the tested
derivatives were ab le to donate non-bonding electron s to Mg2+ ,
Ftg ure 4-05: Docked structure of Compo und -Ih atth c AT!' binding sue of IQZR.
T a b le -1-2: Calcu lated interactions of Cornpound 4h atth e All' binding site.
Pol ... lh dro hobic
03,1 "Stl'J ca.e ILE1Q.l cu ", PHE111(1"1 1;;' ('''I (co': (W] ,Ct'c:
Q.I('Q: A$Im CI('! 1t-E1001 C16(", PHI'12l(,"' I IOC,: ("1 (Cc'l (l"j IC('''-"1
03(1 AS/1M Cll;," 1t-E12G C71'1I PHE121
(Jl 'l ICC') (J'!I ICll (,'1 "';:'J
0 1(') SfRl28 C12(,"j 1.E12G
(1'<1 ,~, [3'1 1 (ct,
(» ( '0 1 l"Hl<1! 5 C!(,II II.E120
("'1 lOG': ("01 (CC,:
Cl0(,'1 ILET20
[1"1 (0:'1
Cl"l ll ET20
[!1I1 ,cc"
C6("1 PliE121
(l " l (C;:1
CIS I:: AlAl~o
ie",
129
Chapter 4: Syllll,,·,i., of Novet s-Oxo-I .s-Dikydro Bellw/ I,I/I.J/Tiliazeto/J.2-a!'llli'lOlille Carboxylic Acids ...
4.6 III vitro testin g
HeLa human cervix ade nocarcinoma were grown in DMEM (GIBCO) with 15%
FBS and antibiotics (penicillin 100 Uzml, streptomycin 100 ug/ml ). Cells were
maintained at 3TC in a humidifi ed 5% CO2 atmosphere.
4.6.1 Cytotoxicity assay
Cells were trypsinized and seeded into 96-well cell cultur e plates at 180 ul/well
(about 5000 cells/well) . After 16 h incubation , the cells were treated for 48h by the
compound at final concentra tions of 100, 10, I , 0.1 ug/ml. The compounds were prepared
in DMSO (stock solution of 10 ug/ml), and further di luted with culture medium to obtain
the desired conc entration . All tests included cont rols with equivalent concentrations of
media DMSO corresponding to the relevant diluti ons of the test compound. The 3-(4,5-
Dimethylthia zol-2-yl)-2,5-diph enyl tetrazo lium bromid e (MTT) was added in the final
concentration of I mg/ ml, and 30 ul/well. After 4h incubat ion the M'I'Tvformazan
product was so lubilized using DMSO (150 ul/well) with shaking 10 min. The absorba nce
measurements were carried out using a microplate reader at 490 nm.
4.7 Computationa l method s
All mechanistic modeling calculations were perform ed using Gaussian09 [24J at the
I-IF/6-31 IG(d) and B3LYP /6-3 1IG(d) levels of theory. As the 6-3 1IG( d) basis set for
iodine [25J is not includ ed explicitly in the software package, all basis set information
[25-28J was read in, as a general basis set input as obtained from the EMSL Basis Set
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Exchange [29,30]. Ca lculations were perform ed both in the gas phase and solution phase.
Solution phase calculations were performed with N,N-dimethylformamide as the modeled
solvent, using the Pola rizable Continuum Model (PCM) [31] .
Once transition states were found and confirmed by frequency analysis , intrinsic
reaction coordin ate (IRC) [32,33] calcul ations were performed following both directions
of the reacti on coor dinate. The end geometries of these IRC calculations were then used
as starting point s for geometry optimizations to find the reactant and product complexes
associated with the tran sition state. All energy minimi zed geometries were also
confi rmed by frequenc y analysis.
4.7.1 Computational results
To test the plau sibilit y of the mechani sm describ ed in Scheme 4-3, three individual
steps of the scheme were comput ationally modeled to see if the energe tics of each step
were reasonable in term s of both activation energy barriers and overa ll energy change
from reactants to product s.
As the reaction to give 4a from 3a in the presence of IBr and K2C0 3 has been
observed, the initial modeled step was the form ation of the carbanion form of 3a via
proton abstraction by carbonate. Two possible proton abstractions were attempted, one
for each proton on the - CH2- group next to the sulfur atom. These protons can be
described as the "ringward" proton on the same side of the molecule as the fused-ring
port ion of the molecule, and the "c hainward" proton (Figure 4-6a ) on the other side of
the molecule. Using the reactant complex of carbonate and 3a (Figu re 4-6a ) as the
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reference poin t for zero energy, the chain ward side transition state (Figure 4-6b )
structure lies 10 kl /rnol abo ve the reactant compl ex in the gas phase using 8 3LYP/6-
3 1IG(d), and the product 3a carbanionlbicarbonate complex (Figu re 4-6c) lies 192
kl /mol below the reactant complex. The proton abstraction is highly exothermic , as the
formation of the carbanionlb icarbonate complex creates two negatively charged ions that
electros tatically repe l each other. It should be noted that attempts to mode l the abstraction
of the chainwa rd proton were unsuccessful at this level of theory.
Attempts to model the proton abstracti on on the ringward side using 8 3LYP/6-
3 11G(d) were success ful, but gave a transition state barrier of 22 k.I/mol, while the
product complex lies below the reactant complex by 195 kl/mol. However. regardless of
the side from which the proton is removed, the resultin g carbanion struct ure is the same.
The transition state barrier for the ringward proton abstract ion is 39 kI/mo l in the
gas phase using HF/6-311 G(d), with the produ ct compl ex lying 237 kl /mol below the
reactant complex . Attempts at finding the chainward transition state were unsuccessful at
this level of theory.
In the so lution phase it is interesting to note that at the HF/6-31I G(d) level of
theory, the proton abs trac tion occurs on the chainward side with a higher transition state
barrier of 50 k.l/m ol than is seen in the gas phase. Also, the step is only exo thermic by 21
kl /mol as compared to 195 kl /rnol in the gas phase. For the 8 3LYP calculations in
solution, the barrier on the chainw ard side is 7 kl /mol and the ove rall step is exothermic
by 43 kl /mol, In the solution phase calcul ations, the two negatively charged ions do not
move as spatially dis tant from each other in the gas phase, as the ions can be stabi lized by
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the somewhat polar solvent molecule s. This will tend to reduce the energy difference
between the reactant and product comp lexes.
Overa ll, the proton abstraction step has been shown to have a reasona bly sized
activation energ y barrier at the modeled levels of theory. and the step is exothermic
overall.
Figure 4-6: Reactant com plex (a) , transition state (b) and produc t complex (c) for the
carbauion formation step calculated at the B3LYP/6· 311G(d) level of theory.
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The next modeled step involves the nucleophilic attack of the 311 carbanion IBr to
fonn Compound 311-11. Initial attempts to find the transition state for this step were
unsuccessful. but the product complex of 311-11 and bromide was found as shown in
Ftgure 4-7 for the structure calculated at the HF/6·31IG (d) level of theory.
Figure 4-7: Th e structure of the Ja- a 'bromidc product complex at the IIF/6-31IG(d)
level of theory.
In the B3LYP/6-31IG(d) product complex the iodine is 2.36 A from the carbon.
while the bromide lies 2.98 A from the iod ine atom, which significantly differs from the
equilibrium bond length of IBr, which is calculated at B3LYP/6-31IG(d) to he 2.53 A.
Ihcsc three atoms effectively lie in a straight line, with an angle of 178.5 degrees.
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In the next attempt to find the transition state, a fixed coordinate scan was
undertaken at HF/6-3I I G(d) where the C-I bond length was increased by increments of
0.1 A and the rest of the compl ex was optimized with the fixed C-I bond length . As the
C-I bond length is increased, the energy of the resu lting co mplex increases, indicating
that this step appears to have no activation energy barrier, and instead shows an energe tic
profile very similar to a barrierless bond dissociation . Unfortunately this also means it is
very difficult to identify a carbanion/ IBr reactant complex for this reaction. However,
when the C-I distance is fixed at 5.0 A the IBr bond length is 2.51 A, which is not
significantly differ ent from the HF/6-311G (d) bond length in IBr of 2.49 A,and so for
energe tic comp arisons, we choose our "reactant compl ex" to have a fixed C-I distance of
5.0 A. We then compare the energy of this complex to that of the product complex to
estimate the energy change of the 3a-a /iodide formati on step.
At the HF/6-311G(d) level of theory, the product complex lies 199 kl /rnol below
the "reactant complex" in the gas phase, and 254 kl /mol below in the solution phase. For
B3LYP, the product complex lies energetically below the reactants by ISO kl / mol and
206 kl /mol in the gas and solution phases respective ly. Overa ll, this step has no
activation barrier and is highly exothermic at all levels of theory exa mined.
Modeling the abstraction of the phenoli c-type proton of interm ediat e 3a-a by either
carbona te or the so lvent N,N-dimethylformamide was not undertaken, as this step
represent s acid-ba se type chemistry. The electron withdra wing ester group next to the
phenolic group and the extended aromatic system allow for many resonance structures to
be drawn for the phenolate form of 3a-a , includin g one which puts the negative charge on
135
Chapter 4: Syllthe.,i., of Novel s-Oxo-l.s-Dihydr o Bem o{hlll ,3{TlIiazeto{3,l -a{qllinoline Carboxylic Acids ...
the nitrogen atom of the ring system. Because of this, the phenolate form should be
reasonably stable and the abst raction of the proton step of the mechanism should occur
with some facility. In fact, compa rison of the calculated HF/6-3 1IG(d) Mulliken charges
of 3a-a and the pheno late form do show an increase in the negative charge on the
nitrogen atom of the phenolate from -0.6 Ie to -0.68e, increasi ng its nucleophilicity. This
has the potenti al to affect the energetics of the nucleophilic cycliza tion step of the
mechanism.
The import ance of the phenolic proton abstrac tion prior to the nucleophil ic
cyclization step was explored by modeling the ring closing of both the phenolic and
phenolate form s of 3a-a . For HF calculations, the ring closing of 3ll-a to give protonated
4a and iodide has an activa tion energy barrier of 149 kJ/mol (gas phase) or 110 kJ/mol
(so lution phase), while the product complex lies energetica lly above the reactant comp lex
by 87 kJ/mol in the gas phase or 40 kJ/mol below the reacta nt comp lex in the solution
phase. For the phenolate form of 3a-a , the ring clos ing to give 4a and iodide at HF/6-
3 11G(d) has an energy barrier of only 77 kJ/mol (gas phase TS - Figure 4-8b ) or 81
kJ/mol (so lution phase) while the product complex lies below the reactant complex by 59
kJ/mol in the gas phase and 120 kJ/mol below the reactant complex in the solution phase.
Calculations carried out with B3LYP show similar trend s. The ring closing of 3lHI
to protonated 4:1and iodid e has an activation energy barrier o f 108 kJ/mol (gas phase) or
79 kJ/mol (so lution phase), whil e the produ ct compl ex lies energetically above the
reactant complex by 86 kJ/mol in the gas phase or I kJ/mol above the reactant complex in
the solution phase. However, for the phenolate form of 3a-a (Figure 4-8l1), the ring
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clos ing to give 4a and iodide (Figure 4-8c) at B3LYP/6-31 IG(d) has an energy barrier of
only 44 kl lm ol (gas phase TS - Figure 4-8b ) or 49 kl /mol (so lution phase) whi le the
product complex lies below the reactant compl ex by 25 kl /mol in the gas phase and 70
kl /mol below the reac tant compl ex in the solution phase.
The large di fference in the energetics of the modeled ring closing steps can be
attributed to the crea tion of the positively charged protonated 4a and the negative ly
charged iodid e. The ring closi ng of the phenolic form would create separation of
opposing charges, which should be ener geticall y prohibiti ve. However, when the
negatively charged 3a-a phenol ate form under goes ring closing, the sing le negative
charge is carried away by the iodide leaving group. With the removal of the phenolic
proton, all model chemis tries show a reasonable activa tion energy barrier and an
exot hermic step overa ll.
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product complex (el for the ring d osing step at ItK:R3LYP/6--31I G(d) level of theory.
Overal l. model ing of these three steps of the proposed mechan ism sho w that tbc
lirsl two steps have small 10 nonexistent activation energy barriers. and are highly
exothermic in concert. Even if the abst raction of the pheno lic proton were 10 have a
relat ively large act i...-ation energy barrier in the o rde r of 250 I,J/mol (which is unlikely for
such acid-base chemi stry ) the transition state would still lie ener get icall y below the
-'II/carbonate reactant complex of the first step . Comb ined with the reasonable transition
state harrier of the phenolate form ring closing step. whic h is itself exother mic, the
theoretical calcu lation s support the notion tha t the propo sed mechanism is energe tically
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favo urable. In fact, since the activation energy barri ers to reverse any of the mechanist ic
steps would be prohib itively high , reve rse reac tions are unl ikely to occ ur, and the
proposed mech anism wo uld have to lead to fairly high yields of product 4a at a
reasonable temp eratur e. As the experimental result s show yields in the order of 75% for
the reaction run for 24 hour s at 70 ·C , the modeled energe tics of the proposed mechanism
support the observe d yield as well.
4.8 Conclusion
We have presented herein a novel and effective method for a facil e synthe sis of the
4-oxo-thiazetoquinoline nucl eus via a homo- or heterohalide ca ta lyzed ox idative
cycl ization of 2-((2 -ethoxy-2-oxoethy l)thio- 2-((cya no-methyl)thio)-4-
hydroxyben zo[h]quinolin e-3-carboxylate. The designed structures did not show
cytotox icity as show n in the MIT cytotoxicity bioassay on the HeLa ce ll line. The
synthesized deri vati ves exihibited a good bind ing af finity to the ATP binding site of the
hum an topoisomerase but did not show any chelat ion to the Mg2+.
4.9 Experimental
' H and 13C NMR spectra, HSQC, and COSY spectra were record ed on a Bruker 500
MHz NMR spectrometer using TMS as an internal standard. LC-MS and HR-M S were
conducted using a GCT Premier Microm ass spectrometer. X-R ay structures were
measured on a Rigaku Saturn 70 instrument, equipped with a CC D area detector and a
SHIN E optic , usin g Mo Ka radiation. Silicycle Ultrapure silica ge l (0-20 urn) G and F-
254 was used for the preparati ve-la yer TLC, and Silicycle Silia-P Ultrapure Flash silica
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gel (40-63 11m) was used for flash column chrom atograph y. TLC was conducted on
Polygram SIL G/UV2 54 precoated plast ic sheets. So lvents were purifi ed using standard
co nditions before use. The reaction yields are includ ed in the co rrespo nd ing schemes.
Sod ium 3-cth oxy-2-(cthoxy ca r bony l)- l-( napht halcn- l -y lami no)-3-oxo prop- l -cnc-l-
th iolat c ( l a) :
To a suspens ion of sodium hydrid e (0.60 g, 25 mmol ) in MeCN (50 mL) at 5- 10 °c was
added dropwi se dieth yl mal onate (4.0 mL, 26.34 mmol ) over a period of 15 min . The
mixture was stirred at 5- 10 °c for add itiona l 30 min ., then I-naphthyli sothiocyanate (5.0
g, 26.99 mmol) was added portionwise at the same temperature and stirring was
contin ued for another 30 min . Evaporation of MeCN yielded a yellowish so lid which was
washed with Et20; mp 118-1 20 °C; ' H-NMR: (500 MHz, DM SO- d6) : 8 = 12.33 (s, NH),
8.57 (d, J = 7.1 Hz, I H), 8.16 (t, J = 7.7 Hz, IH ), 7.91 -7 .86 (01, IH ), 7.52 (ddd, J = 4.7,
11.1, 8.8 Hz, 3H), 7.46-7 .38 (01, IH ), 4.02 (q, J = 7.0 Hz, 4H ), 1.16 (t, J = 7.0 Hz.
6H);13C NMR (175 MHz, DMSO-d6) : 8 = 181.6, 166.4 , 136.1 , 132.5 . 127.0, 126.6,
124.3, 124.2, 123.9, 121.2, 120 .6, 119.4, 116.8 ,95.2, 56.8 (2C H2), 13.3 (2C H3); APC I-
MS : 368.4 (M ++I , 100) .
Ethy l 2-((2-cthoxy-2-oxocth yl)thi o)-4-hyd roxy bcnzo lh )quinoIinc-3-carboxylat c (3a) :
To the above yellow solid ( l a, 2.0 g, 5.44 mm ol) in TH F (50 mL) was added
BrCI--hCOOCH2CH3 (0 .60 rn l. , 5.44 mmo l) dropwi se at 0 °c and the mixtur e was stirred
for I h at room temp erature. The solvent was then evaporated, extr acted with CHCb and
dried over Na2S0 4, The organic layer was evaporated by rotar y evaporator to give a
yellow oil (2a). Th e obtained oil was heated at 170-180 "C in an oil bath under vacuum
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for 10 min. The result ing oil was solidified, then washed with ether to afford (3a) as
white needles; mp 136-138 °C; IH-NMR: (500 MHz, CDCb) : 8 = 13.11 (s, IH. OH).
9.22-9.15 (rn, IH ), 8.10 (d. J = 8.9 Hz, IH), 7.89 (dd, J = 3.1, 6.0 Hz. IH), 7.76-7.68
(m, 3H), 4.61 (q,J = 7.0. 6.9 Hz, 2H), 4.22 (q, J = 7.0. 6.9 Hz, 2H), 4.13 (s, 2H). 1.60 (t,
J = 7.0 Hz, 3H), 1.29 (t, J = 7.0 Hz, 31-1); I3C NMR (175 MHz, CDCb): 8 = 170.9, 170.4,
168.2,158.1,147.6,1 35.8.130.6,1 29.4,1 28.1,1 27.1, 126.2, 125.9, 119.9, 115.1, 104.0,
63.2, 61.9,34.6, 14.6, 14.6; HR-MS (TOFEI) calcd for C2oHI9NOsS: (385.0984); found
(385.0991).
Ethy l 2-« ethoxymethy l)thio)-4-hydroxybenzo lh Iquin olin e-3-ca rboxylat e (3b) :
This compound was prepared according to the same procedure as that applied for 3a
using chlorom ethyl ethyl ether; yellow crystals; mp 120-122 °C; IH-NMR: (500 Mllz ,
CDCb) : 8 = 13.11 (s, IH, 0 1-1), 9.26-9.19 (rn, IH), 8.13 ( d, J = 9.0 Hz, 11-1), 7.91 (d. J
= 3.3 Hz, 11-1),7.75 (d, J = 9.0 Hz, IH), 7.72 (dd, J = 3.2, 6.1 Hz, 2H). 5.76 (s, 2H), 4.60
(q, J = 7.1 Hz, 2H), 3.76 (q, J = 7.0 Hz, 2H), 1.59 (t, J = 7.0 Hz, 3H), 1.25 (t, J = 7.0
Hz. 3H);13C NMR (175 MHz. CDCb) : 8 = 171.1, 168.3, 158.2. 147.4, 135.8, 129.4,
128.2,1 27.3,1 26.2,1 25.7,1 20.0,11 5.1,104.3,71.4, 65.7, 63.1, 31.2, 15.4, 14.6; HR-
MS (TOFEI): calcd for CI9HI9N04S (357.1035); found (357.1031).
Ethy l 2-((cyan om eth yl)thi o)-4-hydroxy benzo lh [qui nulin e-S-ca r boxylate (3c):
Following a reported procedure [34], to a stirring solution of 4 (0.8 g, 2.67 mmol) in TI-IF
(10 mL) and H20 (40 mL) was added NaHC03 (I g, 7.23 mrnol ), and stirred for 15 min.,
then bromoacetonitrile (0.5 g, 4.16 mmol) was added to the resultin g solution and stirred
for 4 h at room temperatur e. After completion of the reaction, the solution was acidified
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by acetic acid, extracted with chloroform, dried ove r Na2S04, filtered to give 3c as a
white powder; mp 208-2 10 °C; ' H-NM R: (500 MHz, DMSO-d6) : 8 = 12.42 (s, IH, OH) ,
9.26-9.21 (m, IH), 8. 12 (d, J = 8.8 Hz, IH ), 8. 10-8.07 (m, IH ), 7.97 (d , J = 9. 1 Hz,
I H), 7.82 (m, 2H), 4.53 (q, J = 7.09, 7.08 Hz, 2H), 4.4 3 (s, 2H), 1.45 (t, J = 7.1 Hz, 3H);
I3C NMR (175 MHz, DM SO-d6) : 8 = 169.9, 168.0, 155.0, 147.2, 135.5, 130.1, 129.4,
127.9, 127.4 , 126.6,1 25.3, 119.3,1 17.4, 115.0,1 03.4, 63 .1, 17.2, 14.2; HR-MS (TOFE I)
calcd. for C IsHI4N20 JS (338. 0725); found (338.0722).
Dicth yI4-oxo-l,4-dihydrobcnzolll][1,3]thiazctoI3,2-alguinolinc-l,3-dicarboxylatc
(4a):
Oxidativ e Cyclization using KI and 1,2-dibrol1lopropane
To a mixture of 3:1 (0.385 g, I mmol) and K2COJ (0.386 g, 2.8 mmol) in dry DMF
(25 mL) under nitrogen atmos phere was added 1,2-dib romopropane (0.56g, 2.8 mmo l)
along with KI (0.464 g, 2.8 mmol). The reaction mixture was heated at 70 °C for 24 h,
and then poured into ice-Hjt) . The resultin g thiazetoquin oline derivative was collected by
filtration and recrystallized from hexane: CHCIJ (I :3) to afford yellowis h crystals; yie ld =
75%
ii) Oxidative Cyclization using iodobromld e and/or iodin e
To a mixture of 3a (0.385 g, I mmo1) and K2C03 (0.386 g, 2.8 mmo1) in dry DM F
(25 mL) under nitrogen atmos phere was added iodob romid e and/or iodine (2.8 mmol).
142
Chapter s : Synt hesis of NOI'e1./.0xo- l•./.DiI'.l'clroB, " zofhlfl ,3fT hiaUlOf3,l-(Ifqllhwli ne Carboxyl ic Ac ids ...
The reactio n mixture in case of iodobromide was stirred at room temperature for 24 h (in
case of iod ine the reac tion mixture was heated at 70 °C for 24 h). After coolin g, both
reaction mixtures were poured into ice- l-bO. The resu lting thiazetoquinoline derivative
was collected by filtra tion and recrystallized from hexane : CI-ICI) (1 :3) to afford
yellowish crystals; yield (IBr) = 40%, yield (h) = 49%. mp 223-225 DC; I H-NMR: (500
MHz, CDCI)): 0 = 8.42 (d , J = 8.6 Hz, 1H), 7.9 1 (d, J = 8.3 Hz, 1H), 7.82 (d, J = 8.5 Hz,
11-1),7.68 (d, J = 8.7 Hz, IH ), 7.61 (t, J = 7.4 Hz, 11-1),7.56 - 7.52 (m, IH) , 6.67 (s, 1H),
4.38 (q, J = 6.7, 6.2 Hz, 2H), 4.23 (q, J = 7.2 Hz, 2H), 1.41 (t,.! = 7.3 Hz, 3H), 1.08 (t, J
= 7.3 Hz, 3H); I3C NM R (175 MHz , CDC I3): 0 = 173.2, 165.7, 165.4, 136.1, 135.8, 129.9,
129.0, 127.5,123.9 ,122.4,122.4,121.7,121.6, 106.9,67.7, 64.1, 6 1.7, 3 1.3, 14.7, 14.1;
HR-MS (TOF EI) calcd for C2oH17NOsS (383.0827); found (383.0826) .
4-0xo-l ,4-dihydrobcnzo[It)[l ,3Ithiazcto[3,2-a)quinolinc-1,3-dicarboxylic acid (4b):
Followi ng a reported procedure [35] , a mixt ure of ester (4a) (0.385 g, 1 mmol ) and
sodium hydroxide (0.08g, 2.2 mmol) in water (20 mL) was stirred and heated at 100 °C
for 3-4 h. After coo ling, the reaction mixture was neutralized with hydrochl oric acid (1
mol/L), extracted with CH2Ch, dried over MgSO~ , then evaporat ed . The solid obtained
was purified by recrystallization from EtOH to afford Compound 4b as yellowish white
powder ; mp 233- 235 DC; I H-NMR: (500 MHz, DMSO-d 6) : 0 = 8.27 (d, .! = 8.8 Hz, IH),
8.25 (d, .! = 8.4 Hz, IH), 8.17 (d, J = 7.5 Hz, IH), 8.02 (d, J = 8.8 Hz, IH), 7.83 (dd, .! =
11.0,4.0 Hz, 11-1), 7.81-7.76 (m, IH), 7.73 (s, 1H); 13C NM R ( 175 MHz, DMSO-d6) : 0 =
175.7,165 .6, 165.2, 164.2, 136.0,1 35.2,129.5,128.9, 127.5, 126.0, 122.6,122.3,1 21.5 ,
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121.1 ,1 03.6,70.4; HR-MS (TOFE I) calcd for C, sH9N03S (283.0303); found (283.0313)
[36] .
Ethyl l -cyano- 4-oxo-I ,4-dih ydr obenzolll 111,3]thiazetoI3,2-a lquinoline-3-
carboxy late (4c).
This compound was prepared using the same procedure as that used for the synthesis of
4a using KI, K2C0 3 and 1,2-dibromopropane starting from 3c; white powder; mp 220-
222 °C; 'H-NMR: (500 MHz, CDC!}): 8 = 9.35 (dd, ./ = 5.3, 3.1 Hz, IH), 8.17-8.02
(m, IH), 7.90 (dd,./ = 5.5, 3.4 Hz, IH), 7.86-7.81 (m, IH), 7.79-7.72 (m, 2H), 4.59 (g, ./ =
7.11,7.08 Hz, 2H), 4. I7 ( IH, s), 1.56 (t, ./ = 7.13Hz, 3H); 13CNMR (175 MHz, CDCb):
8= 168.3, 167.9, 149.3, 147.9, 135.5, 130.2, 130.0, 128.0, 127.8, 127.7, 126.1. 118.9,
115.8, 109.3, 103.2, 63.8, 30.9, 14.2; HR-MS (TOFE I) calcd for CIsHI2N203S
(336.056 8); found (336 .056 I) .
Ethy l 4-(3-brom opropoxy)-2-((2-et hoxy-2-oxoe thyl)thio)be nzo [II]quino line-3-
carboxy late (5):
To a mixture of 3a (0.385 g, I mmol) and K2C0 3 (0.386 g, 2.8 mmo l) in dry DMF (25
mL) under nitrogen atmosphere was added I,3-dibromopropane (0.56 g, 2.8 mmol) along
with KI (0.464 g, 2.8 mmol). The reaction mixture was heated at 70 °C for 24 h., and then
poured into ice-Hjf) . The resultin g product was collected by filtration and recrystallized
from hexane: CHCI3 (1:3) to yield a white powder; mp 162-164 DC; I H-NMR: (500 MHz,
CDC!}): 8 = 9.2 1-9. 14 (m, IH), 7.95(d, J> 8.9 Hz, IH), 7.91-7.85 (rn, IH), 7.76 (d, ./ =
8.9 Hz, IH), 7.70 (m, 2H), 4.53 (g,./ = 7.1Hz, 2H), 4.35 (t, J = 5.8 Hz, 2H), 4.22 (q, J =
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7.1Hz, 2H), 4.15 (s, 2H), 3.70 (I. CH2Br, J = 6.4 Hz, 2H), 2.42 (q, CH2CH2CH2.J = 6.1
Hz, 2H), 1.49 (t, J = 7.1 Hz, 3H), 1.27(t, J = 7.1 Hz, 3H); I3C NMR (175 MHz, CDCb) :
8 = 162.1, 160.6, 160.2, 153.7. 148.0, 134.2, 130.2, 129.0, 127.6, 127.0, 125.9, 125.4,
119.9, 115.8, 113.8, 70.9, 70.0, 61.2, 33.8, 29.8, 25.0, 14.4, 14.3; APCI-MS: 506.40
(M++ I, IOO).
Ethyl 8,9-dih yd ro-7, I O-di oxa- 12-th ia-13-azaa zul eno 18,1-ab]ph en:mth rene-l l -
car boxylate (6) :
This compound was prepared using the same procedure as that used for the synthesis of
4a using 1,2-dibromoethane to afford a yellow crystalline product ; mp 250-252 °C; 11-1-
NMR : (500 MHz, CDCb) : 8 = 9.35-9.28 (m, 1H), 8.14 (d, J = 9. 1 Hz, 1H), 7.93-7.87 (rn,
11-1),7.74 (dt, J = 5.9, 9.7 Hz, 3H), 4.96-4 .92 (m, 2H), 4.84-4. 79 (m, 2H), 4.42 (q, J = 7.1
Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H); 13C NMR (175 MHz, CDCb) : 8 = 162.1. 159.5, 158.2,
152.8,148.3,134.3,1 30.1 ,1 29.1,1 27.6,1 27.0,1 25.8, 125.4 , 119.4, 113.8, 111.4, 104.8,
73.6 , 72.2, 61. 1, 14.4; HR-MS (TOFEI) calcd for C2oHI5NO~S (365.0722); found
(365 .0727) .
4-0xo-l ,4-dih ydr o benzo l" III ,3]thiaze to I3,2-a ]quinoline- l-c arboxylic acid (4d) :
Following a reported proc edure [37], to a solution of 4b (2.43 g, 8.6 mmol) and N-
methylmorpholine (0.960 g, 9.5 mmol ) in THF ( 15 mL) at 0 °C was added ethyl
chloroformate (1.03 g, 9.5 mmol ) dropwise and the mixture was stirred for 30 min. The
solid was filtered off and the filtrate was added to the solution of hydrox ylamin e
hydrochloride (0.896 g, 12.9 mmol ) and Et3N (1.3 g, 12.9 mmol) in DMF (20 mL) for 10
min . The reacti on mixture was stirred for 30 min at 25 °C. DM F was evapora ted in vacll o.
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The residue was extracted with EtOAC (80 mL) and washed with water. The solvent was
dried over MgS04 and evaporated to dryness. The crude product was purified by silica
gel column chromatography using EtOAC: hexane ( I: I); yellow powder; mp 250-252
°C; 'H-NMR : (500 MHz, DMSO -d6) : Ii = 8.28 (t, J = 9.1 Hz, 2H), 7.98 (d, J = 7.9 Hz,
IH), 7.68 (m, 2H), 7.55 (t, J = 7.6 Hz, IH) , 6.43 (s, IH), 5.68 (s, IH). I3C NMR (175
MHz, DMSO-d6) : s = 178.9, 173.5, 171.1, 170.5, 141.5, 139.8, 133.5, 133.3, 131.2,
129.5, 128.2, 128.2, 128. 1, 116.7, 76.1; HR-MS (TOFEl) calcd for C, sH9N03S
(283.0303); found (283.030 1).
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A h~t ract
The title compound. C I ~lIqNO'iS. (~a ) was obtained from the reaction of ethyl 2-
1(2- ethoxy·2-oxoethyl)thio)-~-hydroxyben7.o (hlquinoline·3-carboxylate with 1,2-
dibromopropane in the presence of KI (2.8 mmol), followed by Saponification using
sod ium hydroxide. A combination of intermolecular interactions led to Jt- stacked
molecules that were further organized into 0--11·· ·0 hydrogen-bonded chains.
0 " 0
~A.I Relatl'd lit er a tu re
For background on the biological importance of thlazetoquinofine antibiotics sec
reference [B b]. For similar work using different procedures sec references 1151and [38)
~A .2 Exper imenta l
~A.2 .1 Crys tal data
Mr ""327.3 1 Z ""~
Monoclinic. PZl /e Mo s« radiation, A:; 0.71075 A
a » 7.237 (2) A ll ""0.27 mm- l
b » 16.171 (5) A T = 153 K
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c = 11.929 (4) A 0.18 x 0.04 x 0.04mm
p= 106.081 (8)0
4A.2.2 Data collection
Rigaku Saturn
Diffractom eter 2769 independ ent reflections
Absorpti on correction: Numerical
[46] 2614 reflections with 1> 2cr(1)
Tmin = 0.974 , Tmax = 0.996 Rint = 0.074
17300 measured reflecti ons
4A.2.3 Refinement
R[Fl > 2cr(Fl)] = 0.088 2 restraints
wR(Fl ) = 0.164 H atoms treated by a mixture of indep endent and constrained
refinement
S > 1.306pmax =0.31 eA-3
2769 reflecti ons Aprnin = - 0.31 e A- 3
2 14 parameters
Data colle ction: Crys tatCle ar [38]; cell refin ement : Crys talClear; data reduction:
CrystaiClear; program (s) used to solve structure : SHELXL9 7 [39]; program(s) used to
refine structure: SHELXL97; molecul ar graphics : Mercur y [40]; software used to prepare
material for pub lication : publ CIF [41].
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Tablc 4-3: Hydrogen-b ond geo metry (A, 0).
03 -H3. .. 04'
0.96 (4)
0.97 (3)
1.57 (4)
1.62 (3)
2.504( 4)
2.569 (4)
161 (4)
166 (3)
Symmetry code: (i)x - / , -y+//2. =-//2 .
Tablc 4-4: n ..... n interacti ons (A, 0)
Angle of elevation defined as the angle of the Cg(I)-tCg(J) vector and the nonnal to plane 1. Cg I, Cg2 and
Cg3 are the centroids of the C7-C I2, N l/Cl -C4/C I3 and C4-C7/C I2/C I3 rings, respectively.
Il .. ... Il Distance Angle of Elevat ion
Cg l . .Cg2' 3.560( 2)
Cg3. .Cg2' 3.644 (2) 22.75
Cg3 .. Cg3' 3,688( 2)
Symmetry code: (i) -x + I, -y,-=.
4A.3 Comment
Compound 1 crystallized in P2 1/c, with one entire molecule contained in the
asymmetric unit. Multip le short n contacts between aromatic ring centro ids (Figure 4-7)
result from the close asso ciation of molecules in n-stacks (Figure 4-8). Centroid-centroid
distances range from 3.57 to 3.69 A with angles of elevation between 65.6 and 69.1°
(T able 4-4), while the inter-planar distance, as defined by adj acent 14-atom (N I. C I-
C 13) ring systems is 3.34 A. Further, ( I) exhibits intra- (0 5- H5a " 'O I) and
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intermolecular (03 - H3· ·-0 4i) hydrogen bonding. leading to a chain -like arran gement of
molecules which run perpendicular to the n stacks.
4AA Refine ment
Hj and H~a were located from differe nt Fourier maps. and were refined positionally
with restrained distance s (shclxl DFIX 0.96) and fixed Uiso values (L 2Ueq of the
attached atom). All other H atoms were introduced in ideali zed positions with constrained
distances and with Uiso( lI ) values set to either 1.2Ueq or 1.5Ueq of the attached atom.
They were relined on a riding mod el. All non-hydrogen atom s were relined
anisotropically.
i"i ~ure 4-9: A view ofthe molecular structure of the title molec ule. with displacement
ellipsoids drawn at the 50% probability level .
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Figurt: -1· 10: A partia l view of the crystal packing of the t itle compound.
Both the hydrogen bonding [symmetry codes: (i ) x-I , y, z: (ii) x, -y+l l2. z+1/2; (iii)
x+l. y. z+l] and n' ··n interactions [symmetry codes: (ii ) x. -y+1I2. z+ll2; (iv) -x+l ,
y+112, -z+II2J are shown as dashed lines; ring centroids are marked by small spheres.
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Preface
This chapter describes the synthesis and biological evaluation of furoquinolines as
isosteres of the thienoquinolines that were previou sly discus sed in Chapter 3. The
previously described thienoquinolines did not show in vitro cytotoxicity on cancer cell
lines. althou gh the docking study showed binding affinity for the ATP binding site in
topoisomerase II (1QZR). The synthesized furo derivatives showed no cytoxicity, as well.
either in the Brine Shrimp Lethality assay or the MIT assay. The structural similarity and
the angular configuration of this class of compounds to the previously reported
furocoumarins encoura ged us to test and explore their antivi ral propertie s.
Abstract
Recently. thienoquinoline derivatives have attracted the attention of medicinal
chemists due to the demonstration of diverse biological activities. including memory
enhancing, anti-aller gic, antiinflammatory, immunore gulator, analgetic and antipyretic,
antibacterial and anaphylactic activities . Previousl y, the biological activiti es of the
thienoquinolin e derivatives were designed, synthesized and evaluated. In this chapter
preparation of a series of angular benzo[h]furo[2,3-b]quinolines as bioisos teres of the
previously synthesized angular benzo[h]thieno[2,3-b]quinolines is described. Much
literature has shown that the furoquinolines have a wide range of pharmacological
activities, but few papers have addressed the activities of the benzo[h] furo[2,3-
b]quinolin es.
Keywords: Furo[2,3-b]quinolines, dowtherm, Vilsmeier - Haack , Chloroacety l chloride.
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5.1 Introduction
Two forms of furano-coumarin condensation occur in nature, The first form
comprise linear molecules. that are constructed by linking the 3'.2' furan bond to the 6,7
coumarin bond. The 3',2' bond may also link to the 7.8 coumarin bond to produce angular
furocoumarins (Angclicin). Linear furocoumarins (Psoralen de rivatives). as structural
representatives of furoquinolincs. are a well-known family of natural and synthetic
photosensitizing compounds which exihibit interesting photobiological and
phototherapcutical activities (1.2].
c:»:
lJJ
Psnr alen
Some of these compounds arc used in I'UVA photoch crnother apy (psoralcn plus
lJV-A) to treat a variety of skin diseuzses. They arc also employed in extracorpored
photochemothcrapy (photopheresis) to treat cutaneous Tcccll lymphomas; Psoralcn plus
UV-A is also used as a selective immunosuppressive agent for the cure of various
autoimmune diseases and to prevent rejection in organ transplants 11.2).
Moreover. psoralen derivatives arc also used as tools in biophysical studies on
nucleic acids and are now recognized as effect ive antiviral agents. especially against
enveloped viruses such as the Herpes simpl ex virus or IIIV-1 [3.4].
The preferred derivative is 8-mcthoxypsoralcn (8-MO!') but also 5-
mcthoxypsoralcn ( 5-~tOI') and 4. 5'_ 8-lrimethylpsoralen (TMP) are used. They exhibit a
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good antipro liferative effect due to their capabilit y of photodamaging DNA, leading to
monofuncti onal and two different kinds of bifunct ional adducts, interstrand cross -links
(lSC) [5] and DNA-pro tein cross- links (DPC), connectin g a DNA base and a protein A.A
together [6-8] .
0 /
~ DCo hero-o 0 ~ 0 o 0 ~ 0 o 0 ~ 00 ,
8-MOP 5-MOP TMP
The bifun ctional damage, especially the induction of ISe , was shown as the main
cause responsible for the furoco umarin toxicit y i.e. skin erythemas, genotoxic ity with
induct ion of point mutations in bacteria [1,9-12].
Recentl y, the formation of chromoso mal aberrations was main ly attributed to ope
[13); therefore, to obtain less toxic compounds, various authors planned to study new
compounds that are characterized by a prevalent ability of formin g monofunct ional
damage. The main resea rch line dealt with Angelicin preventin g the form ation of ISe ,
which was due to its geometrical properties [14,15].
Furoquinoline alkaloids are charac terised as seco ndary meta bolites of the Rutacea
family, in which they occur with the chemically-related furocoumarins [16,17]. Some of
these plant s are used in phytotherapy, e.g. Ruta graveo lens and Dictamnus albus. Others
are known as sources for the isolation of antineoplastic agents like acronycine from
Acronychia baueri and Fagara zanthoxyloides [18,19].
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Furo[2,3-b]quinoline constitutes an important group of bioactive natural products
such as dictamine, acrophylline, confu sameline. skim rnianine, kokusaginine, and
haplopine [20-23].
OH 0
/
0
ceo COo c6=).0 N/- 0 o --::; N 0 HO --::; N/- 0
A:ro Phym"\
0 ...... 0 ...... 0 ......q;o ~ -O~I "" '-':: ~' 0 .0 N/- 0 o .0 N/- 0 ' 0 .0 N/- 0
......0 '-0
Haplopine Kokusag inin e
Figure 5-1: Structura lly-re lated furoquinoli nes natural prod ucts .
The furoqu inoli ne alkaloids were found to have a wide range of biological activities
[24] including anti-allerg ic [20], cytotoxic [21], antiplatlet aggrega tion [13. 23] and
voltage-gated potassium channel blocking [24].
The developm ent of efficient syntheses of furoquinolines has been the focus of
much research for many decad es and continues to be an active and rich research area
[25,26].
Most procedu res used for the synthesis of furoquinolines suffer from the limited
availability of substrates or require multistep procedur es to construct the furan ring
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individually . In the last decade. many new procedur es for the synthes is of furoquinolines
have been publ ished [27- 38] .
DNA-intercalators containing a linear or angular planar chromophore with a
polyaromatic ring can influence the structures and physiological funct ions of DNA [39].
Some intercalators such as furocoum arines, acridines, anthraquinones,
naphth alimid es, and phenanthridin es are used in cancer treatment [40-43]. Angelicin, an
angular furoc oum arin , has been used to treat pain in the loins and knees [44], and skin
diseases in phototherap y [45]. Guiotto et al. have synthes ized a series of furoquinolinones
[46-51], in which the oxy gen atom of furocoumarin has been substituted by NH, and
some of them showed strong antiprolifer ative activity aga inst tumor cell lines upon UVA
(Ultraviolet-A) irradiation . However, these furoquin ol inones also demonstrated skin
phototoxicity and marked clastogenic activity due to the formation of cova lent
monoadduct s (MA) with DNA base and cova lent DNA-protein cross -links (DPC) upon
UVA activation. In the dark , these furoqu inolinones exhib ited weak antipro liferative
activ ity with a mechanism of action related to topoisomerase II inhibition. In contra st to
normal cell s. many tumor cells show high expressio n levels of topoiso merase II , making
this enzyme an idea l dru g target [52-54] .
For understandin g the biological importance of furoquinolines , much of the
literature has addresse d the synthes is and biological activities of seve ral substituted
furo[2,3-b]quinoline derivativ es [55-57] .
Yeh-L ong Chen et al. [56] had reported the synthesis of certain linear 4-
anilinofuro[2,3-b]quin olin e and angular 4-anilin ofuro[ 3,2-c]qu inoline derivatives and
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their in vitro anticancer activity against the full panel of NCI's 60 cancer cell lines.
Among the linear 4-anilinofuro£2.3-b)quinoline derivatives. l-14-(furo[2.3-b]quinolin-4-
yluminojphenyljethanon e I is the most cytotoxic with a mean GI<,o value of 0.025 IJ.M.
Among the angular -t-anilino furojj .j -c jquinclinc derivatives. (E)- I-(3-(furo[3.2-
£')quinolin-4-ylamino)phenyl]ethanone oxime I I exhibited pote nt inhibitory activities on
UO-31. UACC-257. and UACC· 62 cells. with G I ~o values of 0.03. < 0.01. and < 0.01 11M
respectively.
II
Based on the latest data obta ined on furoquinclines (58) explaining the importance
of furoquinolines as inhibitors of multiple targets in the PI3KJAkt-mTOR Pathway. we
became interested in the design and synthesis of the angular benzo[h]furo[2,3. h]
quinolines as potential cytotoxic agents. The synthesis pan has been done in an attemptto
prepare a bifunctiona l compou nd in which furo[2.3-h)quinoline moiety acts as an
intcrcalator while the lactone ring plays the role of an alkylating unit.
Synthesis of the title Compounds .' 11 and 3h was accomp lished by adding the
activated dicthylmalonate solution to chloroacetylchloridc in TIIF followed by
triethylamine and l -naphthylaminc. This procedure resulted in the formation of the
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uncyclizcd intermediate afte r overnight stirring at room temperature. Thermal cyclization
of this mixture in dowt hcrm under vacuum affords the cyclized furo[2 .3-h]quinoline s as
depicted in Scheme 5-1 .
~I : OO R'" I N::::,.. 3a R'H , 6S'llo
Scheme 5-1: Synthesis of cyclizcd Furo[2.3-b]qui nolines.
Further reactions o f .' 11 to afford several substituted analogues arc depicted in
Schem e 5 -2. Namely. the reaction of .'a with phen yltrimethylammonium tribromide
(Pl AB) in TII F afforded 3c in a reasonable yield.
Also, croton condensat ion took place upon reacting 311 with p-fluorobenl.aldehyde
in acetic acid in the presence of l lCI to afford Compo und 3('
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Scheme 5-2: Synthesis orFuw/2,3-hJquinolincs deriva tives
In our attempt to improve the hydrophobic-hydrop hilic balance in these molecules.
Compounds 3a and 3h were allowed to react with hydrazine hydrate and acetone to
afford Compounds 3f and 3g:in reasonable yields. as depicted in Scheme 5-.'
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Scheme 5-3: Synthesis of the hydrazone derivative s 3r and .~~
ln a trial to develop a bioisostcrc to the previously synthesized derivative (fill)
(Chapter 3), Compou nd 3i was synthesized as shown in Scheme 5-4. Compound .' a was
allowed to react with carbo n disu lfide and 30% sodium hydroxide in dimet hylsulfoxide to
obtain Compound .' h, further reaction of which with sodium hydroxide in methanol
afforded Compound 3i
169
~: O 'sI ~9' N 0 $ -~I
3J 6I'I%
Sch em e 5-~ : Synthesis of the fUTO bioisus tere.
Since our cytotoxic screening failed 10 generate potential leads 10 initiate a drug
discovery effort, we embar ked on a mo lecu lar doc king approac h to ex plore other possib le
bio logica l activ ity profiles of this class of compounds,
5.2 Molecul ar mlldclin ~
5.2. 1 ;\I t'th uds
Docking ca lcu lations were ca rried out accordi ng to the DockingServer methodology
(60]. The MMF F94 force field [61 J was used for energy mini mization of ligand molecule
(R HODAM INE B) using DockingScrvc r. PM6 scmicmpirical charges calcu lated by
MO l'AC2009 (J. P. Stewart , Com puter code MOP AC2009. Stewart Com putationa l
Chemis try, 2009) were added 10 the ligand atoms. Non-polar hydrogen atoms were
merged , and rotatab le bonds were defined.
Docking calc ulat ions were ca rried out on IICV hclic asc struc ture with the pdb code
3KQN. Esse ntial hydrogen atoms. Kollman united atom type charges, and solvation
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parameters were added with the aid of AutoDock tools [62]. Affi nity (grid) maps of
25x25x25 A grid points and 0.375 A spacing were generat ed using the Autogrid
program . AutoDock parameter set- and distance-dependent dielectric functions were
used in the calculation of the van der Waals and the electrostatic terms, respectively.
Dockin g simulations were performed using the Lamarckian genetic algorithm
(LGA) and the So lis & Wets local search method [63]. Initial posit ion, orientation, and
torsions of the ligand molecul es were set randoml y. Each dock ing experiment was
derived from 100 differen t runs that were set to termin ate after a maximum of 2,500,000
energy eva luation s. The popu lation size was set to 150. During the sea rch, a translational
step of 0.2 A,and quat erni on and torsion steps of 5 were appli ed.
5.2.2 Result s
Novel Benzo[h]fur oquin oline derivatives have been synthes ized and now are being
experimentally tested for their antivira l properties. In the present study in-silico
inves tigation of HCY inhibitor properties of the novel compounds is carri ed out. As there
are many X-Ray structures for the Hepatiti s C virus helica se availab le in the Protein Data
Bank, inhibiti on of HCY helicase has been wide ly studied. Acco rding to the recent
publ ications there are different classes of inhibit ors: AT P binding inhibitors, HCY
replication activity inhib itors, and allosteric inhibit ors which influence conformationa l
change of the prot ein . Thu s, the protein for dockin g calculation should contain A TP as
well as bound DNA tha t enab les us to explore all possible bindin g sites and modes of the
ligands. X-Ray struc tures 3KQL , 3KQN and 3KQU meet these criteria, with 3KQN
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possessing the most accurat e XiRay determinat ion (lowest resolution). Therefore. 3KQN
was chosen for docki ng calculations.
5.23 Blind dockin~ res ults
First. docking calculations of Compound s 3a were carried out on the whole protein
(blind docki ng method) in order to explore the possible binding sites of the ligands. Blind
docking methodolo gy calculate s the energy of ligand binding at different sites of the
protein. The site where the ligand is bound with the lowest energy is then funhe r
subjected to focused dock ing calculation. All docking calculations revealed that the
compounds under study are most likely to bind 10 the All' binding site of the protein.
Fi~urt· 5-1 shows the first rank result of blind docking calculation of Compound 3r .
Figure 5-1: Compound 3c docked toi lCY helicasc ATP binding site.
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5.2.4 Focu sed docking result s
Based on the result s of blind docking calcula tion, all of the investigated compound s
were docked into the ATP binding site of 3KQ
Table 5-1: Docking energie s of the investigated compounds at the ATP bindin g site.
Com pound Dockin g ene rgy (kcaUmo l)
3c -8.77
3g -8.66
3c -8.56
3f -8.38
3j -8.27
3i -8.2 1
3d -8.04
3h -7.93
3b -7.79
3a -7.41
Table 5.1 shows the ca lculated interaction ener gies at the ATP bindin g site. Among
the investiga ted Compounds 3c was calculated to bind to the protein with the highest
affinity . ext the interactions of the compounds with the best affinitie s were analy zed.
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Table 5-2: Interactions of Compo und 3c with HCY helicase at the ATP binding site.
Hydrogen bonds
SER211
(00)
Halogen-bondMetal-l igand
R-EZE C4
(W, CEI) (31'1
R-EZE El1
(CEI) (2371
::,rn
(0) (3141
(CllOO)
pi-pi
(J" I
Ol
{J "' I
NAZl4 a;
(Cll) {J " I
(Cll) {J251
Hydrophobic
SER21 C13
(00) [JIllI
_ C14
("") {J 811
;:2rn
~2 ~77J
(001) {J OfI
G-Y417 Nt
(0)(2191
{J:!>I
[""1
{JWI
(Jll»
C13
{J371
Compound 3c is mainl y stabilized by hydro gen bond s and pi-pi interactions. It
forms five hydrogen bond s with both side chain (SER2 11, THR2 l2, THR4 19) and main
chain (OLY207, OL Y4 17) of 3KQN. The planar aromatic moiety of the ligand fits in the
hydrophobic cavity formed by PHE238, TYR24 1 and PHE418. An additional halogen
bond is observe d with the side chain of SER2 11. Mn2+ is in interacting distance of the
ring oxygen and bromo group.
5.3 Conclusion
This Chapter describ es the design and synthes is of the novel furoq uinoline
deriva tives. These co mpounds were found to demonstrate wea k or no cytotoxici ty to
cancer cell lines. Moreove r, docking of the compounds in the ATP active site of HCY
helicase may sugges t that the synthes ized comp ound s possibly act as HCY inhibitors and
this may contribute in part to their antiviral properti es.
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5.4 Experimental
' H and 13CNMR spectra, HSQC, and COSY spectra were recorded on a Bruker 500
MHz NMR spectrome ter using TMS as an interna l standard. LC-MS and HRM S were
conduct ed using a GCT Premier Microm ass spectrometer. X-ray structures were
measured with the Rigaku Saturn 70 instrum ent, equipped with a CC O area detector and
a SHINE optic, using Mo Ka radiation. Silicycle Ultrapure silica gel (0-20 urn) G and F-
254 were used for the preparative TLC, and Silicycle Sili a-P Ultrapure Flash silica gel
(40-63 urn) was used for flash column chromatograph y. TLC was conducted on
Polygram SIL G/UV2 54 precoat ed plastic sheets. Solvents were purifi ed using standard
conditi ons before use. The reaction yields are includ ed in the correspondin g schemes .
Ethyl (2E)-2-(nap hthalen-l -ylimino)-4-oxo tetrahydrofuran-3-ellrboxyhlte (2a):
Sodium hydride (3.35 g, 139.67 mmol) washed with dry n-hexane was suspended in
dry tetrah ydro furan (250 mL) and a solution of diethyl malonate (2 1.20 ml. , 139.67
mmo l) in tetrahydrofuran was added dropwi se. The clear salt was transferred to droppin g
funnel , and added dropwise to a solution of chloroacetylchloride (5.93 ml. , 74.48 mmol)
in tetrahydrofur an (6 mL) over a period of I h. The reaction mixture was stirred for 2 h.
Triethyl amine (25 .95 ml. , 186.21 mmol) was added to the reaction mixtur e and it was
stirred for 2 h. l-n aphth ylamin e (10 g, 69.83 mmol) in tetrahydrofuran (100 mL) was
then added dropwis e over a period of I h. The reaction mixtur e was stirred overnight;
TI-IF was evap orat ed in va C1IO, followed by the additi on of water and extraction with
chloroform. The orga nic layer was washed with water. and dried over sodium sulfate.
Chlorofo rm was evaporated under vacuum and the residu e was triturated with ether,
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filtered and washed with additional ether to yield yellowish brown crystals. Mp 148-
150°C. I H-NMR: (500 MHz, CDC!)): 0 = 10.72 ( IH, s, OH), 8.01 ( IH, d, J = 8.3 Hz),
7.93 (IH , d, J = 8.0 Hz), 7.82 ( 1H, d, J = 8.2 Hz), 7.69 (lH , d, J = 7.4 Hz), 7.66-
7.6I(1H, m.), 7.58 (lH, t,J =7.5 Hz), 7.5I(1H , t, J = 7.8 Hz), 7.26 (l H, s), 4.66 (21-1, s),
4.48-4.42 (21-1, q, J = 7.2, 9.0 Hz, 0lliCI-b), 1.45 (3H, t, J = 7.1 Hz, OCHzQ:b). 13C
NMR (175 MHz, CDCb): 0 = 188.5, 178.6, 165.9, 134.1 , 129.9, 128.7, 127.4, 127.4,
127.2,126.8,1 25.3, 120.9,87.9,75.4, 60.7, 30.9,1 4.6. APCI-MS 296.30 (M+-I, 100).
Synthesis of 7-hydroxy benzo js Ifu ro [2,3-b Iquin olin -8(9H)- one(311) :
Compound 2a (2.0 g, 6.74 mmol), as a fine powder , was added with stirring in one
lot to Dowtherm (50 mL) maintained at 240 °C. The temperature was then raised to 255
"C and mainta ined for 10 min. The mixture was then cooled to room temperature and
diluted with a large volume of hexane to precipitate a brown solid that was collected and
washed with hot hexane . Mp>300 0c. I H-NMR: (500 MHz, DMSO-d6): 0 = 8.82 (l H, d,
J =7.5 Hz), 8.15 (lH, d, J = 7.7 1-lz), 8.07-8.11 (lH, m), 7.85 ( IH, d, J = 7.5 I-Iz), 7.75-
7.80 (2H, m), 4.90 (2H, s). I3C NMR (175 MHz, DMSO-d 6): 0 = 193.2, 178.2, 173.5,
148.3, 134.8, 130.6, 127.1, 126.9, 125.0, 124.6, 122.7, 122.3, 119.5, 99.5, 71.7. I-IR-MS
(TOFE I) calcd for C IsH9N0 3 (25 1.0582); found (25 1.0581).
Synthesis of (4Z ,5E) -4-(ethoxy methylidene)-2-methy1-5-(naphthalen- l -
ylimino)dih ydrofuran-3(2H) -one (2b) :
Sodium hydride (3.35 g, 139.67 mmol) washed with dry n-hexane, was suspended
in dry tetrahydrofuran (250 mL) and a solution of diethyl malonate (2 1.20 ml., 139.67
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mmol) in tetrahydro furan was added dropwise. The clear salt was transferre d to dropping
funnel , and added dropwise to a solution of 2-chloro propionyl chloride (7.22 ml. , 74.48
mmol) in tetrah ydrofur an (6 mL) over a period of I h. The reaction mixtur e was stirred
for 2 h. Triethy l amine (25.95 rnl. , 186.21 mmol ) was added to the reaction mixture and it
was stirred for 2 h. l- Naphthylamine (10 g, 69.83 mmol) in tetra hydrofu ran (100 mL)
was then added dro pwise over a period of I h. The reaction mixture was stirred
overnight; THF was eva porated in vaCIIO, followed by the addition of water and
extraction with chloroform. The organic layer was washed with water and dried ove r
sodium sulfate. Chloroform was evaporated under vacuum and the residue was triturated
with ether, filtered and washed with additional ether to yield redd ish brow n powder . Mp
140-142°C. I H-NMR: (500 MHz, CDCb) : 8 = 10.75 (l H, s, 0 1-1), 8.00 ( 1/-1, d, J = 8.2
Hz), 7.91 ( IH, d. J = 7.6 Hz), 7.80 (1/-1, d, J = 8.2 I-1z),7.69 ( IH, d, J = 7.4 Hz). 7.67-
7.46 (3H, m, J = 4.5,1 5.7, 27.3 Hz), 7.28 (l H, d, J = 5.1 Hz), 4.75 ( IH, g, J = 6.9 Hz),
4.43 (21-1, q, J = 7. I I-Iz), 1.54 (3H, d, J = 7.0 Hz), 1.44 (3H, t, 7. I I-Iz). 13C NMR (175
MHz, CDCb): 8 = 191.4 , 177.1, 166.2, 134.1, 130.1, 128.7 , 127.3, 127.3, 127.1, 126.7,
125.3, 120.9, 120.7,86.7,84.1, 60.6,1 6.9,14.5. APCI-MS : 3 10.33 (M+-I , 100).
Synthesis of 7-hy droxy-9- methylbenzo[Il)furo[2,3-bl guinolin-8(9H)-o ne (3b):
Compound 2b (2.0 g, 6.42 mmol), as a fine powder, was added with stirring in one
lot to Dowth erm (50 mL) maint ained at 240 0 C. The temp eratur e was then raised to 255
DC and maintained for 10 min . The mixture was then cooled to room temp erature and
diluted with a large volume of hexane to precipitate a pale yellow solid that was collected
and washed with hot hexane. Mp > 300 °C. ' I-I-NM R: (500 MHz, DMSO -d6): 8 = 8.82
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( IH. d. J = 7.7 Hz). 8.14 ( I H. d. J = 8.7 Hz). 8.10-8 .02 ( I H. m), 7.83 ( IH, d,J= 8.5 Hz),
7.79-7.71 (2H, rn), 5.11-5.02 ( 11-1. q, J = 7.0, 7.0 Hz). 1.53 (31-1, d, J = 7.0 Hz). HR-M
(TOFE I) ca1cd for C I6HII 0 3 (265.0739); found (265 .0735) .
Synthesis of 9-brom o-7-h)'dr oxyb enzo[1t)furoI2,3-b)quino lin-8(9 H)-o ne (3e):
A mixtur e of furoquinoline 3:1(0.5 0 g, 2.0 mmol) and 175 mL of anhydrous
tetrah ydrofuran was heated to 40 °C. A solution of (0.75 g . 2.0 mmol ) phenyltrim ethyl
ammonium tribromide (PTAB) in 65 mL of dry TI-IF was added dropwise over 30 min
and the mixture was stirred for an additional 75 min at 40 "C and kept at room
tempe rature for 20 min. The insolub le material was removed by suction filtration and the
filtrate was evapor ated . The residue was recrystalli zed from toluene and the precipit ate
was dissolved in acetone. After addition of 150 mg of charc oal, the mixture was stirred at
room temper atur e for 30 min . and filtered . The filtrate was eva pora ted to dryness to
obtain a light brow n solid. Mp> 3 10 °C. I H_ MR : (500 MHz, DMSO-d6): 8 = 12.08
(l H, s), 9.98 (l H, d, J = 8.3) . 8.13 (l H, d,J = 7.8), 7.91-7.85 (2H, m), 7.82 (2H, i.J » 6.0
Hz), 5.95 ( IH, s). 13C MR (175 MHz, DMSO-d 6): 8 = 192.9, 180.5, 157.4, 142.0.
136.2, 130.2, 128.9, 128.8. 128.2. 127.3, 123.5. 123.0, 12 1.3, 118.2, 100.8. I-IR-MS
(TOFE I) ca1cd for C1sHgBr 0 3(328.9688); found (328.969 8).
Synthesis of 7-hydroxy-8-chloro-8,9-dih ydrobenzollt Ifu ro 12,3-bIquinolin e-9-
carbaldchyde (3d) :
Phosphorus oxychloride (2.3 mL) was added dropwi se to DMF (2 mL) at 10 "C. A
solution of Compound 3 11 (2.25 g, 9 mmol ) in 25 mL of DMF and 75 mL dioxane was
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then added to the POCIJ-OMF mixture. The reaction mixture was then heated for 2 h in a
water bath. The precipitate was filtered off, washed by water and hot acetone (3 times).
The reaction mixtur e was poured into water (700 ml. ) and then heated for 5-7 min at 80-
90 °C. The soluti on was left overnight ; the formed red precipitate was then filtered off
and recrystalli zed from acetone. Mp 230-232 "c. ' 1-1_ MR: (500 Ml-lz, OMSO-d 6): I) =
10.17 (11-1,s), 9.25-9.20 (11-1 . rn), 8.32 (11-1. d. J = 9.2),8.24-8 .18 (21-1, m), 8.00-7.90 (21-1,
m). DC NMR (175 MHz, OMSO-d6): I) = 178.7, 157.2, 154.9. 146.5, 146.2. 133.7, 130.2,
129.5,1 28.6,1 28.3,1 28.1,1 24.8, 122.3,11 9.9, 90.0, 79.7. TO F-MS El: 316.13 (M++ I,
100).
Synthesis of (9Z)-9-(4-flu orob enzylid ene)-7-hydrox yb enzolll Ifur oI2,3-b]quinolin -
8(9H)-one (3e). (croton condensation):
A mixture of Comp ound 3a (0.575 g . 2.3mmol), glacial acetic acid (12 ml. ),
conc.I-ICI (6 mL) and p -flurobenzaldehyde (2 ml., 19 mmol) was heated for I h under
reflux. The precipit ate was filtered off and recrystallized from OMSO to give rise to a
dark brown powder. Mp >300 "c. ' 1-1- MR: (500 Ml-lz, OMSO-d 6): I) = 9.02-8.93 ( 11-1.
m), 8.21 (11-1, d, J = 8.8 I-Iz), 8.09 (3H, dt, J = 5.5, 10.6 I-Iz), 7.87 ( IH, d, J = 8.8 Hz).
7.79 (2H, dd, J = 3.5, 5.7 I-Iz), 7.42 (21-1, t, J = 8.8 Hz), 6.92 (11-1, s). DC MR (175
Ml-lz. OMSO-d6): I) = 169.5. 164.2, 135.0, 133.3, 133.2. 129.1, 128.6, 128.2, 126.9 (8
aromatic carbons), 124.5, 121. 1, 116.3, 116.0, 108.8, 99.8. HR-MS (TOFEI) calcd for
Cn I-l ll N0 3F (356.0723) ; found (356.0721).
Synthesis of (8Z)-8-(propan-2-yIideneh ydrazinylid ene)-8,9-d ihydro benzo IIII
fur oI2,3-b]quinolin- 7-ol (3f) :
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A solution of 3:1(0.55 g. 2.2 mrnol), 10 mL of 80% aquoes hydrazine hydrate and
30 mL of ethyl alcohol was heated at reflux for 2 h, the alcohol was removed in vacuo
and the resulting oil was allowed to stand for several days at room temper ature; crystals
were separated out , collected and washed with a small amount of ethyl alcohol. An
equimolar quantit y of acetone was added and the mixture was refluxed in alcohol for 4 h
in the presence of a few drops of glacial acetic acid. The solvent was evaporated and the
product was poured onto cold water, filtered and dried. The crude solid was recrysta llised
from ethanol to give the product 3f. Mp>300 "C. 'H-NMR: (500 MHz, DMSO-d6): Ii =
8.97 ( 11-1, d, J = 7.8), 8.19 ( ll-I, s), 8.06 ( ll-I, d, J = 8.9), 7.93 ( II-I, d, J = 7.4), 7.74-7.60
(3H. m), 5.24 (2H. s), 2.30 (6H. d, .J = 11.6). I3C NMR: (175 MHz, DMSO-d6): Ii =
171.2.170.5,1 66.4. 162.8, 149.3. 134.9, 129.7, 128.6, 127.5. 126.1, 124.9, 123.1. 120.6,
114.5, 98.1,70.7, 24.0 ,18.5. HR-MS (TOFEI) calcd for Cis HISN30 2 (305.1164); found
(305.1171).
Synthesis of (8Z)-9-methyl-8-(propan-2-ylideneh ydn1zin yliden e)-8,9-dih ydrobenzo
IIllfuro[2 ,3-blquinolin-7-o1 (3g) :
This compound was prepared using the same procedure as that for the Compound
3r. Mp 270-272°C. I H-NMR: (500 MHz, DMSO-d6): s = 15.33 (11-1, s), 7.88 (l H. dd,.J
= 7.7, 9.0 Hz), 6.85 ( IH, d,J = 8.5 Hz), 6.59 (lH . dd,.J = 7.1, 8.7 Hz), 6.38 (3H, m), 4.05
( l H, q, .J = 6.4, 3.5 I-Iz), 1.00 (6H, d, .J=3.3 Hz ), 0.43 (3H, t, .J = 3.0)YC NMR: (175
MHz, DMSO-d 6): 0 = 169.9, 169.8, 169.5, 163.2, 150.1, 135.2, 130.1. 128.6, 127.4,
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126.0, 125.2, 123.3, 120 .7, 114.8, 97.6, 78.6, 24.4, 19.9, 18.6. APCI-MS : 3 18.10 (M+-
1,100).
Synthesis of 9- [bis( mcthylsuffanyhmethylidenel-?-hydroxybenzo [" Ifuro[2 ,3-
blquinolin-8(9H)-one (3"):
Ca rbon disul fide (0 .176 g, 2.2 mmol) was added dropwise to a stirred solution of 33
(0 .55 g, 2.2 mm ol ) in dimethyl sulfox ide (5 mL ) and 30% aqueo us sodium hydroxide (0.7
mL) at 5°C, and stirring was continued at the same temp eratur e for 0.5 h. Dimeth yl
sulfate (O.77g , 6. 1 mmo l) was added dropwise to the mixtu re at 5 °C, and stirring was
continued at the same tem perat ure for 1.5 h. Ice-water was add ed , and the mixtur e was
extrac ted with ethyl acetate (2 x 100 ml. ), The combined ex trac t was washed with brine
and dried ove r magnesium sulfate and then filtered . The so lvent was removed and the
crud e product was purified by recrystalli zation from ethylacetate-hexa ne to afford 3h as
yellow crysta ls. Mp > 300°C. I\-I-NMR: (500 MHz, DMSO -d6): 0 = 8.95-8 .79 (1\-1 , m),
8.10 ( IH, d,J = 8.6 Hz), 7.97-7 .83 (1\-1,m), 7.76-7.44 (3H, m), 2.54 (3\-1,s), 2.46 (3 1-1, s).
I3C NM R: (17 5 MH z, DMSO-d6): 0 = 161.3, 160.8, 159.0, 157.9, 15 1.5, 135.4, 134.9,
130.3, 128.8, 127.2, 122.8, 120.8, 119.3, 118.4, 114.3, 100.9, 25.2, 20.2, APC I-MS :
354.43 (M+- I, 100).
Synthesis of meth yl 7-hydroxy-8-oxo-8,9-dihydrobenzo[" ]furoI2 ,3-blquinoline-9-
carboxylate (3i):
A so lution of sodium hydroxide (3.5 g, 60 mm ol) in methanol (35 mL) was added
to a stirred so lution of 3h (2. 13 g, 6 mmol) in TI-IF (45 mL), and the mixture was heated
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at 50 °C for 1.5 h. After addition of 10% hydroc hloric acid (20 ml. ), the mixture was
extracted with ethylacetate (2 x 300 mL). The combined extract s were washed with brine
(3x50 mL) and dried over magnesium sulfate . After removal of the solvent, the crude
product was purified by column chromatography on silica gel using ethylacet at-hex ane
(1:4) as an eluent , followed by recrystallization from ethylacetate-hex ane to afford 3i as
pale yellow crystals . Mp 211-2 13 Dc. IH-NMR: (500 MHz, DMSO-d6 ): 15 = 9.02-8.75
(11-1, m), 8.15 (lH, d,./ = 8.7), 8.13-8.05 (lH , m), 7.89 ( IH, d,./ = 8.8 Hz), 7.77 (2H, dd,
./ = 5.2, 9.1 Hz), 5.83 ( IH, s), 3.83 (3H, s). 13C NMR : (175 MHz, DMSO-d6): 15 = 170.3,
160.8, 159.0, 157.9, 151.5,135.4, 134.9,130.3, 128.8, 127.2, 122.8, 120.8, 119.3, 118.4,
114.3,95 .3,40.2, I-IR-MS (TOFEI) calcd for C17H11NOs (309.2729) ; found (309.2722).
Synthesis of 9-(1,3-dithiol:m-2-ylidene)-7-hydroxybenzol "1 furol2 ,3-bIquinolin-
8(9H)-one (3j):
This compound was prepared using the same procedure as that for Compound 3h,
using L2-dibromoethane. Mp 256-258 Dc. I H-NMR: (500 MHz, DMSO-d 6): 15 = 8.87
(lH , d,./ = 7.8 Hz), 8.09 (lH, d,J = 8.7 Hz), 7.88 ( IH, d,./ = 7.5 Hz), 7.64-7 .53 (3H, m),
3.60-3.56 (2H, m), 3.55-3.49 (2/-1, m). J3C NMR: (175 M/-Iz, DMSO-d6): 15 = 178.0,
175.6,172.9,169.0,156.9,137.3 ,134.8, 127.7,127.5, 125.6, 124.6, 122.0, 12104, 101.5,
66.2, 64.7, 38.9, 38.6, HR-MS (TOFE I) calcd for Cis/-lIIN0 3S2 (353.0180); found
(353.0188).
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6.1 Co nclusion and future researc h
Quinolones are among the widely prescribed antibac teria l agen ts for the treatment
of a wide variety of infections in humans. Apart from the founding members of this drug
class, which had little clini cal impact. success ive genera tions include the most active and
broad spectrum ora l antibacterials that are currently in use. Quinolones have a very
distincti ve mechanism of action as they do not only kill bacteria by inhibiting a crit ical
cellular proce ss but also they corrupt the activities of two esse ntial enzymes, DNA gyrase
and topoisom erase IV, resultin g in generating high levels of doubl e-stranded DNA breaks
and bacteria l death . The import ant characteristic of quin olones is their different ial ability
to target these two enzy mes in different bacteria. Either DNA gyrase or topoisomerase IV
serves as the primary cytotox ic target of drug action. This unusual feature of quinolones
opened new aspects for the clinical use of this drug class. In addition to the antibac terial
quinolones, specific mem bers of this drug family displa y high activ ity against eukaryotic
type II topoisomerases, as well as cultured mamm alian cells and in vivo cance r cell lines.
These antineop last ic quino lones represen t a potentially important source of new
anticancer agents and provide an oppo rtunity to exami ne drug mechanisms across diverse
species .
Antib acterial t1uoroquin olones were shown to be effec tive aga inst the vaccinia
virus and popavav irus. These preliminar y results prompt ed the synthesis of new
quinolone derivatives to optimize the antivira l action and improve their selectivity index.
The introduction of an aryl group at the pipera zine moiety of the t1uoroquin olone shifted
the activity from antibacter ial to antivira l, with a spec ific action agai nst HlV. The
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antiviral activit y seemed to be related to an inhibitor y effect at the transcript ional level,
and further evidence sugges ted a mechani sm of action mediated by inhibition of Tat
functions.
The mech anism of action of antiviral quin olones remains unclear. Most of the tested
drugs were proved to be effec tive aga inst HIV-I but, when assaye d agai nst a variety of
different viru ses, quin olones were shown to possess nonspecific activity. These data
indicate that the drugs' targets are likely to be structures comm on to a wide range of
viruses .
In this dissertation , a literature review (Chapter 2) focuses on the differ ent
biological activ ities of the quin olines scaffold. More than 10,000 derivatives have been
patented or publ ished, which explains the enormous progress that has been made in
understandin g the molecul ar mechanisms of action behind the different pharmacological
actions of this privi leged molecule.
Quinolones as a class of antibacterial agents have been known for over 40 years .
Although considerable result s in the research of new antibacteria l quinolones have been
already achieved, they are still a matter of study because of the continuous demand for
novel compounds active aga inst resistant strains of bacteria. Research ef forts are mainly
focused on obtaining new comp ound s active against very resistant bacterial strains or
acting on the mechanisms of resistance.
Currently, lluoroquinolones are approved as second-line drug s by the WHO to treat
TB but their use in MDR- TB is increasing due to the fact that they have a broad and
potent spectrum of activity and can be administered ora lly. Moreover, they have
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favourable pharm acok inetic profiles and good absor ption, includi ng proficient
penetration into host macrophages.
Quin olones are not new in the antiviral field . Their previously reported data on
bindin g with bacteria l chromoso me has strengthened the hypot hesis that these drugs
could also bind to the viral nucleic acid and has prompt ed the investigation of their
antiviral activity.
Many structures containing the basic quin olone carboxylic acid templ ate and
different lipoph ilic substituents were patented as antiviral agents: most of them were
tested aga inst human immunodeficiency virus-I (HIY- I) and were claimed to be
effective in the treatm ent or proph ylaxis of Acquired Immun e Deficiency Syndrome
(A IDS). Also, quin oline/one derivatives used as anti HCY agents have been discussed
focusing on the structural requirements to act as anti HCY agents.
In Chapter 3 we tried to complete our search for novel small molecule heterocycles
with potenti al antineoplastic activity, which the Daneshtalab gro up started years ago . The
idea started when a jo int patent published by Japanese pharmaceutical companie s.
Kyori n/Kyowa-Hakko, in which thiazoloquin olone carboxy lic acids, including
Compound A. were claimed as novel comp ound s with an impressive anticancer profi le.
The clinic al candidate compound had exhibited favourabl e dru g-like properties in
different anim al models in preclinical studie s.
Compound A, like other quinol one carboxylic acid derivatives, was presumed to
interact with topoisomerase 11via its p-keto acid functi onal group and chelati on with the
Mg2+ion to inhibit the enzyme. Considering this mode of action, we hypothesized that a
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quin olone with a p-dik eto functionality may be able to mimic the action of p-keto acid
functionality, thus potentially providing the same level of complexity with the Mg2+ ion
at the active site of the topoisomerase II. Also, due to the abse nce of a free carboxy lic
acid, the target quinolone may cause less gastric damage when used via oral
administration.
The target compounds were designed using the Hyperchem-J " molecular
modelin g program . By applying Molecul ar Mechanics Optimization (MMO) and
Molecular Dynamic Option methods we were able to identi fy linear tricyclic quinolones
with p-diketo components that matched the angular featur e of Compound A. In this
respect, Compound B, 9-benzyl-7-fluoro- 3-hydrox ythi eno [4,5-b]qu inolin e-4(9H)-one, at
its optimized ster ic/energe tic confi guration , was found to have the best match, with a
perfect 3-point ove rlay with Compound A.
Compound B and its derivat ives were synthesize d in our group using the Gould-
Jacob method. This series of compo unds displayed prom ising cytotoxic activity aga inst
seve ral cancer cell lines. Furthermore, we succeded in annelating a thieno ring to the
benzo[h]quinoline nucleus in an angular pattern . In this context. we attemp ted the
syntheses of benzo[h]thieno[2,3-b]quinoline derivatives. The weak cytotoxici ty on HeLa
and KB cell lines by most cytotoxic derivatives in the Brine Shrimp Lethality Bioassay
prompted us to explore, theoretically. the possib ility of these deri vatives to act as
topoisomera se inhibit ors.
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The ln silica study revealed the possibilit y of the synthes ized de rivatives to bind to
the ATP bindin g site in hum an topoisomerase II while not be ing ab le to make approp riate
chelation with Mg2+,a charac ter istic that is requi red for inhibit ion of topoisomerase II.
On the othe r hand , ano ther successful stra tegy has been ap plied in order to
synthes ize a quin olin e-fused isoth iazolone moiety. This was designed in acco rdance with
what was in the literatur e: the isothiazole moiet y was able to replace the Cj-carboxyl ic
acid group with retain ed (or enhanced) antib acter ial activity either in fused or isolated
forms. In this co ntext we synthesized isothia zolobenzo[h]quinolin e through the
interaction of the thiol intermediate 4 with hydrox ylamin e-O- sulph onic acid to yie ld the
corre sponding thio amino deri vati ve. The synthe sized derivat ive did not show cytotoxicity
either.
In an attem pt to low er the log p of the synthes ized derivat ives. Co mpound 6:\ was
allowed to react with hydrazine hydrate to yie ld the pentacycl ic pyrazo loquinoline 9.
Pyrazoloquin olines are co ns ide red as a very attrac tive scaffo ld for medicinal chemis ts.
The structure of Co mpound 9 was confirm ed by spec tra l ana lysis and X-ray
crystallog raphy.
Most of the synthesize d derivativ es are within the limit s of the Lipinski rule of 5.
Much work is needed to decrease the log p to be in the most optimum range to effec t
100% absorpti on of the synthes ized derivati ves and this can be done by phosphorylation
of the free hydroxyl group in Compound 6b followed by reducti on usin g I-h,Pd /C and
then sodium salt formati on as outlined in Scheme 6-1. This will imp rove the so lubility
and deph osphor ylation will be effected by phosphat ases ins ide the bod y.
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Scheme 6-1: Phosphorylation of quino line derivatives.
Furthermore, the synthesized derivatives had been docked into the IICV-Il elicase
(data net shown) show ing good binding affinities to the ATP binding region. Screening
of these derivatives on MOLT-4 cells will be the aim in the near future.
In Chapter 4. in continuat ion of the Dancshtatab' s ongoing researc h towards the
discovery of novel polycyclic qu inoline-based antineoplastic agent s using conventiona l
synthetic procedures. it was possi ble to isolate and identify, unexpectedly , a 4-oxo-
bcn7.o[hlthia7.ctoqui noline derivative (4a). The structure of this novel molecule was
elucidated by lll _NMR. I.lC_NMR. HR-MS. and X-ray crysta llography. Despite the
availabi lity of seve ral papers on the syntheses and bioactivity of angu lar 4-oxo-
thia/.olo(3.2-a]quin oline-3-carhoxylic acid deriva tives, there arc limited reports on the
synthesis of 4-oxo-thia7cto(3.2-uJquinolines and there is no reported synthesis of 4-oxo-
bcnzo[h]thiazetol3 ,2-u ]quinoline der ivatives . In the synthesis desc ribed herein, the 4·
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oxo-thiazetoqui noline nucleus is formed via reactio n of the carbanion at the alkyl sulfide
group of the C-2 position of the quin oline ring with a pseudohalogen (IBr), formed via
reaction of the iodide anion with the vic-diha loalkan e, or a halogen (12), followed by
nucleophili c attack of the N-l on halogenated carbon and the depa rture of halogen. The
role of the vicina l dihaloa lkane in this process is the provision of a pseudohalogen (such
as IBr) without direct interaction with the quinoline system . This synthetic procedure
provides us with diverse 4-oxo-thi azetoqu inoline-3-carboxylic acid der ivatives
possessing electron-w ithdrawing groups at the C- I position .
To test the plausibil ity of the mechanism described in Sche me 4-3 , three individual
steps of the scheme were comput ationally modeled to see if the energe tics of each step
were reasonable in term s of both activation energy barriers and overa ll energy change
from reactants to produ cts.
Overall, modeling of these three steps of the proposed mechanism shows that the
first two steps have small- to -nonexistent activa tion ener gy barriers, and are highly
exothermic in concert. Even if the abstraction of the phenolic pro ton was to have a
relatively large activa tion energy barrier on the order of250 kl lm ol (which is unlikely for
such an acid-base chemis try) the transition state would still lie energetically below the
3a/carbonate reacta nt complex of the first step. Combine d with the reasonab le transi tion
state barrier of the phenolate form ring closing step, which is itself exo thermic, the
theoretic al calculations support the notion that the propo sed mechanism is energe tically
favourable. In fact, since the activation energy barriers to reverse any of the mechanistic
steps would be prohibiti vely high, reverse react ions are unlike ly to occur , and the
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proposed mechanism would have to lead to fairly high yields of product .fa at a
reasonable temperature . As the experimental results show yields on the order of 75% for
the reaction run for 24 h at 70"C. the modeled energetics o f the proposed mechanism
support the observed yield as well.
Generally, synthesis of novel system (benzo[h]thiazetoquinolone) derivatives has
been achieved using in sil ll halogenations and alkylation methodologies. The mechanism
by which the cyclizatio n occurs is confirmed using computational calculations.
Compound 21l has also been prepared during this study. This derivative showed a
better log p in comparison with the tested derivati ves. Also. this compound did not show
any cytotoxic propertie s against cancer cell lines in MIT assay.
Compound 21lis structurally different from the other compounds synthesized in this
series, in which the main requirement of the a-quinolon es component is missing.
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Starting from this derivative. much work must be done in order to get a new series
capable of demostrating the potentialto ad as antimycobactcrial agents.
In Chapter 5. lsostcric replacements of sulfur in thicnoquinoline s by oxygen
revealed a new series of furoquinnlincs. The synthesized derivatives did not show a
cytotoxic pattern lin cancer cell lines. Since our screening failed to generate potential
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leads to initiate a drug discovery effort, we embarked on a structure -based design
approach. The diketo acid class of compounds has been most aggressively developed
because of its marked antiretroviral activities. Also, it was proven that 4-quinolone-3-
carboxylic acid is a good alternative to the diketo acid structure for potent strand transfer
inhibition . All the investigated compounds were docked into the ATP binding site of
3KQN . The protein for docking calc ulat ion should contai n AT P as well as bound 0 A
that enables us to explore all possible bind ing sites and modes of the ligands. X-Ray
structures 3KQ L, 3KQN and 3KQU meet these criteria , with 3KQN possessing the most
accurate X-ray determin ation (lowest resoluti on). Therefore, 3KQN was chosen for
docking calcul ations.
All the synthes ized furo derivatives showed good binding affinities to the A1'1'
portion of the pro tein. In conclusion the synt hesized furoquinolines did not exhibit
cytotoxici ty against cancer cell lines; meanwhile they showed good binding affinities to
the HCV-helicase.
6.2 Originality of the the sis
With the continuous progress in protein crystallography and MR. structure-based
drug design is acq uiring increasi ng importa nce in the searc h for new drugs. Modeling
usually starts from the 3-D structure of the target protein in order to construct molecules
which are compl ementary to a bindin g site, in their chemi stry and geometry as well as in
their physicochemical properties. The main contribution of this thesis is firstly the design
and synthesis of different fused quin oline derivatives (ligands) using structure-based drug
desig n starting with the synthesis of the novel angu lar benzo[h]thienoquinolines. The
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synthesis of a novel series of thienoquinolines focusing on some criteria of the new
system is described in chapter 3; for exampl e, the constant producti on of the O-alkylated
derivatives upon alkylation with different alkylating agents. Also, the synthesis of a novel
pentacyclic derivat ive appli es a new method which was based on reac ting the starting
material with ethylace toace tate. The reaction with hydrazine hydrate also was designed to
add a hydroph ilic moiet y to the designed molecule which unexpectedly produced a new
pyrazoloquinoline derivative .
As there are not man y reports on thiazeto-quinolone derivat ives, the synthes is of the
novel thiazetoben zo[h ]quin olones via a novel oxidative cycli zation process was
success fully achieved. Also, to come up with a reasonable structure activity relationship,
the novel furobenzo[h]quinolines which are considered as structura l isosteres of the
newly synthesize d thienoquin olines were designed and synthesize d.
None of the syn thes ized derivatives exhibited cytotoxic prope rties at the nanomolar
levels aga inst norm al or cancer cell lines. The only risk which faced us with lead
structure optimizat ion by structure-based design was the neglect of other importa nt
biological prop erties, such as bioavailabil ity and metab olic stability, which will be the
focus of futur e research .
Secondl y, in order to come up with a possible explanation for the lack of
cytotoxicity of these derivatives, the in-silica study was initiated which highlighted the
possibility of these synthes ized derivatives to bind to the ATP bindin g site of the human
topoisomeras e with no chelati on to Mg2+.
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The inability to chelate Mg2+ explains in part the weak cytotoxicity of the prepared
derivatives. Anothe r possible explanation may also be due to the difficulty for the drug
to enter the cell and this can be explained on the basis of the pharmacokinetic parameters
of the drug or the efflux pump mechanis ms.
Synthesis of qu inoline derivat ives with different fusio n rings ; for example , thieno,
thiazolo, thiazeto and furobe nzo[h]q uinolines, have introd uced a new library of quinoline
derivatives with wea k or no cytotoxic properties on cancer cell lines. All the synthesized
derivatives showed a bindin g affinity toward s the ATP bindin g site in the topoisomerase-
II with no chelation to Mg2+.
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